| "MIA PaCa-2 and BxPC-3 human pancreatic cancer cells were treated with CCKs or CCKu (10(-12) to 10(-9) M) for 48 or 72 h in the presence of [3H]thymidine to evaluate DNA synthesis." | ( Heald, EB; Kramer, ST; Smith, JP, 1992) |
| "In advanced pancreatic cancer, chemotherapy has no curative potential, and the goal is to palliate symptoms or delay their onset so as to improve the quality of life of patients." | ( Shimada, Y; Yokoyama, T, 1992) |
| "Work has been done in gastric cancer, pancreatic cancer, and colon and rectal cancer, all of which demonstrate an advantage in certain clinical situations for combined-modality therapy." | ( Tepper, JE, 1992) |
| "The current treatment of pancreatic cancer with resection and/or radiation is considered unsatisfactory because of a high incidence of failure and a moderate incidence of complications." | ( Arredondo, MA; Chaudhuri, B; Chaudhuri, PK; Crist, KA; Kar, R; Thomford, NR, 1990) |
| "Several advances in the radiotherapy of pancreatic cancer have been made for the patient with resectable disease." | ( Bronn, DG; Dobelbower, RR, 1990) |
| "Nineteen patients with resectable pancreatic cancer have been treated by a multidisciplinary approach at the National Cancer Center Hospital." | ( Egawa, S; Kinoshita, T; Kosuge, T; Ozaki, H; Shimada, K; Yamamoto, J, 1991) |
| "Findings in this animal model of pancreatic cancer suggest that it treatment of anticancer agents or IL-2 might become an effective therapy for advanced pancreatic cancer." | ( Makino, I; Moriai, T; Takeba, T, 1990) |
| "Application of antiandrogens for pancreatic cancer treatment is discussed." | ( Bassalyk, LS; Klimenkov, AA; Kushlinskiĭ, NE; Lisianskiĭ, VI; Samoĭlenko, VM, 1990) |
| "Chemoradiotherapy was recommended to 40 pancreatic cancer patients following exploratory and palliative operations." | ( Barkanov, AI; Itin, AB, 1985) |
| "In this study we evaluated human pancreatic cancer xenotransplanted into nude mice as a model suitable for adoptive immunotherapy studies." | ( Drucker, BJ; Goodwin, DA; Holder, WD; Keeling, CA; Marincola, FM; Siao, DY; Starnes, HF, 1989) |
| "Four patients with unresectable pancreatic cancer and one with metastatic liver tumor after curative pancreatic resection for carcinoma of the pancreas had undergone intra-arterial infusion chemotherapy using an implantable drug delivery system." | ( Asamura, M; Kakizaki, K; Kikuti, H; Takahashi, N; Yamauchi, H, 1989) |
| "In vivo treatment of hamsters bearing pancreatic cancers with microcapsules of agonist [D-Trp6]-LH-RH and the somatostatin analog RC-160 alone, or in combination, caused histopathological regression of tumors and concomitantly decreased the Kd and Bmax of [D-Trp6]-LH-RH, and increased the Bmax of the SS-14 binding sites." | ( Fekete, M; Schally, AV; Zalatnai, A, 1989) |
| "In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition." | ( Comaru-Schally, AM; Fekete, M; Schally, AV; Zalatnai, A, 1989) |
| "An enhancement of pancreatic cancer induced by N-nitrosobis-(2-oxopropyl)amine (BOP) was reported previously in Syrian hamsters fed high-fat diet following carcinogen treatment." | ( Birt, DF; Julius, AD; Pour, PM; White, LT, 1989) |
| "The incidence of pancreatic cancer in the EGF + BOP-treated animals was 75% versus 44% in those treated with BOP alone (P = 0." | ( Chester, JF; Gaissert, HA; Malt, RA; Ross, JS, 1986) |
| "Two patients who had unresectable pancreatic cancer were treated with a combined chemotherapy using Cisplatin, PSK and UFT." | ( Kanda, M; Kitagawa, T; Mutoh, E; Namiki, M; Okamura, K; Okano, S; Sohma, M; Suzuki, Y; Takeda, S; Utsumi, M, 1987) |
| "One hundred forty-three patients with pancreatic cancer were treated with a number of chemotherapeutic agents, while ninety-eight patients did not receive any chemotherapy." | ( Fujimoto, T; Ishida, T; Kurogoh, F; Ohyanagi, H; Okumura, S; Saitoh, Y; Shimada, Y; Tagashira, Y; Uchida, K; Yamamoto, M, 1988) |
| "A case of pancreatic cancer with liver metastasis is reported, in which chemotherapy had a marked effect, with the responses clearly documented." | ( Hijikata, A; Mukai, T; Nakamura, K; Ohkura, H; Saito, D; Tajiri, H; Yamaguchi, H; Yoshida, S; Yoshida, T; Yoshimori, M, 1987) |
| "Previous reports have shown that pancreatic cancer was induced preferentially in male versus female azaserine-treated rats." | ( Brinck-Johnsen, T; Lhoste, EF; Longnecker, DS; Roebuck, BD, 1987) |
| "To examine the role of diabetes in pancreatic cancer, 4 groups of Chinese hamsters--2 from genetically diabetic and 2 from non-diabetic lines--were treated with N-nitrosobis(2-oxo-propyl)amine (BOP) at different dose levels and intervals." | ( Bell, RH; Pour, PM, 1987) |
| "Although the incidence of pancreatic neoplasms is not significantly different in these 2 groups, the data are consistent with the hypothesis that initiated foci are promoted to grow and become neoplasms in the pancreas of rats that are fed diets with a high content of unsaturated fat--as was demonstrated in the HPOP-treated rats." | ( Kuhlmann, ET; Longnecker, DS; Roebuck, BD, 1985) |
| "Since pancreatic cancer is still increasing and has a poor prognosis, there is great interest in improving treatment results by combined modality approaches." | ( Ghosh, BC; Kisner, DL; Metzger, UF, 1983) |
| "Forty-seven patients with unoperable pancreatic cancer were included in a controlled, prospective study of combination chemotherapy." | ( Andrén-Sandberg, A; Holmberg, JT; Ihse, I, 1983) |
| "Consequently, pancreatic cancer represents a serious international problem and requires urgent resolution, especially with regard to its etiology, early diagnosis, prevention, and therapy." | ( Birt, D; Gingell, R; Lawson, T; Nagel, D; Pour, PM; Runge, RG; Salmasi, SZ; Wallcave, L, 1981) |
| "Although chemotherapy of pancreatic cancer is a developing field, clinically meaningful responses correlated with improved patient survival can be obtained with existing regimens." | ( Schein, PS; Smith, FP; Zimmerman, SE, 1981) |
| "The inhibition of pancreatic neoplasms was not related to reduced calorie consumption, since this occurred in the BOP-treated hamsters that were pair-fed the PCD diet." | ( Birt, DF; Götz, U; Pour, PM; Salmasi, SZ, 1983) |
| "For the CBP pancreatic cancer line, CHS treatment increased tumor immunogenicity significantly, as demonstrated by diminished tumor growth rate and by increased duration of survival after challenge." | ( Kurman, CC; Sindelar, WF; Skornick, Y, 1984) |
| "Forty patients with inoperable pancreatic cancer were included in a prospective, randomised, controlled trial of multiple chemotherapy." | ( Cocking, JB; Cwynarski, MT; Diffey, BL; Fox, CA; Hanley, J; Jackson, GA; Mallinson, CN; Rake, MO; Wass, VJ, 1980) |
| "Patients with irresectable pancreatic cancer (n = 16) were treated with either ibuprofen (1200 mg day-1 for 7 days (n = 10) or placebo (n = 6)." | ( Carter, DC; Falconer, JS; Fearon, KC; Maingay, JP; Plester, CE; Ross, JA; Wigmore, SJ, 1995) |
| "Thirty-thousand new cases of pancreatic cancer are diagnosed each year, most are metastatic at diagnosis and no effective systemic therapy is available." | ( Eble, ML; Grochow, LB; Hathorn, JA; Hohneker, JA; Spriggs, D; Trump, DL, 1994) |
| "However, raw soya did not potentiate pancreatic cancer in hamsters treated with N-nitrosobis(2-oxopropyl)amine (BOP)." | ( Adrian, TE; Bilchik, AJ; Herrington, MK; Kazakoff, KR; Permert, J; Pour, PM; Zucker, KA, 1994) |
| "The number of animals with pancreatic cancers was significantly lower in the group treated with 60 micrograms/day of RC-3095 and the weight of tumorous pancreata was reduced." | ( Groot, K; Halmos, G; Schally, AV; Szepeshazi, K, 1993) |
| "To assess the treatment effect of pancreatic cancer, thallium 201 chloride (201TlCl) SPECT was performed in three patients." | ( Fujita, T; Hamanaka, Y; Nakada, T; Nakanishi, T; Suga, K; Suzuki, T; Uchisako, H; Utsumi, H; Yamada, N; Yoneshiro, S, 1993) |
| "Recent studies have revealed decreased pancreatic cancer cell growth upon administration of peptide YY (PYY)." | ( Balasubramaniam, A; Garvey, L; Liu, CD; McFadden, DW; Rongione, AJ, 1996) |
| "Human pancreatic cancer cell growth is further decreased when pretreated with PYY or its synthetic analog prior to chemotherapy." | ( Balasubramaniam, A; Garvey, L; Liu, CD; McFadden, DW; Rongione, AJ, 1996) |
| "Effective chemotherapy for pancreatic cancer is urgently needed." | ( Furihata, K; Homma, T; Imai, H; Kawa, S; Kiyosawa, K; Nikaido, T; Oguchi, H; Tokoo, M; Yoshizawa, K, 1996) |
| "Thus, chA7Fab-NCS can inhibit human pancreatic cancer growth in an animal and may be useful for targeting chemotherapy to pancreatic cancer in humans." | ( Kato, M; Kitamura, K; Kotani, T; Nishi, H; Okamoto, K; Otsuji, E; Takahashi, T; Taniguchi, K; Tsuruta, H; Yamaguchi, T; Yata, Y, 1996) |
| "Twenty-one patients with pancreatic cancer pain were studied to evaluate the effectiveness of celiac plexus block (CPB) on pain relief and quality of life (QOL), compared to the traditional NSAID-morphine treatment." | ( Ishikawa, K; Ishitani, K; Kawamata, M; Namiki, A; Omote, K; Ota, K; Sasaki, H, 1996) |
| "The effective treatment of unresectable pancreatic cancer remains to be elucidated." | ( Amano, M; Aoki, T; Dohno, K; Gotoh, M; Kishimoto, S; Monden, M; Monden, T; Oosato, H; Sakon, M; Sekimoto, M; Takekuni, K; Umeshita, K, 1996) |
| "A phase III study of newly diagnosed pancreatic cancer patients treated with either gemcitabine or fluorouracil (5-FU) and a phase II trial of gemcitabine in patients whose disease had progressed despite prior treatment with 5-FU both demonstrated that a significant number of patients achieved a CBR with gemcitabine." | ( Rothenberg, ML, 1996) |
| "Recently, the goal of chemotherapy for pancreatic cancer is thought to be quality of life." | ( Sakata, Y; Suzuki, H; Takemori, H, 1996) |
| "The prognosis of pancreatic cancer is extremely poor in digestive cancers even with systemic therapy including surgery." | ( Chung, YS; Sawada, T; Sowa, M, 1996) |
| "Growth of BxPC-3 human pancreatic cancer cell in serum-free medium was inhibited by the addition of the CCK-B/gastrin receptor antagonist L-365,260, and gastrin treatment reversed the inhibitory effect of the antagonist." | ( McLaughlin, PJ; Shih, A; Smith, JP; Wu, Y; Zagon, IS, 1996) |
| "These results show that eight pancreatic cancer cell lines are broadly sensitive to CDDP, and that chemotherapy for pancreatic cancer may improve the prognosis by more effective drug delivery to cancer cells." | ( Oka, T; Sawabe, Y; Yamagishi, H; Yamaguchi, N; Yamamura, Y, 1996) |
| "Chemotherapy for pancreatic cancer does not satisfactorily improve prognosis." | ( Oka, T; Sawabe, Y; Yamagishi, H; Yamaguchi, N; Yamamura, Y, 1996) |
| "Treatment of inoperable pancreatic cancer pain is of paramount importance." | ( Angelini, L; Caratozzolo, M; Consalvo, M; Fumarola, E; Lirici, MM; Marzano, F, 1997) |
| "The prevalence of pancreatic cancer among DMBA-treated rats evaluated after 10 months was 39% (19 of 49)." | ( Fernández-del Castillo, C; Graeme-Cook, F; Rattner, DW; Rivera, JA; Rustgi, AK; Warshaw, AL; Werner, J; Z'graggen, K, 1997) |
| "Advanced pancreatic cancer is a rapidly fatal disease whose course has been little influenced by chemotherapy." | ( Ahlgren, JD; Auerbach, M; Fryer, D; Fryer, JG; Lokich, JJ; Wampler, GL, 1997) |
| "Effective chemotherapy for pancreatic cancer is urgently needed." | ( Aoki, Y; Fujii, S; Furihata, K; Kawa, S; Kiyosawa, K; Kumagaya, T; Nikaido, T; Zhai, Y, 1997) |
| "The status of chemotherapy for pancreatic cancer (PC) has been difficult to assess because of the problem of evaluating tumor response, which id dependent on the accurate measurement of tumor size using imaging modalities such as computed tomography." | ( Okada, S, 1997) |
| "Chemotherapy treatment for advanced pancreatic cancer is universally disappointing." | ( Flett, MQ; John, WJ, 1998) |
| "Because of the poor response of pancreatic cancer to conventional therapy, the authors performed a phase II pilot study to evaluate whether beta-interferon and retinoids, added to active chemotherapeutic agents, could increase response rate and survival in a group of patients who had metastatic disease." | ( Casucci, D; Frati, L; Gulino, A; Rea, S; Recchia, F; Sica, G, 1998) |
| "For locally advanced non-resectable cancer of the pancreas, we have routinely performed intra-arterial chemotherapy: Each catheter is placed in the splenic artery and gastroduodenal artery during laparotomy, and a mixture of Methotrexate and Angiotensin-II is infused within 30 minutes." | ( Fujita, M; Furukawa, H; Hiratsuka, M; Hosomi, N; Imaoka, S; Ishikawa, O; Kabuto, T; Kameyama, M; Kuroda, C; Murata, K; Nakaizumi, A; Nakano, H; Ohigashi, H; Sasaki, Y; Uehara, H; Yasuda, T, 1998) |
| "For advanced pancreatic cancer, there is no typical chemotherapy regimen non single chemotherapeutic agent." | ( Kobayashi, A; Yamaguchi, M, 1998) |
| "Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors that are commonly overexpressed in pancreatic cancer: fibroblast growth factor 2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF)." | ( Büchler, MW; Friess, H; Ishiwata, T; Kleeff, J; Korc, M; Kumbasar, A; Lander, AD, 1998) |
| "In cultured human pancreatic cancer cells, levels of COX-2 mRNA and protein were induced by treatment with tumor-promoting phorbol esters." | ( Daly, JM; Dannenberg, AJ; Fahey, TJ; Koki, AT; Masferrer, JL; Soslow, RA; Teng, L; Tucker, ON; Woerner, BM; Yang, EK; Zhang, F, 1999) |
| "Two human pancreatic cancer cell lines were treated with CCK-8 alone, CCK-8 and staurosporine, or CCK-8 and indomethacine." | ( Fujimoto, Y; Hirata, M; Inoue, H; Iwao, T; Kajiyama, G; Kariya, K; Kawasaki, Y; Matsubara, K; Morinaka, K; Sasaki, T; Tsuchida, A; Yamamoto, S, 1999) |
| "The prognosis of pancreatic cancer is poor, and current medical treatment is mostly ineffective." | ( Günzburg, WH; Jesnowski, R; Karle, P; Liebe, S; Löhr, M; Müller, P; Nizze, H; Püschel, K; Renz, R; Saller, R; Salmons, B; Stein, H; von Rombs, K; Wagner, T, 1999) |
| "Combination chemotherapy in pancreatic cancer adds to the side effects of treatment, but has had no proven effect on effectiveness." | ( van Groeningen, CJ, 1999) |
| "We used a BxPC-3 human pancreatic cancer xenograft model in athymic mice to examine drug levels in tumor, liver, and kidney tissue following administration of: (a) 5-FU/epi gel (30 mg 5-FU/ml) intratumorally (i." | ( Chen, JY; Jones, RE; Kanekal, S; Orenberg, EK; Patawaran, MB; Smith, JP; Yu, NY, 1999) |
| "In patients with disseminated pancreatic cancer chemoradiotherapy has so far not been effective in prolonging survival." | ( Jeekel, J; van der Schelling, GP, 1999) |
| "This agent has demonstrated activity in pancreatic cancer, is generally well tolerated, and can safely be administered on an outpatient basis." | ( Stucky-Marshall, L, 1999) |
| "Experimental data obtained with this pancreatic cancer specific in vitro screening system suggest that dose escalation or prolonged administration of gemcitabine, as well as the combination of this drug with cisplatin or epirubicin might result in improved therapeutic results." | ( Bauer, J; Kreil, A; Scheithauer, W, 1999) |
| "Patients with pancreatic cancer have only short survival after diagnosis, irrespective of treatment." | ( Ragnarson-Tennvall, G; Wilking, N, 1999) |
| "One hundred fourteen patients (55%) had pancreatic cancer (54 in the observation group and 60 in the treatment group)." | ( Arnaud, JP; Couvreur, ML; de Wit, LT; Gonzalez, DG; Hennipman, A; Jeekel, J; Klinkenbijl, JH; Sahmoud, T; van Pel, R; Veenhof, CH; Wils, J, 1999) |
| "IGF-I levels in serum and in pancreatic cancer tissue remained unchanged after therapy, suggesting that an effect on IGF-I is not involved in tumour inhibition." | ( Armatis, P; Groot, K; Halmos, G; Hebert, F; Schally, AV; Szepeshazi, K, 2000) |
| "The treatment of pancreatic cancer has remained dismal despite advances in medical and surgical care." | ( Kwan, D; Liu, CD; McFadden, DW; Saxton, RE, 2000) |
| "A patient with pancreatic cancer and malignant ascites was treated with dFdC 1,500 mg/m2 over 150 minutes weekly for 3 weeks, repeated every 4 weeks." | ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| "For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival." | ( Hirakawa, K; Nishino, H; Ohira, M; Shimizu, S; Tamamori, Y; Tanaka, H; Yamada, N, 2000) |
| "Forty-seven patients with pancreatic cancer were treated with two different schedules of 5-fluorouracil (5FU) and leucovorin (LCV): standard and dose-intense schedules." | ( Figer, A; Gal, R; Klein, B; Koren, R; Levin, I; Mishaeli, M; Sadikov, E, 2000) |
| "Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease." | ( Heinemann, V, 2001) |
| "In locally advanced pancreatic cancer, the combination of chemotherapy with radiotherapy is gaining increasing importance; although, in view of the reported long-term results of several contemporary trials, further improvements are certainly warranted." | ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001) |
| "In IrinoGem, two of three previously untreated metastatic pancreas cancer patients had durable radiologic partial responses." | ( Brescia, FJ; Brunson, CY; Green, MR; Rocha Lima, CM; Sherman, CA, 2001) |
| "Binding assays showed that pancreatic cancer cells have specific binding sites for angiotensin II and that binding could be eliminated by treatment with a selective AT1 antagonist in a dose-dependent fashion." | ( Chayama, K; Fujimoto, Y; Sasaki, T; Tsuchida, A, 2001) |
| "Quiescent BxPC3 and Panc-1 human pancreatic cancer cells treated with or without 20 ng/mL rapamycin (FRAP inhibitor) were repleted with 10% FCS to induce cell cycle entry." | ( Callery, MP; Perugini, RA; Potter, MW; Ricciardi, R; Shah, SA, 2001) |
| "Currently, there is no satisfactory treatment for pancreas cancer." | ( Hodysh, YY; Procopchuk, OL; Susak, YM; Zemskov, SV; Zemskov, VS; Zemskova, MV, 2000) |
| "Thus, in TGF-beta-responsive pancreatic cancer cells with activating Ki-Ras mutations, TGF-beta1 treatment caused an EMT associated with a more invasive phenotype." | ( Adler, G; Boeck, W; Ellenrieder, V; Gress, TM; Hendler, SF; Menke, A; Ruhland, C; Seufferlein, T, 2001) |
| "Best supportive care in pancreatic cancer consists of the treatment of symptoms, such as pain, jaundice, duodenal obstruction, weight loss, exocrine pancreatic insufficiency, and tumor-associated depression." | ( Meyer, F; Ridwelski, K, 2001) |
| "The 5-year survival for pancreatic cancer is usually less than 5%, and no treatment has demonstrated consistent effect on patient survival and disease-related symptoms." | ( Calandri, C; Chiara, S; Corgna, E; Crinò, L; Mosconi, AM; Nobili, MT; Porrozzi, S; Tonato, M, 2001) |
| "Fifteen patients with unresectable pancreatic cancer were treated with gemcitabine, 900 mg/m(2), and docetaxel, 90 mg/m(2), every 3 weeks." | ( Fine, RL; Sherman, WH, 2001) |
| "The study of SSH in pancreatic neoplasms will provide clues about its origin, development, tumoral behavior, prognosis and more specific hormonal therapy." | ( Duarte-Rojo, A; Robles-Diaz, G, 2001) |
| "The conclusions of this overview in pancreatic cancer are based on 10 randomised studies with, and 18 randomised studies without, an untreated control group." | ( Glimelius, B; Hafström, L; Nygren, P; Permert, J, 2001) |
| "AsPC-1 and Panc-1 human pancreatic cancer cells were treated with Ad-alpha CaSm and examined by MTT assay for in vitro proliferation changes." | ( Cole, DJ; Fraser, MM; Kelley, JR; Schweinfest, CW; Vournakis, JN; Watson, DK, 2001) |
| "MIA-PaCa-2 human pancreatic cancer cells were treated in vitro with the 26S-proteasome inhibitor PS-341." | ( Bold, RJ; McConkey, DJ; Virudachalam, S, 2001) |
| "Locally advanced pancreatic cancer patients should continue to be enrolled on prospective studies investigating novel combinations of cytotoxic and/or biologic agents with concurrent radiotherapy." | ( Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, A, 2001) |
| "Five pancreatic cancer cell lines, Panc-1, MIA-PaCa-2, Capan-1, ASPC-1 and T3M4, were treated with Bcl-x(L) sense or antisense oligonucleotides and gemcitabine and the cell viability was examined by the SRB method." | ( Aebi, S; Büchler, MW; Friess, H; Kleeff, J; Korc, M; Solioz, M; Xu, Z, 2001) |
| "The role of adjuvant treatment in pancreatic cancer remains uncertain." | ( Almond, J; Bassi, C; Beger, H; Büchler, MW; Dervenis, C; Dunn, JA; Falconi, M; Fernandez-Cruz, L; Friess, H; Kerr, DJ; Lacaine, F; Link, K; Neoptolemos, JP; Pap, A; Pederzoli, P; Spooner, D; Stocken, DD, 2001) |
| "Co-treatment of pancreatic cancer cells with ActD and agonist anti-CD95 antibodies showed no effect on the abrogation on the DNA binding activity of NF-kappaB, but decreased the expression of phosphorylated Akt." | ( Adsay, VN; Alhasan, S; Chinni, S; Glazyrin, AL; Sarkar, FH; Vaitkevicius, VK, 2002) |
| "Because pancreatic cancer has a poor survival rate and only 20% of patients present with potentially resectable disease, a key goal of therapy is to provide palliation." | ( Moore, MJ, 2002) |
| "Thirty-six patients with advanced pancreatic cancer received once daily oral treatment with seocalcitol with dose escalation every 2 weeks until hypercalcaemia occurred, following which patients continued with maintenance therapy." | ( Anthoney, DA; Colston, KW; Cunningham, D; de Bono, JS; Evans, TR; Gogas, H; Hamberg, KJ; Lofts, FJ; Mansi, JL; Skov, T, 2002) |
| "BxPc3 and Panc-1 human pancreatic cancer cells were treated with three different schedules before radiation: (A) a sequential incubation of gemcitabine for 2 h followed by cisplatin for 2 h, (B) gemcitabine for 2 h, followed by washout of drug, replenishment of media for a 24-h incubation, followed by cisplatin for 2 h, and (C) gemcitabine for 24 h with a concurrent incubation of cisplatin for the last 2 h." | ( Davis, M; Lawrence, TS; McGinn, CJ; Symon, Z; Zalupski, MM, 2002) |
| "Fifteen patients with locally advanced pancreatic cancer that was histologically confirmed as adenocarcinoma were enrolled in this phase I trial of weekly gemcitabine (150-350 mg x m(-2)) with concurrent radiotherapy (50." | ( Ikeda, M; Okada, S; Okusaka, T; Tokuuye, K; Ueno, H, 2002) |
| "Because the prognosis of patients with pancreatic cancer is very poor, development of a novel approach for treatment of this disease is vital." | ( Akiyama, Y; Cheng, JY; Hojo, T; Maruyama, K; Mori, T; Nara, N; Wiltrout, RH; Yamaguchi, K, 2002) |
| "This randomised study in pancreatic cancer compares marimastat (orally administered matrix metalloproteinase inhibitor) in combination with gemcitabine to gemcitabine alone." | ( Baillet, M; Bramhall, SR; Brown, PD; Buckels, JA; Nemunaitis, J; Schulz, J, 2002) |
| "After establishment of pancreatic cancer, groups 1 and 5 received no therapy, groups 2 and 6 were fed 7 mg Celebrex daily, groups 3 and 7 were given 28 mg Zyflo and groups 4 and 8 received Celebrex and Zyflo orally daily in weeks 17-32." | ( Achucarro, P; Guski, H; Heinicken, D; Jacobi, CA; Kilian, M; Müller, JM; Schimke, I; Wenger, FA, 2002) |
| "To determine if pancreatic cancer patients would be suitable for MAGE- or GAGE-based immunotherapy, the expression frequency of MAGE-A1, -A2, -A3, -A4, -A6 and GAGE1-8 genes was assessed in 15 pancreatic tumor cell lines and 23 pancreatic tumor specimens using reverse transcription-polymerase chain reaction (RT-PCR)." | ( Bert, T; Gangsauge, S; Lubomierski, N; Münch, K; Prasnikar, N; Printz, H; Robbel, C; Simon, B, 2002) |
| "Patients with pancreatic cancer generally do not benefit from chemotherapy." | ( Aulmann, M; Dihlmann, S; Eisold, S; Linnebacher, M; Ridder, R; Ryschich, E; Schlehofer, JR; Schmidt, J; von Knebel Doeberitz, M, 2002) |
| "Patients with pancreatic cancer often present initially in advanced disease with many compromising factors, and yet they may still be responsive to chemotherapy." | ( Chao, Y; Chen, LT; King, KL; Lan, C; Li, AF; Lin, WC; Liu, JM; Perng, CL; Tiu, CM; Whang-Peng, J, 2002) |
| "Gene therapy with HSV-TK for pancreatic cancer seems effective in only a limited number of tumor-derived cell lines, and this limits its application in vivo." | ( Basso, D; Fogar, P; Gallo, N; Greco, E; Mazza, S; Navaglia, F; Pedrazzoli, S; Piva, MG; Plebani, M; Scarpa, A; Stefani, AL; Zambon, CF, 2002) |
| "Progress in the treatment of pancreatic cancer in the past several decades has been very modest." | ( Philip, PA, 2002) |
| "Future directions in therapy for pancreatic cancer include the development of agents targeting signal transduction pathways and nuclear transcription factors based on the continually improving understanding of the role of molecular events in carcinogenesis." | ( Abbruzzese, JL, 2002) |
| "In this study in patients with advanced pancreatic cancer, we evaluated the use of fluorodeoxyglucose (FDG) PET compared with magnetic resonance imaging (MRI) in monitoring hormonal therapy using a highly selective, non-peptide CCK receptor antagonist (SR 27897B)." | ( Decker, M; Eckel, F; Frank, R; Helmberger, H; Lersch, C; Lippl, F; Neverve, J; Schulte-Frohlinde, E; Schusdziarra, V; Schwaiger, M; Weber, W, 2002) |
| "To investigate treatment of human pancreatic cancer cell lines and xenografts with combinations of Erbitux (IMC-C225) anti-epidermal growth factor receptor (EGFR) antibody, gemcitabine, and radiation." | ( Bohlen, P; Bonner, JA; Buchsbaum, DJ; Carpenter, M; Grizzle, WE; Hicklin, DJ; Raisch, KP; Stackhouse, MA, 2002) |
| "With regard to pancreatic cancer, a palliative second-line therapy has not been established, yet." | ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| "Prognostic indicators in pancreatic cancer (PC) are poorly defined and difficult to quantify preoperatively, hence they may lead to inappropriate patient selection for treatment." | ( Biankin, AV; Biankin, SA; Head, DR; Henshall, SM; Hook, HC; Hugh, TB; Kench, JG; Lee, CS; Morey, AL; Sutherland, RL, 2002) |
| "Tumors established from two pancreatic cancer patients [Ontario Cancer Institute Pancreas number (OCIP#) 2 and OCIP#7] were treated with various combinations of the above three drugs and harvested for analyses of the following: the levels of phosphorylated and nonphosphorylated forms of EGFR, protein kinase B (PKB/Akt) and extracellular-regulated kinase (ERK1/2), and the extent of apoptosis using immunofluorescence image analysis and TUNEL assay, respectively." | ( Hedley, DW; Ng, SS; Nicklee, T; Tsao, MS, 2002) |
| "Patients with pancreatic cancer (n = 33), periampullary carcinoma (n = 1), or bile duct cancer (n = 2) were treated with 3-day conformal RT with 50." | ( Baum, U; Bautz, W; Brunner, TB; Grabenbauer, GG; Hohenberger, W; Klein, P; Papadopoulos, T; Sauer, R, 2003) |
| "In the early model, using the human pancreatic cancer lines MIA-PaCa-2 and BxPC-3, treatment began when the orthotopic primary tumor was approximately 7 mm in diameter." | ( Bouvet, M; Hoffman, RM; Moossa, AR; Nassirpour, R; Sun, FX; Tohgo, A; Yagi, S, 2003) |
| "AsPC-1 human pancreatic cancer cells, transfected with a PPRE-luciferase construct, demonstrated increased luminescence following treatment with PPARgamma ligands, indicating the presence of functional PPARgamma protein." | ( Evers, BM; Farrow, B, 2003) |
| "Forty-five advanced pancreatic cancer patients received this regimen for a total of 180 cycles of chemotherapy." | ( Barni, S; Beretta, GD; Cascinu, S; Catalano, G; Catalano, V; Ferraù, F; Foa, P; Frontini, L; Graziano, F; Labianca, R; Mare, M; Pancera, G; Priolo, D, 2003) |
| "A total of 57 patients (f/m 23/34) with pancreatic cancer was treated, of whom 33 patients had irresectable tumors, 19 patients following resection (R1 and/or pN+) and five patients with local recurrent disease." | ( Dühmke, E; Heinemann, V; Rau, HG; Stoffregen, C; Thoma, M; Wagner, A; Wilkowski, R, 2003) |
| "Moreover, pancreatic cancer cell invasiveness was significantly suppressed after treatment with a nontoxic dose of 15d-PGJ2, which was associated with a reduction of MMP-2 and MMP-9 protein levels and activity." | ( Ethridge, RT; Evers, BM; Hashimoto, K, 2002) |
| "Assessment of response to therapy of pancreatic cancer has been a difficult challenge." | ( el-Rayes, BF; Philip, PA; Shields, AF; Vaitkevicius, V, 2003) |
| "Recent advances have been made in the treatment of pancreas cancer." | ( Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD, 2003) |
| "In patients with resectable pancreatic cancer, particularly in UICC-stage II neoadjuvant radiochemotherapy, this results in an improvement in survival: the median survival is between 15 and 30 months." | ( Beger, HG; Gansauge, F; Poch, B; Schwarz, M, 2003) |
| "Advances in chemotherapy for pancreatic cancer have been limited." | ( Berlin, JD; Rothenberg, ML, 2003) |
| "A patient with liver metastasis of pancreatic cancer received chemotherapy using mitomycin C and degradable starch microspheres." | ( Aoki, T; Kato, F; Katsumata, K; Koyanagi, Y; Sumi, T; Suzuki, Y; Takagi, M; Tomioka, H; Yamasaki, T, 2003) |
| "Since pancreatic cancers are frequently discovered in an advanced stage, the expectations for chemotherapy are high." | ( Kumazawa, K; Ogawa, K; Shiozawa, S; Tsuchiya, A, 2003) |
| "Because of the resistance of pancreatic cancer against radiation and/or chemotherapy surgery is still the only possibility for cure." | ( Büchler, MW; Fischer, L; Friess, H; Uhl, W; Z'graggen, K, 2003) |
| "The analgetic treatment of inoperable pancreatic cancer patients is of paramount importance." | ( Krause, J; Kretzschmar, M; Palutke, I; Schirrmeister, W; Schramm, H, 2003) |
| "To improve the prognosis of pancreatic cancer, effective non-surgical therapy is necessary." | ( Ikenaga, SK; Maruyama, M; Odagiri, H; Sasaki, M; Sato, T, 2003) |
| "Forty-nine patients with unresectable pancreatic cancer (stage IV disease) received gemcitabine in a multi-center trial in the Fukuoka pancreatic cancer chemotherapy group, Japan." | ( Eriguchi, N; Funakoshi, A; Ito, T; Migita, Y; Mizumoto, K; Muranaka, T; Niyahara, T; Sakai, T; Shinozaki, H; Sumii, T; Tanaka, M; Ueki, T; Yamaguchi, H, 2003) |
| "A human pancreatic cancer cell line PC-3 was transfected with lipofectin-mediated recombinant p14ARF gene, and was then administered with 5-Fu." | ( Gan, J; Jin, C; Luo, J; Ni, Q; Shen, Z; Zhang, N; Zhang, Q; Zhang, Y, 2003) |
| "MIA-PaCa-2 human pancreatic cancer cells were treated with the proteasome inhibitor bortezomib either before, simultaneously or following exposure to gemcitabine." | ( Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S, 2003) |
| "Human pancreatic cancer cells (PANC-1, MIA PaCa-2, and SUIT-2) were treated with inhibitors of PKA (H89 or PKI) and cell growth, kinase activity, and induction of apoptosis measured." | ( Evers, BM; Farrow, B; Iwamura, T; Murillo, C; O'connor, KL; Rychahou, P, 2003) |
| "PPARgamma ligands inhibit pancreatic cancer cell invasion, suggesting that these agents may represent novel strategies to treat pancreatic cancer." | ( Evers, BM; Farrow, B; Hashimoto, K; Iwamura, T; O'Connor, KL, 2003) |
| "For locally advanced and nonresectable cancer of the pancreas, we performed intra-arterial infusion chemotherapy with angiotensin-II (AT-II)." | ( Imaoka, S; Ishikawa, O; Nakaizumi, A; Ohigashi, H; Sasaki, Y; Uehara, H; Yamada, T; Yokayama, S, 2003) |
| "Patients with pancreatic cancer are treated with combined treatment modalities." | ( Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E, 2003) |
| "In order to develop chemotherapy for pancreatic cancer, we are analyzing mRNA expression of pancreas cancer cell lines and examined their resistant against to GEM." | ( Abe, H; Akada, M; Egawa, S; Fukuyama, S; Matsuno, S; Motoi, F; Ottomo, S; Sunamura, M; Takeda, K, 2003) |
| "Metastatic or non-resectable (stage IV) pancreatic cancer has a rapidly fatal outcome (median survival: 3-6 months), thus making gene therapy a viable therapeutic option." | ( Cornelio, GH; Gordon, EM; Hall, FL; Levy, JP; Liu, L; Lorenzo, CC; Reed, RA, 2004) |
| "In locally advanced pancreatic cancer, the utilization of chemotherapy and radiotherapy is increasing, although in view of the reported long-term results of several contemporary trials, further improvements are certainly needed." | ( Adsay, V; Al-Sukhun, S; Ben-Josef, E; Forman, JD; Heilbrun, LK; Levin, K; Philip, PA; Shields, AF; Soulen, R; Vaitkevicius, VK; Weaver, D; Zalupski, MM, 2003) |
| "It is known that pancreatic cancer is resistant to chemotherapy and that cancer cells are surrounded by extracellular matrix (ECM) proteins including collagen I, collagen IV, fibronectin, and laminin." | ( Miyake, H; Miyamoto, H; Murakami, T; Sugino, H; Tashiro, S; Tsuchida, K, 2004) |
| "Unresectable cancer of the pancreas was treated with the combination of weekly paclitaxel and external beam irradiation in an effort to improve palliation and extend life expectancy." | ( Abrams, R; Doherty, M; Erickson, B; Harris, J; Paradelo, J; Rich, T; Safran, H; Small, W; Wanebo, HJ, 2004) |
| "These gene-modified pancreatic cancer cells were sensitive to the treatment of GCV compared with unmodified tumor cells (t=4." | ( Chen, DZ; Li, SF; Lu, XX; Wang, J; Zhang, LS, 2004) |
| "In conclusion, in a model of orthotopic pancreatic cancer in mice, we induced a tumour suppressive effect by treatment with a synthetic lipopeptide." | ( Behrens, P; Lee, KM; Märten, A; Mühlradt, PF; Sauerbruch, T; Schmidt, J; Schmidt, T; Schmidt-Wolf, IG; Schneider, C; Tiemann, K; Uhlinsky, V; Ziske, C, 2004) |
| "Between 2000 and 2002, a total of 30 pancreatic cancer patients were treated." | ( Dühmke, E; Heinemann, V; Rau, HG; Thoma, M; Wilkowski, R, 2004) |
| "We treated various pancreatic cancer cell lines with receptor-selective ligands and cytotoxic agents and monitored the effects on cell proliferation, markers of apoptosis and cell cycle." | ( Balasubramanian, S; Chandraratna, RA; Eckert, RL, 2004) |
| "Athymic nude mice bearing CaPan1 human pancreatic cancer xenografts were administered 2 mg of gemcitabine on days 0, 3, 6, 9 and 12 with concurrent (90)Y-DOTA-cPAM4 (100 microCi) provided on day 0." | ( Cardillo, TM; Gold, DV; Modrak, DE; Schutsky, K, 2004) |
| "Human estrogen-receptor (ER)-positive pancreatic cancer cells MiaPaCa-2 and ER-negative pancreatic cancer cells PANC-1 were treated by 0." | ( Dai, DJ; Guo, JM; Liu, Q; Ma, HH; Xiao, BX, 2004) |
| "We investigated whether pancreatic cancer cells activate the NF-kappaB pathway in response to chemotherapy and whether inhibition of this response altered the apoptotic efficacy of chemotherapy." | ( Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S, 2004) |
| "Part of the apoptotic resistance of pancreatic cancer may be mediated by activation of the NF-kappaB survival pathway in response to chemotherapy." | ( Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S, 2004) |
| "Flow cytometric analysis revealed that pancreatic cancer cells treated with 50 micromol/L LY294002 underwent G1 arrest, which was associated with dephosphorylation of the ppRB protein, a decrease in the protein expression of cyclin D and E, and their activating partners Cdk2, 4, and 6 with simultaneous accumulation of P27/Kip1." | ( Adachi, K; Honjo, S; Ito, H; Osaki, M; Takeda, A, 2004) |
| "BxPC-3 pancreatic cancer cells were pretreated with 30 micromol/L genistein for 24 hours and then exposed to lower concentrations of chemotherapeutic agents for an additional 24 hours." | ( Ali, S; El-Rayes, BF; Ellis, KL; Kucuk, O; Li, Y; Nedeljkovic-Kurepa, A; Philip, PA; Sarkar, FH, 2004) |
| "Patients with pancreatic cancer have a poor prognosis although systemic treatment has slightly improved the outcome for those with advanced pancreatic cancer, The approach to a patient with pancreatic cancer remains a great challenge." | ( Aerts, R; Haustermans, K; Topal, B; Van Cutsem, E; Van Steenbergen, W; Verslype, C, 2004) |
| "In all, 42 patients with pancreatic cancer that was unresectable but confined to the pancreatic region were treated with external-beam radiation (50." | ( Ikeda, H; Ikeda, M; Ito, Y; Kagami, Y; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2004) |
| "Treatment of BNIP3-negative pancreatic cancer cell lines with a DNA methylation inhibitor, 5-aza-2' deoxycytidine, restored hypoxia-induced BNIP3 expression." | ( Logsdon, CD; Okami, J; Simeone, DM, 2004) |
| "Thirty-six patients with advanced pancreatic cancer were randomized to two groups: brachy-chemotherapy group (n = 18) and control group (n = 18)." | ( Duan, XN; Liu, YH; Shen, WJ; Wan, YL; Wang, DM; Yang, YM; Yu, SP; Zhou, G, 2004) |
| "Advanced pancreatic cancer has limited treatment options." | ( Baranda, J; Garcia, AA; Leichman, CG; Leichman, L; Lenz, HJ; Pandit, L, 2003) |
| "The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria)." | ( Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S, 2004) |
| "Local therapy of pancreatic cancer with microencapsulated CYP2B1-producing cells and ifosfamide showed an effect both on the primary tumor and on distant metastatases." | ( Engel, A; Fabian, OV; Harms, W; Jesnowski, R; Löhr, M; Ringel, J; Ryschich, E; Saller, R; Schmidt, J; Schrewe, M, 2005) |
| "When pancreatic cancer cells were treated with a peptide antagonist of NF-kappaB nuclear translocation, or stably transfected with a dominant-negative mutant of MYC, their proliferation was markedly inhibited." | ( Abbruzzese, JL; Asano, T; Li, D; Reddy, SA; Yao, Y; Zhu, J, 2004) |
| "TZD treatment in pancreatic cancer cells has potent inhibitory effects on growth and invasiveness suggesting that these drugs may have application for prevention and treatment of pancreatic cancer in humans." | ( Casini, A; Ceni, E; Crabb, DW; Galli, A; Grappone, C; Mello, T; Milani, S; Salzano, R; Surrenti, C; Surrenti, E, 2004) |
| "PANC-1 and MIAPaCa-2 pancreatic cancer cells were treated with PGE(2) or rofecoxib, a selective COX-2 inhibitor." | ( Ashley, SW; Benoit, E; Clancy, TE; Duxbury, M; Ito, H; Whang, EE; Zinner, MJ, 2004) |
| "Human pancreatic cancer AsPC-1 cells were orthotopically injected into severe combined immunodeficient/beige mice to evaluate primary tumor growth and liver metastasis after treatment with rapamycin alone or in combination with anti-vascular endothelial growth factor antibody 2C3." | ( Brekken, RA; Datta, K; Li, J; Mukhopadhyay, D; Parangi, S; Stephan, S; Thorpe, PE; Wang, E, 2004) |
| "In the treatment of pancreatic cancer, further exploration of vitamin D analogues could be fruitful." | ( Albrechtsson, E; Axelson, J; Ohlsson, B, 2004) |
| "In conclusion, pancreatic cancer cell growth arrest and death are closely associated with a characteristic decrease in glycogen breakdown and glucose carbon re-distribution towards RNA/DNA and fatty acids during CP-320626 treatment." | ( Bassilian, S; Boren, J; Boros, LG; Cascante, M; Go, VL; Guo, P; Lee, ST; Lee, WN; Lim, S, 2004) |
| "Advanced pancreatic cancer is mainly treated by chemotherapy with poor prognosis." | ( Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX, 2004) |
| "Twenty patients with advanced pancreatic cancer were treated by selective continuous transarterial infusion chemotherapy." | ( Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX, 2004) |
| "Treatment of pancreatic cancer cells with 5-FU induced Caspase-dependent processing of pro-IL18 leading to the secretion of biologically active IL-18." | ( Addeo, A; Bellone, G; Bertetto, O; Carbone, A; Emanuelli, G; Gaspari, F; Mauri, FA; Novarino, A; Prati, A; Robecchi, A; Rodeck, U; Smirne, C; Sozzi, M, 2005) |
| "Patients with advanced pancreatic cancer who had not received chemotherapy and had acceptable organ function were eligible for the study." | ( Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ, 2005) |
| "The second included 42 patients with pancreatic cancer treated with single-agent octreotide (200 or 500 microg subcutaneously three times a day)." | ( Alberts, SR; Block, M; Burch, P; Foster, N; Jatoi, A; Kugler, J; Morton, R; Nguyen, PL, 2005) |
| "Eighteen patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy, received oxaliplatin 130 mg/m2 i." | ( Androulakis, N; Aravantinos, G; Georgoulis, V; Mallas, K; Polyzos, A; Stathopoulos, GP; Syrigos, K; Vamvakas, L; Ziras, N, 2005) |
| "Current treatment of pancreatic cancer is generally associated with poor prognosis, even if diagnosed early, owing to its aggressive rate of metastasis and non-responsiveness to chemotherapy and radiotherapy." | ( Ivanov, V; Kalinovsky, T; Niedzwiecki, A; Rath, M; Roomi, MW, 2005) |
| "Combined chemoradiotherapy of pancreatic cancer is a safe treatment with an acceptable profile of side effects when applied with modern planning and radiation techniques as well as considering tissue tolerance." | ( Dühmke, E; Heinemann, V; Thoma, M; Weingandt, H; Wilkowski, R, 2005) |
| "In this small series of pancreatic cancer patients, treatment with imatinib was not associated with a significant control of cancer progression." | ( Chen, J; Ebert, MP; Gschaidmeier, H; Hosius, C; Kahl, S; Malfertheiner, P; Nitsche, B; Röcken, C, 2006) |
| "Treatment of human pancreatic cancer cells with specific MEK inhibitor, PD98059 or U0126, inhibited ERK1/2 phosphorylation and cell growth." | ( Fukuda, M; Kohgo, Y; Motomura, W; Nagamine, M; Okumura, T; Takahashi, N; Tanno, S, 2005) |
| "Treatment of pancreatic cancer with the common dietary polyphosphorylated carbohydrate IP6 significantly decreased cellular growth and increased apoptosis." | ( Cunningham, C; Jackson, BJ; McFadden, DW; Riggs, DR; Somasundar, P; Vona-Davis, L, 2005) |
| "Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate." | ( Abbruzzese, JL; Crane, CH; Delclos, ME; Evans, DB; Ho, L; Tamm, EP; Wolff, RA; Wong, AA; Xiong, HQ, 2005) |
| "Data on 262 patients with advanced pancreatic cancer treated from 1987 to 2003 were analyzed retrospectively." | ( Barauskas, G; Brasiūniene, B; Juozaityte, E, 2005) |
| "Patients diagnosed with advanced pancreatic cancer in addition to surgical treatment should be treated by chemotherapy, concomitant chemoradiotherapy or radiotherapy." | ( Barauskas, G; Brasiūniene, B; Juozaityte, E, 2005) |
| "Patients with advanced pancreatic cancer previously treated with Gemcitabine were included in the study." | ( Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A, 2005) |
| "The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research." | ( Lopes, G; Rocha Lima, CM, 2005) |
| "Effective chemotherapy for pancreatic cancer is urgently needed." | ( Kawa, S; Kiyosawa, K; Nikaido, T; Yoshizawa, K, 2005) |
| "Unfortunately, >80% of pancreatic cancer patients bear inoperable, locally advanced, chemoresistant tumors demonstrating the urgent need for development of novel therapeutic approaches to treat this disease." | ( Andreeff, M; Evans, R; Gilbert, HF; Gribble, GW; Hail, N; Honda, T; Hsu, T; Konopleva, M; McQueen, T; Safe, S; Samudio, I; Shi, YX; Sporn, M, 2005) |
| "The actual cost of pancreatic cancer treatment was surveyed especially with respect to the difference after April 2001, which was the date that gemcitabine was introduced in Japan." | ( Furuse, J; Gotohda, N; Ishii, H; Kinoshita, T; Konishi, M; Nakachi, K; Nakagohri, T; Suzuki, E; Takahashi, S; Yoshino, M, 2005) |
| "To establish an effective therapy for pancreatic cancer, we made a retrospective survey of gemcitabine treatment performed at 20 hospitals in Nagano Prefecture." | ( Fujimori, Y; Furuta, K; Hanazaki, K; Hasebe, O; Hayashi, K; Hisa, T; Hosokawa, K; Kajikawa, S; Kaneko, G; Kawa, S; Kiyosawa, K; Maejima, S; Matsuda, Y; Miwa, S; Miyagawa, S; Mukawa, K; Ochi, Y; Shikama, N; Tajiri, K; Takeuchi, N, 2005) |
| "The use of chemoradiotherapy for pancreatic cancer has been advocated for its potential ability to downstage locally advanced tumors." | ( Adhoute, X; Béllannée, G; Brunet, R; Collet, D; Laurent, C; Masson, B; Rault, A; Sa Cunha, A; Vendrely, V, 2005) |
| "Hepatocellular carcinoma (HCC) and pancreatic cancer are at the forefront of chemotherapy-resistant tumors with poor prognosis." | ( Imazeki, F; Kanda, T; Nagao, K; Saisho, H; Tada, M; Yokosuka, O, 2005) |
| "Resiniferatoxin induced apoptosis in pancreatic cancer cells indicates that vanilloids may be useful in the treatment of human pancreatic cancer." | ( Büchler, MW; di Mola, FF; Di Sebastiano, P; Felix, K; Friess, H; Giese, NA; Hartel, M; Hinz, U; Mascetta, G; Selvaggi, F; Wente, MN, 2006) |
| "Although approved for the treatment of pancreatic cancer, the chemotherapeutic agent ifosfamide is not an effective therapy for this type of tumour." | ( Günzburg, WH; Salmons, B, 2005) |
| "Conditioned media from pancreatic cancer cells pretreated with IL-1alpha remarkably stimulated in vitro HUVECs growth." | ( Funahashi, H; Manabe, T; Matsuo, Y; Okada, Y; Sakamoto, M; Sawai, H; Takeyama, H; Yamamoto, M, 2005) |
| "The human pancreatic cancer cell lines Hs 700T, PANC-1, and MIA PaCa-2 were treated in vitro with NV1066 at multiplicities of infection (MOI; ratio of the number of viral particles per tumor cell) ranging from 0." | ( Adusumilli, PS; Chan, MK; Chou, TC; Eisenberg, DP; Fong, Y; Hendershott, KJ; Mullerad, M; Yu, Z, 2005) |
| "Sixty-seven unresectable or metastatic pancreatic cancer patients treated with gemcitabine were included in the study and a total of 258 cycles of treatment were applied." | ( Goker, E; Goksel, G; Karabulut, B; Sanli, UA; Sezgin, C; Uslu, R; Yuzer, Y, 2005) |
| "Here we report a case of unresectable pancreatic cancer treated with gemcitabine on the basis of a drug sensitivity test." | ( Hyodo, M; Koizumi, M; Kurihara, K; Nagai, H; Sata, N; Shimura, K; Tsukahara, M; Yasuda, Y; Yoshizawa, K, 2005) |
| "Treatment options for pancreatic cancer are limited and often ineffective." | ( Buer, J; Gamrekelashvili, J; Garbe, AI; Greten, FR; Greten, TF; Korangy, F; Manns, MP; Schmid, RM; Vermeer, B; von Wasielewski, R; Westendorf, AM, 2006) |
| "Patients with invasive ductal pancreatic cancer who underwent radical surgery with clear histological margins at 11 Japanese institutions were enrolled and randomly assigned to one of two groups: surgery-alone group (no further treatment after surgery) and the surgery + chemotherapy group [two courses of postoperative adjuvant systemic chemotherapy with cisplatin (80 mg/m(2), Day 1) and 5-fluorouracil (500 mg/m(2)/day, Days 1-5)]." | ( Kakizoe, T; Kiuchi, T; Kosuge, T; Mukai, K, 2006) |
| "Human pancreatic cancer PANC-1 cells were treated by various concentrations of ATRA, and then the cell growth was determined by MTT viability assay." | ( Guo, J; Lou, Y; Wang, D; Xiao, B; Yan, C; Zhan, L; Zhao, W, 2006) |
| "Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival." | ( Hirono, S; Ina, S; Kawai, M; Tani, M; Terasawa, H; Uchiyama, K; Yamaue, H, 2006) |
| "The role of adjuvant therapy in pancreatic cancer remains controversial." | ( Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T, 2006) |
| "The patient diagnosed as recurrent pancreatic cancer was treated with UFT combined gemcitabine (GEM) chemotherapy." | ( Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T, 2006) |
| "In the mouse model for pancreatic cancer, treatment with tolfenamic acid (50 mg/kg of body weight), compared with control treatment, statistically significantly decreased tumor growth and weight (P = ." | ( Abbruzzese, JL; Abdelrahim, M; Baker, CH; Safe, S, 2006) |
| "However, it would obviously decrease in pancreatic cancer patients after chemotherapy (P < 0." | ( Cai, LZ; Fu, YW; Liang, QL; Liu, GX; Pan, DC; Xie, JR; Yang, Q; Yin, ZM, 2006) |
| "At present, the advanced pancreatic cancer is known to be one of the most resistant malignancies on chemotherapy." | ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasada, T; Yamada, Y; Yamamitsu, S, 2006) |
| "Resected pancreatic cancers from 14 patients were xenografted and expanded in successive groups of nude mice to develop cohorts of tumor-bearing mice suitable for drug therapy in simulated early clinical trials." | ( Altiok, S; Amador, ML; Bouraoud, N; Cusatis, G; Danenberg, K; Danenberg, PV; Eshleman, J; Hidalgo, M; Hruban, RH; Iacobuzio-Donahue, C; Jimeno, A; Karikari, C; Kulesza, P; Kuramochi, H; Maitra, A; Messersmith, W; Rubio-Viqueira, B; Salimi-Moosavi, H; Shi, C; Singh, S; Tanaka, K; Yeo, C; Zhang, X, 2006) |
| "In this study, we treated pancreatic cancer cells (L3." | ( Chu, W; Di, W; Healey, S; Kouttab, N; Qiu, L; Scheffler, E; Sun, Y; Wan, Y; Wanebo, H; Zhou, C, 2006) |
| "Human pancreatic cancer MiaPaCa-2 cells were treated with 1, 5, 10, 20, 30, 40 and 50 microM ATRA for 1, 2, 3, 4, 5 or 6 d, respectively." | ( Guo, JM; Lou, YR; Wang, DH; Xiao, BX; Yan, CH; Zhan, L; Zhao, WH, 2006) |
| "In two patients with advanced pancreatic cancer with cervical lymph node or liver metastasis and no indication of pancreatic resection and radiotherapy, oral treatment with S-1 (an anti-cancer agent of fluoropyrimidine derivative) exerted high anti-tumor activity on the metastatic lesions." | ( Funakoshi, A; Senju, T; Sumii, T, 2006) |
| "We report two metastatic pancreatic cancer patients who showed marked tumor shrinkage following administration of the oral fluorinated pyrimidine anticancer drug, S-1." | ( Ikeda, M; Ueno, H, 2006) |
| "Recently, the European Study Group for Pancreatic Cancer 1 trial demonstrated substantially increased survival from adjuvant chemotherapy with 5-fluorouracil-folinic acid and preliminary data showed prolonged disease-free survival from adjuvant gemcitabine." | ( Eckel, F; Schmid, RM; Schneider, G, 2006) |
| "Patients with locally advanced pancreatic cancer who received gemcitabine chemotherapy or 5-FU-based CCRT showed better survival than those who received supportive care only." | ( Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB, 2006) |
| "The 18 recurrent pancreatic cancer patients treated by gemcitabine were divided into 2 groups by RRM1 levels." | ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, Y; Takemasa, I; Tsujie, M; Umeshita, K; Yamasaki, M; Yoshioka, S, 2007) |
| "Thirty patients with unresectable pancreatic cancer, who presented with jaundice and underwent chemotherapy using GEM after EBD were included in this study (GEM group)." | ( Fujita, N; Horaguchi, J; Ito, K; Kobayashi, G; Noda, Y; Takasawa, O, 2006) |
| "Thus far, the therapy of pancreatic cancer remains an insurmountable challenge." | ( Abe, M; Baranowska-Kortylewicz, J; Enke, CA; Nearman, J, 2007) |
| "The improved responses of pancreatic cancer xenografts to the multimodality treatment comprising radioimmunotherapy and platelet-derived growth factor receptor-beta inhibition suggest that this approach to therapy of pancreatic cancer may also be successful in patients." | ( Abe, M; Baranowska-Kortylewicz, J; Enke, CA; Nearman, J, 2007) |
| "Thirty-three patients with metastatic pancreatic cancer (22 men and 11 women) were treated and 31 were evaluable." | ( Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T, 2007) |
| "To establish pancreatic cancer in mice, dimethylbenzanthracene (DMBA) was administered into mice pancreata." | ( Endoh, M; Hamada, S; Hirota, M; Kanno, A; Kimura, K; Masamune, A; Satoh, K; Shimosegawa, T, 2007) |
| "The combined treatment of the pancreatic cancer cells with L1BR1 and these anticancer drugs enhanced apoptosis significantly." | ( Fujii, T; Goshima, F; Kanazumi, N; Kasuya, H; Nakao, A; Nishiyama, Y; Nomoto, S; Nomura, N; Shikano, T; Takeda, S; Watanabe, I, 2007) |
| "MIA PaCa2, CFPAC-1 and Capan-1 pancreatic cancer cell lines were treated with GEM, fluouracil (5-FU), docetaxel (DCT), oxaliplatin (OXP), irinotecan (CPT-11), pemetrexed (PMX) and raltitrexed (RTX) as single agent." | ( Beghelli, S; Dandrea, M; Di Carlo, V; Formicola, R; Mercalli, A; Piemonti, L; Reni, M; Scarpa, A; Sordi, V, 2007) |
| "Proliferation assays of five human pancreatic cancer cell lines were performed following treatment with erlotinib." | ( Arnoletti, JP; Buchsbaum, DJ; Cannon, EE; Frolov, A; Heslin, MJ; Howard, JH; Ku, BC; Schuller, K; Tzeng, CW; Vickers, SM, 2007) |
| "Treatment of locally advanced pancreatic cancer is challenging." | ( Kim, R; Saif, MW, 2007) |
| "We report a resected case of advanced pancreatic cancer after successful chemotherapy." | ( Aikou, T; Kitazono, M; Maemura, K; Mataki, Y; Noma, H; Shinchi, H; Takao, S, 2007) |
| "22 patients with advanced pancreatic cancer were subjected to concurrent chemoradiotherapy (GEM 1,000 mg/m(2) weekly, three times during 4 weeks)." | ( Iishi, H; Ioka, T; Ishikawa, O; Koizumi, M; Nakaizumi, A; Nishiyama, K; Ohigashi, H; Tanaka, E; Uehara, H; Yamazaki, H, 2007) |
| "Although surgical techniques for pancreatic cancer have developed in a high level, the treatment results have not been improved and the 5 year survival rates after curative operation has been about 15% in Japan." | ( Nimura, Y, 2007) |
| "Ten patients with advanced pancreatic cancer (4 in Stage IVa and 6 in Stage IVb) were treated with this new regimen." | ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Koito, K; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| "To improve the prognosis of pancreatic cancer, there is the need to develop effective non-surgical treatment for this disease." | ( Fritsch, R; Hamacher, R; Reichert, M; Saur, D; Schmid, RM; Schneider, G, 2007) |
| "A new era in the treatment of advanced pancreatic cancer commenced a decade ago with the advent of gemcitabine as a standard of care." | ( Abou-Alfa, GK; O'Reilly, EM, 2007) |
| "The lack of effective treatment for pancreatic cancer results in a very low survival rate." | ( Ding, I; Fenton, BM; Keng, P; Li, X; Lin, L; Okunieff, P; Paoni, SF; Su, Y; Wang, C; Wang, W; Xiao, Z; Yang, S; Zhang, L, 2007) |
| "In vitro AsPC-1 human pancreatic cancer cells were treated with triptolide alone, IR alone, or triptolide plus IR." | ( Ding, I; Fenton, BM; Keng, P; Li, X; Lin, L; Okunieff, P; Paoni, SF; Su, Y; Wang, C; Wang, W; Xiao, Z; Yang, S; Zhang, L, 2007) |
| "A mouse model of pancreatic cancer with peritoneal dissemination was used to evaluate the in vivo effect of the combination therapy." | ( Kanazumi, N; Kasuya, H; Nakao, A; Nomoto, S; Nomura, N; Shikano, T; Shirota, T; Sugimoto, H; Takeda, S; Watanabe, I, 2008) |
| "Patients with previously untreated pancreatic cancer received gemcitabine days 1, 8, and 15, and oxaliplatin days 1 and 15, repeated at 28-day intervals." | ( Ben-Josef, E; Chang, AE; Colletti, LM; Desai, SP; Francis, IR; Greenson, JK; Lawrence, TS; Normolle, DP; Simeone, DM; Zalupski, MM, 2007) |
| "In the absence of known pancreatic cancer EGFR activating mutations, we sought to identify alternative factors, such as increased gene copy number (genomic gain) and ligand overexpression, which could be associated with aberrant EGFR pathway activation and improved response to targeted therapy." | ( Arnoletti, JP; Buchsbaum, DJ; Frolov, A; Frolova, N; Heslin, MJ; Howard, JH; Jhala, NC; Tzeng, CW; Vickers, SM, 2007) |
| "Overexpression of BCL-2 is common in pancreatic cancer and confers resistance to the apoptotic effect of chemo- and radiotherapy." | ( Bold, RJ; Galante, JG; Gilad, O; Kung, HJ; Mortenson, MM; Schlieman, MG; Virudachalam, S, 2007) |
| "Archived human pancreatic cancer specimens were used to assess gene expression and microvessel density (MVD) status by immunohistochemistry: Small-interfering RNA (siRNA) was used to determine the impact of altered Sp1 expression on tumor growth and angiogenesis, and mithramycin A (MIT) was used to evaluate Sp1-targeted antiangiogenic treatment of human pancreatic cancer in animal models." | ( Jia, Z; Le, X; Li, Q; Wang, H; Wang, L; Wei, D; Xie, K; Yao, J; Yuan, P; Zhang, J, 2007) |
| "We analyzed pancreatic cancer xenografts for growth delay and microvessel density after treatment with enzastaurin, radiation, or both." | ( Ben-Josef, E; Davis, ME; Kim, AC; Lawrence, TS; Spalding, AC; Watson, R, 2007) |
| "We hypothesize that pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies." | ( Dixon, J; Holcomb, B; Kennard, J; Mahomed, J; Matos, JM; Schmidt, CM; Sebolt-Leopold, J; Shanmugam, R; Yip-Schneider, MT, 2008) |
| "Median as well as overall survival of pancreatic cancer patients in the advanced stage is extremely low despite advances in cancer therapy regarding tumor cell biology, therapy resistance, and diagnosis." | ( Heinemann, V; Wilkowski, R; Wolf, M, 2008) |
| "For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life." | ( Benson, AB; Small, W; Wahl, AO; Wisinski, KB, 2007) |
| "We treated 4 cases of advanced pancreatic cancer: 2 cases were nonresectable and the other 2 cases did not choose an operation but arterial infusion chemotherapy with gemcitabine after the transcatheter peripancreatic arterial embolizaiton." | ( Doi, K; Kudoh, K; Matsuo, A; Muranaka, T; Ogata, K; Ohchi, T; Ohtao, R, 2007) |
| "Transgenic RIP1-Tag2 spontaneous pancreatic cancer mice were treated with geldanamycin (GA, 5 mg/kg) and /or 3-Bromo-pyruvate (3-BrPA, 5 mg/kg) from 8 to 12 weeks of age." | ( Cao, X; Cheng, H; Jia, G; Knopp, MV; Sun, D; Wang, B; Wassenaar, PA; Yang, M; Zhang, T, 2008) |
| "More importantly, the treatment of pancreatic cancer cells with Plk-1 siRNA followed by exposure to gemcitabine dramatically decreased cell viability and increased cellular apoptosis, as compared with treatment with either agent alone." | ( Dai, C; Du, Q; Gardner, K; Guo, X; Jacobs, JL; Jiang, K; Li, H; Li, QQ; Miao, Y; Qian, Z; Sun, G; Xu, Z; You, Y; Yu, C; Yuan, D; Zhang, X; Zhu, Y, 2008) |
| "In this study, malignant human pancreatic cancer cells were treated without or with resveratrol in combination with ionizing radiation (IR), and then the mitochondrial function of treated cells was evaluated using several standardized assays." | ( Keng, P; Kim, J; Liu, C; Okunieff, P; Sun, W; Wang, W; Yang, S; Zhang, H; Zhang, L, 2008) |
| "Although the prognosis in patients with pancreatic cancer has been poor, we recently reported unusually high response rate and survival benefit of S-1 treatment in patients with pancreatic cancer." | ( Danenberg, KD; Danenberg, PV; Hatori, T; Hayashi, K; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M, 2008) |
| "Thirty-three recurrent pancreatic cancer patients treated with S-1 were studied." | ( Danenberg, KD; Danenberg, PV; Hatori, T; Hayashi, K; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M, 2008) |
| "Current therapy for advanced pancreatic cancer focuses largely on gemcitabine." | ( Alsamarai, S; Furuie, T; Saif, MW; Urrea, PD; Zergebel, C; Zhang, J, 2008) |
| "However, the role of radiotherapy in pancreatic cancer is increasingly doubted, especially after the introduction of gemcitabine to both domains." | ( Chie, EK, 2008) |
| "In advanced pancreatic cancer, single-agent gemcitabine became the standard therapy approximately 10 years ago." | ( Burris, H; Rocha-Lima, C, 2008) |
| "By today, systemic therapy for pancreatic cancer remains a huge challenge considering the last 10 years existing data." | ( Van Laethem, JL, 2008) |
| "PEFG regimen in gemcitabine refractory pancreatic cancer had an acceptable toxicity profile and interesting activity, and may constitute a treatment option in this setting." | ( Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A, 2008) |
| "Treatment options for unresectable pancreatic cancer, including concurrent chemoradiotherapy, chemotherapy alone, and chemotherapy followed by chemoradiotherapy, are largely ineffective and result in a median survival of approximately 10-12 months." | ( Ben-Josef, E; Lawrence, TS, 2008) |
| "In our cohort of patients with advanced pancreatic cancer treated with second-line chemotherapy, TTP1 <6 months is a strong negative prognostic factor for TTP2 and residual survival." | ( Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W, 2007) |
| "The relatively low incidence of pancreatic cancer and the assumption of treating only 23% of these patients with erlotinib were likely the principal reasons for the low budgetary impact of erlotinib." | ( Danese, MD; Lin, CY; Lubeck, D; Northridge, K; O'Connor, P; Reyes, C, 2008) |
| "In advanced pancreatic cancer, level one evidence has established a significant survival advantage with chemotherapy, compared to best supportive care." | ( Cunningham, D; Ghaneh, P; Neoptolemos, JP; Starling, N; Sultana, A; Tudur Smith, C, 2008) |
| "Finally, E3330 treatment inhibits pancreatic cancer cell migration as assessed by in vitro chemokine assays." | ( Maitra, A; Zou, GM, 2008) |
| "Patients with metastatic pancreatic cancer have poor prognosis and short survival due to lack of effective therapy and aggressiveness of the disease." | ( He, AR; Lindenberg, AP; Marshall, JL, 2008) |
| "Efficacy of chemotherapy for pancreatic cancer may be improved by tailoring it to individual chemosensitivity profiles." | ( Erkan, M; Friess, H; Giese, NA; Giese, T; Kleeff, J; Michalski, CW; Sartori, C; Sauliunaite, D; Stratmann, R, 2008) |
| "Treatment of mice with pancreatic cancer doubled their survival (P<0." | ( Ala-Aho, R; Diaconu, I; Hakkarainen, T; Hemminki, A; Jalonen, H; Jokinen, M; Kähäri, VM; Kanerva, A; Kangasniemi, L; Koskinen, M; Moilanen, H; Pesonen, S; Stenman, UH; Toriseva, M; Ylä-Herttuala, S, 2009) |
| "Liver perfusion chemotherapy (LPC) for pancreatic cancer has been rarely undertaken in a postoperative adjuvant setting." | ( Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N, 2009) |
| "Patients with previously untreated pancreatic cancer received gemcitabine (1 000 mg/m(2) i." | ( Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Sakamoto, T; Shiba, H; Uwagawa, T; Wakiyama, S; Yanaga, K, 2009) |
| "Patients with measurable metastatic pancreatic cancer, progressive after previous gemcitabine-based chemotherapy were treated with irinotecan 150 mg/m(2) every 2 weeks." | ( Chang, MH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lee, JK; Lee, KT; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY, 2009) |
| "A 60-year-old man with pancreatic cancer was admitted due to massive ascites in the course of gemcitabine treatment." | ( Kayahara, M; Kitagawa, S; Minato, H; Mouri, H; Ohta, T; Ohtsubo, K; Tsuchiyama, T; Watanabe, H, 2008) |
| "Human pancreatic cancer cells were treated with apigenin and then underwent glucose uptake assays." | ( Bentrem, DJ; Ding, XZ; Melstrom, LG; Milam, BM; Pelling, JC; Salabat, MR; Strouch, M, 2008) |
| "Locally invasive pancreatic cancer without distant metastases or major arterial invasion is treated most effectively by surgical resection." | ( Aikou, T; Aiura, K; Aoki, T; Asano, T; Doi, R; Funakoshi, A; Hatori, T; Higashide, S; Hirata, K; Hishinuma, S; Hosotani, R; Ikeda, S; Imaizumi, T; Imamura, M; Kakita, A; Maetani, S; Maguchi, H; Matsusue, S; Noda, H; Ogata, Y; Ozaki, M; Sasaki, M; Sunamura, M; Takao, S; Takasaki, K; Tanaka, M; Wakasugi, H; Yamaguchi, K; Yoshida, S, 2008) |
| "We report a patient with pancreatic cancer, challenged with maintaining the international normalized ratio (INR) with gemcitabine-capecitabine combination, and later with gemcitabine monotherapy with concomitant warfarin, as well as, a brief review of the literature." | ( Saif, MW; Wasif, N, 2008) |
| "Patients with locally advanced pancreatic cancer were treated with concurrent radiation therapy (1." | ( Boku, N; Fukutomi, A; Hashimoto, T; Hironaka, S; Nishimura, T; Onozawa, Y; Taira, K; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008) |
| "Current treatments for pancreatic cancer have failed to effectively manage the disease, and hence, more effective treatment approaches are urgently needed." | ( Campbell, RB; Kalra, AV, 2009) |
| "Treatment of pancreatic cancer cells with CC-8075 and CC-8062 reduces their proliferation and increases apoptosis that is caspase dependent in T3M4 cells." | ( Bartlett, JB; Colston, KW; Dalgleish, AG; Man, HW; Mouratidis, PX; Muller, GW; Stirling, D, 2009) |
| "Human pancreatic cancer cells (BxPC-3, AsPC-1, Capan-2, MiaPaCa-2, and Panc-1) and immortalized human pancreatic cells (HPDE-6) were treated with vehicle or with BITC at 5-40 microM, cell survival was evaluated by sulforhodamine B assay, and apoptosis by caspase-3 and poly-ADP ribose polymerase cleavage or by a commercial assay for cell death." | ( Sahu, RP; Srivastava, SK, 2009) |
| "Despite rapid advances in many fronts, pancreatic cancer (PC) remains one of the most difficult human malignancies to treat due, in part, to de novo and acquired chemoresistance and radioresistance." | ( Abbruzzese, JL; Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Gallick, GE; Kong, D; Li, Y; Sarkar, FH; Wang, Z, 2009) |
| "A subgroup of patients with metastatic pancreatic cancer has prolonged survival after treatment with gemcitabine." | ( Clark, JW; Goulart, BH; Grenon, N; Lauwers, GY; Muzikansky, A; Ryan, DP; Zhu, AX, 2009) |
| "The European Study Group for Pancreatic Cancer (ESPAC-1) study is the largest study of adjuvant treatment for pancreatic ductal adenocarcinoma to date and confirmed a survival advantage for adjuvant chemotherapy but not for chemoradiation." | ( Bassi, C; Bramhall, SR; Büchler, MW; Carter, R; Dervenis, C; Friess, H; Ghaneh, P; Kelemen, D; Neoptolemos, JP; Olah, A; Spry, N; Stocken, DD, 2009) |
| "We found that the treatment of pancreatic cancer cells with GSK-3beta inhibitors 5 and 26 resulted in suppression of GSK-3beta activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis." | ( Billadeau, DD; Blond, SY; Gaisina, IN; Gallier, F; Guo, S; Holzle, D; Kim, KH; Kozikowski, AP; Kurome, T; Luchini, DN; Ougolkov, AV, 2009) |
| "Defeating pancreatic cancer resistance to the chemotherapeutic drug gemcitabine remains a challenge to treat this deadly cancer." | ( Bousquet, C; Brizuela, L; Cuvillier, O; Davenne, L; Delisle, MB; Guilbeau-Frugier, C; Guillermet-Guibert, J; Pchejetski, D; Saint-Laurent, N; Susini, C, 2009) |
| "We orthotopically transplanted pancreatic cancer cells stably transfected with a HIF-1-dependent luciferase reporter gene and monitored HIF-1 activity in vivo in control and POP33-treated mice." | ( Hiraoka, M; Hirota, K; Itasaka, S; Kizaka-Kondoh, S; Semenza, GL; Shibuya, K; Takahashi, Y; Tanaka, S; Zeng, L; Zhao, T, 2009) |
| "Overall survival in the pancreatic cancer group is comparable to results obtained with gemcitabine monotherapy." | ( Pawlega, J; Zygulska, AL, 2008) |
| "Patients with advanced pancreatic cancer who were refractory to prior gemcitabine- and 5-FU- based chemotherapy were enrolled in this study." | ( Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2010) |
| "Sixteen patient-derived pancreatic cancer xenografts from the PancXenoBank collection at Johns Hopkins were treated with AZD0530 (50 mg/kg/day, p." | ( De Oliveira, E; Green, TP; Hidalgo, M; Jimeno, A; Messersmith, WA; Morgan, S; Rajeshkumar, NV; Tan, AC; Walker, J; Warren, MV; Womack, C; Wombwell, H, 2009) |
| "After 7 days of treatment, the pancreatic cancer had regressed without the need of chemotherapy or any other treatment." | ( Bouvet, M; Hayashi, K; Hoffman, RM; Nagakura, C; Tomita, K; Tsuchiya, H; Yamamoto, N; Yamauchi, K; Zhao, M, 2009) |
| "In 23 patients with resectable pancreatic cancer, the serum concentration of REG4 was measured before preoperative chemoradiotherapy, and the histologic response was evaluated after the surgery." | ( Eguchi, H; Ishikawa, O; Nakagawa, H; Nakamura, Y; Nishiyama, K; Ohigashi, H; Takahashi, H; Takehara, A; Tomita, Y; Uehara, R; Yano, M, 2009) |
| "Majority of the patients with pancreatic cancer present with advanced disease that is lethal and notoriously difficult to treat." | ( Li, J; Saif, MW, 2009) |
| "The prognosis for advanced pancreatic cancer with peritoneal dissemination is extremely poor, and no effective standard therapy has been established." | ( Inaba, K; Konno, H; Okamoto, N, 2009) |
| "Human pancreatic cancer cell line murine xenografts were treated with recombinant EMAP II (80 mug/kg), gemcitabine (100 mg/kg), or a combination, and survival and local tumor outcomes were studied." | ( Awasthi, N; Cafasso, D; Konduri, S; Schwarz, MA; Schwarz, RE, 2009) |
| "Patients with locally advanced pancreatic cancer without duodenal invasion were treated with 50." | ( Crane, CH; Curran, W; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, K; Wolff, RA, 2009) |
| "NF-kappaB activation in pancreatic cancer cells treated with various agents was examined by electrophoretic mobility shift assay (in vitro) and immunohistochemistry by investigating the location of p65 in cancer cells (in vivo)." | ( Chiao, PJ; Gocho, T; Hirohara, S; Misawa, T; Uwagawa, T; Yanaga, K, 2009) |
| "Treatment of human pancreatic cancer cells (PANC-1, MIAPaCa-2, and BxPC-3) with insulin (10 ng/mL) for 5 minutes markedly enhanced the increase in intracellular [Ca(2+)] induced by GPCR agonists (e." | ( Eibl, G; Kisfalvi, K; Rozengurt, E; Sinnett-Smith, J, 2009) |
| "Of 55 patients who had inoperable pancreatic cancer, 23 elected gemcitabine-based chemotherapy, and 32 elected enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet." | ( Antman, KA; Chabot, JA; Chen, C; Fine, RL; Grann, VR; Kumah, CK; Tsai, WY, 2010) |
| "Advanced unresectable pancreatic cancer has an extremely poor prognosis despite intensive chemotherapy." | ( Abe, Y; Arita, Y; Baba, E; Choi, I; Harada, M; Ito, T; Kawabe, K; Miyamoto, T; Nagafuji, K; Nakano, S; Teshima, T, 2009) |
| "Treatment of MIA PaCa-2 human pancreatic cancer cells with test compounds showed time- and concentration-dependent cytotoxicity with IC50 values in the micromolar range." | ( Banti, I; Breschi, MC; Fogli, S; Lapucci, A; Nencetti, S; Orlandini, E, 2009) |
| "BF in pancreatic cancer is significantly reduced compared with the normal pancreas, which may in part explain the poor success of both radiotherapy and chemotherapy." | ( Kajander, S; Kauhanen, S; Komar, G; Liukko, K; Minn, H; Nuutila, P; Ovaska, J; Seppänen, M, 2009) |
| "Gemcitabine (G) is standard therapy for pancreatic cancer." | ( Asmar, L; Becerra, C; Boehm, KA; Gersh, RH; Gill, JF; Hozak, RR; Kuefler, PR; Mullaney, BP; Myrand, SP; Nicol, SJ; Obasaju, CK; Richards, DA; Wilfong, LS; Zhan, F; Zhao, L, 2011) |
| "Effect of MUC4 on pancreatic cancer cells resistance to gemcitabine was studied in MUC4-expressing and MUC4-knocked down pancreatic cancer cell lines after treatment with gemcitabine by Annexin-V staining, DNA fragmentation assay, assessment of mitochondrial cytochrome c release, immunoblotting and co-immunoprecipitation techniques." | ( Bafna, S; Batra, SK; Kaur, S; Momi, N, 2009) |
| "S-1 treatment for unresectable/advanced pancreatic cancer served to prolong the survival period, suggesting it enabled extension of the recuperation-at-home period." | ( Imamoto, R; Kanbe, T; Kishimoto, Y; Kojo, H; Mukouyama, T; Nishimuki, E; Shabana, M; Tsunoda, H, 2009) |
| "Gemcitabine is a standard therapy for pancreatic cancer." | ( Boytim, ML; Cohen, SJ; Conkling, P; Davis, P; Dorr, RT; Hersh, EM; Modiano, MR; Patt, YZ; Zalupski, MM, 2010) |
| "The treatment of locally advanced pancreatic cancer varies enormously both within the UK and internationally." | ( Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S, 2010) |
| "This combination therapy for pancreatic cancer patients was tolerable at all doses." | ( Hirono, S; Kawai, M; Miyazawa, M; Nakamura, Y; Ohsawa, R; Tani, M; Tsunoda, T; Yamaue, H, 2010) |
| "Silencing of LOXL2 in pancreatic cancer cells resulted in an augmented sensitivity toward gemcitabine treatment, with significantly elevated cell death and reduced viable cells." | ( Grützmann, R; Joensson, P; Pilarsky, C; Rückert, F; Saeger, HD, 2010) |
| "However, pancreatic cancer is resistant to apoptosis including anti-death receptor therapy." | ( Borja-Cacho, D; Chugh, RK; Clawson, KA; Dawra, RK; Dudeja, V; Mujumdar, NR; Saluja, AK; Vickers, SM; Yokoyama, Y, 2010) |
| "Human pancreatic cancer is refractory to chemotherapy partly because of blockage to penetration of anticancer agents." | ( Koga, Y; Kuroda, J; Matsumura, Y; Saito, Y; Yasunaga, M, 2010) |
| "We report a long-term survival case of pancreatic cancer with hepatic metastasis after surgical resection treated by S-1 and gemcitabine combination chemotherapy." | ( Doki, Y; Eguchi, H; Hoshino, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K, 2009) |
| "We report a case of unresectable pancreatic cancer who survived for 29 months after a successful treatment by concurrent chemo-radiotherapy by gemcitabine and systemic administration of gemcitabine." | ( Ami, K; Ando, M; Fukuda, A; Ganno, H; Hataji, K; Maruyama, M; Nagahama, T; Ohara, T, 2009) |
| "The prognosis of pancreatic cancer remains poor, and the standard first-line chemotherapy with gemcitabine (GEM) has a response rate of less than 20%." | ( Funamizu, N; Gocho, T; Kamata, Y; Manome, Y; Misawa, T; Okamoto, A; Uwagawa, T; Yanaga, K, 2010) |
| "shRNA-mediated silencing of RON in pancreatic cancer xenografts inhibited their growth, primarily by increasing susceptibility to apoptosis and by sensitizing them to gemcitabine treatment." | ( Aronow, B; French, R; Hoffman, RM; Jaquish, D; Logan-Collins, J; Lowy, AM; McClaine, R; Mose, E; Stuart, W; Thomas, RM; Waltz, SE; Yu, P, 2010) |
| "Treatment of pancreatic cancer cells in vitro with Pterostilbene leads to inhibition of cell proliferation and/or cell death, cell cycle arrrest, mitochondrial membrane depolarization, and activation of effector caspases." | ( Alosi, JA; Mannal, PW; McDonald, DE; McFadden, DW; Schneider, JG, 2010) |
| "Patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy are still in relatively good clinical conditions and may still require second-line chemotherapy, which is frequently administered in daily clinical practice given to without solid scientific support." | ( Arcara, C; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E, 2010) |
| "Adjuvant therapy for pancreatic cancer remains a controversial topic, with a paucity of randomized controlled trials in this area and various limitations in the trials that have been conducted to date, leaving many questions as to a true "standard of care" for patients with resectable or potentially resectable disease." | ( Backlund, DC; Berlin, JD; Parikh, AA, 2010) |
| "Advanced pancreatic cancer is usually treated with first-line gemcitabine (GEM) (alone or in combination)." | ( Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F, 2010) |
| "Patients with previously untreated pancreatic cancer (n = 12) received gemcitabine intravenously on days 1, 8, and 15." | ( Hayashi, N; Hayashi, Y; Iijima, H; Inoue, T; Kitagawa, T; Konishi, K; Nishida, T; Takeda, Y; Tsujii, M; Tsutsui, S; Yamamoto, K; Yoshioka, Y, 2010) |
| "Novel targets for pancreatic cancer therapy are urgently needed." | ( Kisfalvi, K; Rozengurt, E; Sinnett-Smith, J, 2010) |
| "Current chemotherapy regimens against pancreatic cancer are met with little success as poor tumor vascularization significantly limits the delivery of oncological drugs." | ( Aryal, S; Bouvet, M; Esener, S; Hu, CM; Kaushal, S; Sartor, M; Tran Cao, HS; Zhang, L, 2010) |
| "To develop a molecular therapy for pancreatic cancer, the insulin-like growth factor-I (IGF-I) signaling pathway was analyzed." | ( Shinozaki, F; Sueishi, M; Sugiyama, T; Tomizawa, M; Yamamoto, S; Yoshida, T, 2010) |
| "However, some human pancreatic cancers are intrinsically resistant to TRAIL-mediated apoptosis or therapy." | ( Fan, S; Kauh, J; Khuri, FR; Sun, SY; Xia, M; Yang, L; Yue, P, 2010) |
| "In total, 112 patients with pancreatic cancer who received chemotherapy between April 2001 and April 2007 were divided into 2 groups: PreS-1 (53 patients who started chemotherapy before January 2005) and PostS-1 (59 patients who started chemotherapy after February 2005, the time of S-1 introduction)." | ( Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2010) |
| "Treatment of Panc1, Panc28, and L3." | ( Abdelrahim, M; Andreeff, M; Basha, MR; Chadalapaka, G; Jutooru, I; Konopleva, M; Safe, S; Samudio, I, 2010) |
| "The response of pancreatic cancer to treatments remains unsatisfactory, highlighting the need for more effective therapeutic regimens." | ( Amadori, D; Arienti, C; Carloni, S; Chiadini, E; Fabbri, F; Leonetti, C; Milandri, C; Orlandi, A; Passeri, D; Scarsella, M; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W; Zupi, G, 2010) |
| "Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance." | ( Baumann, B; Büchler, MW; Gladkich, J; Herr, I; Kallifatidis, G; Liu, L; Mattern, J; Rausch, V; Salnikov, AV; Schemmer, P; Wirth, T; Zöller, M, 2010) |
| "The current standard of care for pancreatic cancer is weekly gemcitabine administered for 3 of 4 weeks with a 1-week break between treatment cycles." | ( Baker, JH; Buczkowski, AK; Cham, KK; Chang, CW; Chu, EM; Chung, SW; Flexman, JA; Kozlowski, P; Minchinton, AI; Ng, SS; Owen, DA; Reinsberg, SA; Scudamore, CH; Takhar, KS; Wong, MQ; Yapp, DT; Yung, A, 2010) |
| "This anti-proliferative effect on pancreatic cancer cells helps to explain why human pancreatic cancers in vivo treated with the cardiac hormones decrease to less than 10% of the volume of untreated pancreatic cancers as they proliferate less." | ( Lenz, A; Pi, G; Skelton, WP; Sun, Y; Vesely, DL, 2010) |
| "Sixty-six patients with unresectable pancreatic cancer (pathologically identified) and no prior chemotherapy were divided into three groups." | ( Adachi, M; Hibi, T; Higuchi, H; Hozawa, S; Iizuka, H; Izumiya, M; Nakamura, S; Sakai, G; Takaishi, H; Yamagishi, Y, 2010) |
| "(2) To evaluate the feasibility of pancreatic cancer cell epithelial-mesenchymal transition (EMT) molecular profiling as a potential predictor of response to anti-EGFR treatment." | ( Arnoletti, JP; Buchsbaum, DJ; Christein, J; Eloubeidi, M; Frolov, A; Greeno, E; Jhala, N; Keene, K; Oster, R; Posey, J; Russo, S; Varadarajulu, S; Vickers, SM; Wood, T, 2011) |
| "In xenograft models of human pancreatic cancer established in athymic mice, administration of parenteral NanoCurc significantly inhibits primary tumor growth in both subcutaneous and orthotopic settings." | ( Bisht, S; Chenna, V; Feldmann, G; Goggins, MG; Hong, SM; Karikari, C; Maitra, A; Mizuma, M; Ottenhof, NA; Pramanik, D; Ravi, R; Rudek, MA; Sharma, R, 2010) |
| "We have previously demonstrated that in pancreatic cancer ErbB3 is the preferred dimerization partner of EGFR, ErbB3 protein expression level directly correlates with the anti-proliferative effect of erlotinib (an EGFR-specific tyrosine kinase inhibitor), and transient knockdown of ErbB3 expression results in acquired resistance to EGFR-targeted therapy." | ( Arnoletti, JP; Frolov, A; Heslin, MJ; Howard, JH; Kossenkov, AV; Kulesza, P; Liles, JS; Tzeng, CW, 2010) |
| "Patients with locally advanced pancreatic cancer (LAPC) are most commonly managed with chemotherapy or concurrent chemoradiotherapy (CRT), which may or may not include non-involved regional lymph nodes in the clinical target volume." | ( Dickinson, C; Green, MM; Jackson, AS; Jain, P; Price, PM; Saleem, A; Taylor, MB; Valle, J; Watkins, GR; Whitfield, GA, 2010) |
| "Four pancreatic cancer cell lines were cultured in gemcitabine with synchronous radiotherapy to obtain resistant subpopulations." | ( Du, Z; Peng, C; Qin, R; Shi, C; Tian, R; Wang, M; Wei, C, 2011) |
| "BxPC-3 cell, a human pancreatic cancer, was treated with parthenolide at different concentrations." | ( Cai, MX; Huang, DS; Liu, JW; Ma, J; Wu, QS; Xie, HY; Xin, Y; Yang, P, 2010) |
| "The treatment of pancreatic cancer cell cultures in vitro and in vivo with gemcitabine and ionizing radiation resulted in synergistic cytotoxicity." | ( Ku, Y; Mukubou, H; Sasaki, R; Tsujimura, T, 2010) |
| "Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy." | ( Aggarwal, BB; Asada, M; Chiba, T; Guha, S; Imaizumi, A; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mori, Y; Nishimura, T; Suzuki, C; Yanagihara, K; Yazumi, S; Yoshimura, K, 2011) |
| "Survivin is overexpressed by 70-80% of pancreatic cancers, and is associated with resistance to chemotherapy and a poor prognosis." | ( Diamond, DJ; Ellenhorn, JD; Ishizaki, H; Manuel, ER; Song, GY; Srivastava, T; Sun, S, 2011) |
| "Localized pancreatic cancer is a systemic disease that requires nonoperative therapies to minimize the local and systemic recurrences that almost invariably occur in the absence of such therapy, even following complete surgical resection." | ( Fleming, JB; Katz, MH; Lee, JE; Pisters, PW, 2010) |
| "For eligible patients with pancreatic cancer, 5-FU was administered at a dose of 125 mg/m(2)/day on days 1-5 every week as a continuous pancreatic and hepatic arterial infusion, and gemcitabine was infused intravenously at a dose of 800 mg/m(2) per day once per week for 2 weeks for preoperative chemotherapy." | ( Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y, 2011) |
| "Gemcitabine-resistant pancreatic cancer cell line SW1990/GZ was obtained by treating parental cell line SW1990 in vitro with increasing dosage of gemcitabine in culture medium intermittently for 24 weeks." | ( An, Y; Cai, HH; Dai, CC; Lu, ZP; Miao, Y; Qian, ZY; Wei, JS; Xu, ZK; Yao, J, 2010) |
| "When breast and pancreatic cancer cell lines were treated with imetelstat in vitro, telomerase activity in the bulk tumor cells and CSC subpopulations were inhibited." | ( Bassett, E; Buseman, CM; Go, NF; Harley, C; Joseph, I; Pattamatta, P; Shay, JW; Tressler, R; Wright, WE, 2010) |
| "Treatment of human pancreatic cancer in nude mice with interferon α and gemcitabine was associated with a reduction in tumor volume." | ( Ahad, A; Jacobs, MJ; Nalbantoglu, I; Saidi, RF; Tilak, J, 2012) |
| "Human pancreatic cancer cell lines MIA PaCa-2 and PANC-1 were treated with 4-HPR, followed by measurement of viability, proliferation, ROS and ceramide production, and Western blotting." | ( Cabot, MC; Messner, MC, 2011) |
| "Most chemotherapeutic regimens for pancreatic cancer (PC) use combination therapy." | ( Baumunk, D; Fotopoulou, C; Schmidt, SC; Schumacher, G, 2010) |
| "Chemotherapy of pancreatic cancer often fails due to the development of intrinsic and acquired resistance during drug treatment." | ( Li, Y; Paxton, JW; Reid, G; Revalde, JL, 2011) |
| "In patients with pancreatic cancer treated with curative resection, we evaluated the effect of clinicopathologic parameters on early distant metastasis within 6 months (DM6m) to identify patients who might benefit from surgery." | ( Han, SS; Hong, EK; Kim, DY; Kim, SH; Kim, TH; Lee, WJ; Moon, SH; Park, JW; Park, SJ; Woo, SM; Yoo, T, 2011) |
| "We report two cases of advanced pancreatic cancer whose prognoses are fairly good with surgery and chemotherapy." | ( Baba, H; Goseki, N; Kuwabara, H; Nakajima, K; Ohba, A; Sanada, T; Tanaka, K; Tsubomoto, T; Wakabayashi, M, 2010) |
| "In the case of pancreatic cancer that CRT is effective to the remission of primary lesion, CRT is potentially useful to perform for the control of metastatic lesion or palliative therapy." | ( Aoki, H; Choda, Y; Fujiwara, Y; Harano, M; Matsukawa, H; Ninomiya, M; Nishizaki, M; Ohno, S; Ojima, Y; Shiozaki, S; Takakura, N, 2010) |
| "In the breast and pancreatic cancer animal models, ultrasound-mediated therapy with paclitaxel-loaded PFCE nanoemulsions showed excellent therapeutic properties characterized by tumor regression and suppression of metastasis." | ( Gao, Z; Gupta, R; Jeong, EK; Kennedy, AM; Kim, T; Liu, X; Mohan, P; Nam, KH; Parker, DL; Payne, A; Rapoport, N; Scaife, C; Shea, J; Todd, N, 2011) |
| "We show here that EGCG-treated pancreatic cancer cells AsPC-1 and BxPC-3 decrease cell adhesion ability on micro-pattern dots, accompanied by dephosphorylations of both focal adhesion kinase (FAK) and insulin-like growth factor-1 receptor (IGF-1R) whereas retained the activations of mitogen-activated protein kinase and mammalian target of rapamycin." | ( Beppu, Y; Chi, HT; Hara, Y; Ohdomari, I; Sasaki, K; Sato, Y; Tanii, T; Vu, HA; Watanabe, T; Xinh, PT; Yamamoto, H, 2010) |
| "In gemcitabine-pretreated pancreatic cancer, salvage chemotherapy has not been established, and the prognostic factors are not completely known." | ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY, 2011) |
| "Nine individual patient-derived pancreatic cancer xenografts (6 with p53-deficient and 3 with p53 wild-type status) from the PancXenoBank collection at Johns Hopkins were treated with MK-1775, GEM, or GEM followed 24 hour later by MK-1775, for 4 weeks." | ( Brooks, D; De Oliveira, E; Demuth, T; Hidalgo, M; Hirai, H; Maitra, A; Mizuarai, S; Ottenhof, N; Rajeshkumar, NV; Shumway, SD; Watters, J, 2011) |
| "Nude mice bearing human pancreatic cancer xenografts (Capan-1 and BxPC-3) were treated with a single dose of 90Y-labeled antimucin antibody (hPAM4; clivatuzumab tetraxetan) alone or in combination with an anti-Trop-2-SN-38 conjugate, typically administered twice weekly over 4 weeks." | ( Goldenberg, DM; Govindan, SV; Karacay, H; Sharkey, RM, 2011) |
| "Polymyositis associated with pancreatic cancer may respond to glucocorticoids along with cancer specific treatment." | ( Agrogiannis, G; Gamaletsou, MN; Kechagias, G; Papageorgiou, A; Syrios, J; Tsavaris, N; Xynos, ID, 2011) |
| "Although progress in treatment for pancreas cancer has been incremental, development of combination therapies involving both chemotherapeutic and biologic agents is ongoing." | ( Berlin, J; Cardin, DB; Castellanos, E, 2011) |
| "Early pancreatic cancer response following cetuximab and/or irinotecan therapies was measured by serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and during therapy." | ( Buchsbaum, DJ; Fineberg, NS; Folks, KD; George, JF; Grizzle, WE; Guo, L; Kim, H; Morgan, DE; Sellers, JC; Stockard, CR; Zinn, KR, 2011) |
| "Most of patients have unresectable pancreatic cancer, and systemic chemotherapy remains the only treatment option for them." | ( Park, JY, 2011) |
| "Locally advanced pancreatic cancer patients (n = 20) were monitored during 16 weeks of neoadjuvant therapy." | ( Brostjan, C; Brugger, P; Gnant, M; Kuehrer, I; Schauer, D; Schoppmann, SF; Sommerfeldt, S; Starlinger, P; Tamandl, D, 2011) |
| "Currently, effective drug delivery in pancreatic cancer treatment is a major challenge." | ( Acharya, S; Arya, G; Sahoo, SK; Vandana, M, 2011) |
| "A 71-year-old male with unresectable pancreatic cancer treated with gemcitabine (GEM) by another doctor came to our hospital because of stenosis of duodenum and hydronephrosis." | ( Kenno, S; Kobayashi, T; Kuji, M; Tani, C; Yamamoto, Y, 2011) |
| "In xenograft models of pancreatic cancer, the rate of tumor proliferation on mice coadministered with triphendiol and gemcitabine was significantly reduced when compared with the corresponding tumor proliferation rates from the respective monotherapy-control and vehicle-control groups." | ( Alvero, AB; Brown, DM; Husband, AJ; Kim, KH; McKernan, R; Mor, G; Saif, MW; Thompson, JA; Tytler, EM; Wang, X; Whiting, A, 2011) |
| "Patients with advanced pancreatic cancer who had received no prior chemotherapy were eligible for this study." | ( Kim, S; Moore, MJ; Pithavala, YK; Ricart, AD; Rixe, O; Spano, JP, 2012) |
| "Treatment in mouse pancreatic cancer xenografts showed that intraperitoneal AA at 4 g/kg daily reduced tumor volume by 42%." | ( Chen, P; Chen, Q; Drisko, JA; Stone, J; Sullivan, G, 2011) |
| "In xenograft mouse models of human pancreatic cancer, treatment with either BA or MIT alone showed dose-dependent antitumor activity but led to systemic side effects as measured by overall weight loss." | ( Chang, DZ; Gao, Y; Huang, S; Jia, Z; Kong, X; Le, X; Li, Q; Suyun, H; Wang, L; Wei, D; Xie, K, 2011) |
| "Patients with advanced pancreatic cancer refractory to gemcitabine and S-1 were treated with gemcitabine 1,000 mg/m² over 30 min and oxaliplatin 85 mg/m² over 120 min on days 1 and 15." | ( Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y, 2011) |
| "For specific therapy of pancreatic cancer, we generated a fully retargeted MV that enters cells exclusively through the prostate stem cell antigen (PSCA)." | ( Bossow, S; Cattaneo, R; Grossardt, C; Leber, MF; Rieber, EP; Sawall, S; Temme, A; Ungerechts, G; von Kalle, C, 2011) |
| "Treatment of low passage pancreatic cancer xenografts with a combination of SCH727965 and gemcitabine was significantly more effective than either agent alone." | ( Alvarez, H; Bannerji, R; Bisht, S; Brossart, P; Dadon, T; Feldmann, G; Fendrich, V; Garrido-Laguna, I; Hidalgo, M; Karikari, C; Maitra, A; Matsui, W; Mishra, A; Nelkin, BD; Ottenhof, NA; Rajeshkumar, NV; Rasheed, Z, 2011) |
| "AsPC-1 pancreatic cancer cell murine subcutaneous xenografts were developed in the presence and absence of CAF and were subsequently treated with epidermal growth factor receptor (EGFR) inhibitors (erlotinib) and ErbB3 inhibitors (MM-121, monoclonal ErbB3 antibody)." | ( Arnoletti, JP; Frolov, A; Frost, AR; Heslin, MJ; Kossenkov, AV; Kulesza, P; Liles, JS; Mikhaylina, A, 2011) |
| "Two human pancreatic cancer cell lines, PANC-1 and MIAPaCa-2, were treated with BITC and irradiated with X-rays." | ( Kimura, S; Kubota, N; Ohara, M; Ohnishi, K; Okayasu, R; Tanaka, A, 2011) |
| "We retrospectively studied 136 pancreatic cancer patients with available formalin-fixed paraffin-embedded tumor blocks from 2003 to 2009 to understand the clinical significance of KRAS mutations in pancreatic cancer patients treated with gemcitabine-based chemotherapy." | ( Baek, KK; Choi, YL; Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lim, DH; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, JH, 2011) |
| "Re-expression of miR-34a in human pancreatic cancer stem cells (CSCs) and in human pancreatic cancer cell lines upon treatment with 5-Aza-dC and SAHA strongly inhibited the cell proliferation, cell cycle progression, self-renewal, epithelial to mesenchymal transition (EMT) and invasion." | ( Nalls, D; Rodova, M; Shankar, S; Srivastava, RK; Tang, SN, 2011) |
| "A total of 27 resected pancreatic cancer patients treated with adjuvant gemcitabine were analyzed for tumor hENT1 expression via an immunohistochemical analysis." | ( Akaike, M; Kameda, Y; Mikayama, H; Miyagi, Y; Morinaga, S; Nakamura, Y; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N, 2012) |
| "A high expression of hENT1 in pancreatic cancer was found to be significantly associated with a longer survival in patients who received adjuvant gemcitabine monotherapy after curative resection, and hENT1 immunohistochemistry may well serve as a significant prognostic factor for these patients." | ( Akaike, M; Kameda, Y; Mikayama, H; Miyagi, Y; Morinaga, S; Nakamura, Y; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N, 2012) |
| "In gene therapy of pancreatic cancer, non-viral vectors show an important role." | ( Akbari, H; Dorkoosh, FA; Larijani, B; Safari, S; Soleimani, M; Tehrani, MR; Zarrintan, MH, 2011) |
| "Four human pancreatic cancer cell lines were treated with ZOL, GEM or a combination of both, and the effects of the respective drug regimens on cell proliferation, invasion and matrix metalloproteinase (MMP) expression were examined." | ( Cui, L; Fujita, H; Kozono, S; Maeyama, R; Mizumoto, K; Ohuchida, K; Tanaka, M; Toma, H; Tominaga, Y; Zhao, M, 2012) |
| "One of the hallmarks of pancreatic cancer is its inherent insensitivity to chemotherapy." | ( Bu, HJ; Chen, Y; Liu, QH; Ni, CY; Yu, DH; Zhang, J; Zhao, CY; Zhu, MH, 2012) |
| "Treatment of PANC1 pancreatic cancer cells with dimethylenastron (3 and 10 μmol/L) for 24 h suppressed the migratory ability of the cancer cells in a concentration-dependent manner." | ( Li, DW; Liu, M; Luo, YG; Shi, XJ; Sun, XD; Sun, XO; Wu, XJ; Yao, CF; Yu, HY; Zhou, J, 2011) |
| "Advanced pancreatic cancer, even when treated, is highly lethal." | ( Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Kuo, YH; Tien, YW; Yang, SH, 2011) |
| "Patients (n = 20) with locally advanced pancreatic cancer were monitored during 16 weeks of neoadjuvant treatment with gemcitabine and bevacizumab." | ( Brostjan, C; Brugger, P; Gnant, M; Kuehrer, I; Reiter, C; Schauer, D; Schoppmann, SF; Sommerfeldt, S; Starlinger, P; Tamandl, D, 2011) |
| "Cell growth of human pancreatic cancer cells (AsPC-1 and Miapaca-2) transfected with AT-sDNA were monitored after treatment with gemcitabine." | ( Balasubramaniam, A; Cho, J; Kennedy, MA; Lewis, KB; Sheriff, S; Tinch, SL; Watanabe, M, 2012) |
| "In two patients with locally invasive pancreatic cancer, the pancreatic blood supply was altered under angiographic guidance, and an intra-arterial catheter with a subcutaneous port was left in place for the administration of 5-fluorouracil (5-FU) 1,000 mg/m(2)." | ( Anai, H; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T, 2011) |
| "Patients with severe metastatic pancreatic cancer received chemotherapy comprising S-1 (30mg/m² p." | ( Asagi, A; Hori, S; Iguchi, H; Ikeda, Y; Kajiwara, T; Matsumoto, T; Nadano, S; Nishina, T; Takeji, S, 2011) |
| "Mouse and human pancreatic cancer cells, irradiated in vitro by alpha particles with or without chemotherapy, were evaluated for cell growth inhibition." | ( Arazi, L; Bittan, H; Cooks, T; Efrati, M; Horev-Drori, G; Keisari, Y; Kelson, I; Lazarov, E; Schmidt, M, 2012) |
| "Keywords Phase III, gemcitabine and pancreatic cancer were used to search and collect Phase III-randomized references about gemcitabine and gemcitabine-based combination chemotherapy applied on advanced pancreatic cancer." | ( Li, B; Song, K; Sun, WJ, 2011) |
| "A 62-year-old woman with a diagnosis of pancreatic cancer with splenic invasion, liver metastasis, and peritoneal dissemination was scheduled to receive chemotherapy." | ( Kametaka, H; Koyama, T; Makino, H; Seike, K, 2011) |
| "14 subjects with metastatic stage IV pancreatic cancer were recruited to receive an eight week cycle of intravenous ascorbic acid (three infusions per week), using a dose escalation design, along with standard treatment of gemcitabine and erlotinib." | ( Bazzan, AJ; Deshmukh, S; Levine, M; Littman, S; Mitchell, E; Monti, DA; Newberg, AB; Pillai, MV; Yeo, CJ; Zabrecky, G, 2012) |
| "In this study, three pancreatic cancer cell lines, MIA PaCa-2, MDAPanc-3 and AsPC-1, were treated with the proteasome inhibitor MG-132 together with camptothecin, doxorubicin or paclitaxel, and cytotoxicity was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay." | ( Jaeger, C; Kratz, F; Merfort, I; Naumann, K; Schmich, K, 2012) |
| "Human pancreatic cancer cell line SW1990 was treated with different concentrations of emodin (10, 20, 40 micromol x L(-1)) for 2 h, the effects of emodin on the migration and invasion of SW1990 cells were examined by using wound assay and matrigel counting." | ( Huang, L; Lin, S; Liu, A; Sha, L; Shen, Y; Tang, X, 2011) |
| "Additionally, treatment of pancreatic cancer cell lines, BxPC-3 and PANC-1, with YAP1-targeting siRNA oligonucleotides significantly reduced their proliferation in vitro." | ( Diep, CH; Han, H; Hostetter, G; Hu, C; Munoz, RM; Von Hoff, DD; Watanabe, A; Zucker, KM, 2012) |
| "Treatment of advanced pancreatic cancer with bortezomib in combination with panobinostat is not supported by our clinical study." | ( Cao, Q; Dudek, AZ; Wang, H, 2012) |
| "In our cohort of patients with resected pancreatic cancer, Gem chemotherapy did not improve OS after chemoradiotherapy." | ( Baschnagel, A; Jury, R; Margolis, J; Nadeau, L; Robertson, JM; Shah, C; Stein, J, 2012) |
| "The vast majority of patients with pancreatic cancer present with locally advanced unresectable or metastatic disease, and in this setting only a palliative treatment can be offered." | ( Colucci, G; Di Maio, M; Giuliani, F; Perrone, F, 2012) |
| "The prognosis of patients with pancreatic cancer is extremely poor, and current systemic therapies provide marginal survival benefits for treated patients." | ( Capasso, A; Ciardiello, F; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T, 2012) |
| "Effective systemic treatment of pancreatic cancer remains a major challenge, with progress hampered by drug resistance and treatment related toxicities." | ( Innocenti, F; Soo, RA; Yong, WP, 2012) |
| "We report two cases of advanced pancreatic cancer treated with CPT-11 and CDDP as third-line chemotherapy." | ( Itoh, T; Kawamoto, K; Takagi, K, 2012) |
| "Fifty-three patients with unresectable pancreatic cancer, treated with gemcitabine and capecitabine (GC) or gemcitabine and erlotinib (GE) as first line between October 2006 and July 2010, were reviewed." | ( Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK, 2012) |
| "Gemcitabine is standard treatment for pancreatic cancer but has limited clinical benefit due to chemoresistance." | ( Beane, JD; Crooks, PA; Holcomb, BK; Schmidt, CM; Waters, JA; Yip-Schneider, MT, 2012) |
| "BxPC-3, PANC-1, and MIA PaCa-2 human pancreatic cancer cell lines were treated with gemcitabine and/or DMAPT." | ( Beane, JD; Crooks, PA; Holcomb, BK; Schmidt, CM; Waters, JA; Yip-Schneider, MT, 2012) |
| "After human pancreatic cancer cell line SW1990 was treated with emodin (40 micromol/L), gemcitabine (20 micromol/L), and emodin combined gemcitabine, the cell proliferation was detected by cell counting kit-8 (CCK-8) assay." | ( Liu, A; Luo, J; Zhang, JH, 2012) |
| "Human pancreatic cancer BxPC-3 cells were treated with or without transforming growth factor-β (TGF-β), siRNA against DEC2, or a combination of TGF-β and DEC2 siRNA or DEC2 overexpression." | ( Bhawal, UK; Fujimoto, K; Jin, D; Kato, Y; Kawamoto, T; Kawamura, H; Kijima, H; Morohashi, S; Noshiro, M; Sato, F; Sato, H; Seino, H; Wu, Y, 2012) |
| "MPC-83 pancreatic cancer cells were pre-treated and treated with EGF at different time points and then analyzed using western blotting." | ( Gong, K; Li, X; Liu, W; Luo, K; Wang, K, 2012) |
| "Treatment of pancreatic cancer cells in which BART is stably knocked down with a Rac1 inhibitor decreases invasiveness." | ( Saibara, T; Taniuchi, K; Yokotani, K, 2012) |
| "The development of immunotherapy for pancreatic cancer has been hampered by difficulty in generating tumor-reactive lymphocytes from resected specimens and by a lack of appropriate target antigens expressed on tumor cells." | ( Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL, 2012) |
| "Currently, the therapy of pancreatic cancer remains a challenge." | ( Ruan, JD; Sun, WJ; Wu, W; Xiong, Y; Zeng, J; Zhang, LB, 2012) |
| "In patients who have advanced pancreatic cancer treated with gemcitabine-containing regimens baseline CA19-9 is prognostic for outcome." | ( Bauer, TM; Bekaii-Saab, T; El-Rayes, BF; Hammad, N; Li, X; Philip, PA; Shields, AF; Zalupski, MM, 2013) |
| "At diagnosis, the majority of pancreatic cancer patients present with advanced disease when curative resection is no longer feasible and current therapeutic treatments are largely ineffective." | ( Arumugam, T; Elferink, LA; Gaziova, I; Guerra, YA; Harrigal, L; Hill, KS; Logsdon, CD; Qiu, S; Sastry, SK, 2012) |
| "The study population consisted of 102 pancreatic cancer patients who had been treated with a gemcitabine-based chemotherapeutic regimen." | ( Choi, H; Jang, KT; Kim, KK; Kim, S; Lee, SY; Park, JO; Park, YS; Woo, HI; Yi, JH, 2012) |
| "Treatment of human pancreatic cancer cell lines Miapaca-2, PANC-1 and AsPC-1 with GSPs resulted in inhibition of cell migration (19-82%, P<0." | ( Katiyar, SK; Prasad, R, 2013) |
| "Treatment of human pancreatic cancer cells (Miapaca-2, PANC-1 and AsPC-1) with GSPs In Vitro reduced cell viability and increased G2/M phase arrest of the cell cycle leading to induction of apoptosis in a dose- and time-dependent manner." | ( Katiyar, SK; Prasad, R; Vaid, M, 2012) |
| "Treatment of pancreatic cancer cells with pristimerin also resulted in G1-phase arrest which was strongly associated with a marked decrease in the level of cyclins (D1 and E) and cyclin-dependent kinases (cdk2, cdk4 and cdk6 ) with concomitant induction of WAF1/p21 and KIP1/p27." | ( Cheng, Z; Han, B; Jia, G; Jiang, H; Liu, J; Pan, S; Sun, B; Wang, Y; Zhou, H; Zhou, Y, 2012) |
| "To search for biomarkers identifying pancreatic cancer patients likely to benefit from adjuvant gemcitabine chemotherapy, we investigated the status of several histone modifications in pancreatic tumors and their relationship to clinicopathological features and outcomes." | ( Akaike, M; Kameda, Y; Miyagi, Y; Morinaga, S; Nakamura, Y; Numata, M; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N, 2012) |
| "Sixty one pancreatic cancer patients, primarily treated by surgical removal of tumors, were involved in the study." | ( Akaike, M; Kameda, Y; Miyagi, Y; Morinaga, S; Nakamura, Y; Numata, M; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N, 2012) |
| "Treatment of pancreatic cancer that cannot be surgically resected currently relies on minimally beneficial cytotoxic chemotherapy with gemcitabine." | ( Beckham, TH; Beeson, CC; Beeson, G; Bielawska, A; Bielawski, J; Cheng, JC; Drake, RR; Jones, EE; Lewis, CS; Liu, X; Lu, P; Marrison, T; Norris, JS; Ogretmen, B; Ramshesh, VK; Szulc, ZM, 2013) |
| "Assessment of potential as a target for pancreatic cancer treatment is clearly warranted." | ( Cheng, S; He, Y; Song, MM; Yuan, HS; Zhong, ZQ, 2012) |
| "The human pancreatic cancer cell line PANC-1 was incubated with doxycycline, followed by treatment with tumor necrosis factor (TNF)-α or paclitaxel." | ( Chiao, PJ; Fujioka, S; Fujita, T; Okamoto, T; Onda, S; Schmidt, C; Scrabas, GM; Son, K; Yanaga, K, 2012) |
| "The orthotopic pancreatic cancer animals were prepared with DSL-6A/C cells, and treated with GEM (100 mg/kg/weekly, for 3 weeks)." | ( Hirooka, S; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H, 2013) |
| "The standard treatment for metastatic pancreatic cancer is chemotherapy." | ( Akahori, T; Hokutoh, D; Kinoshita, S; Nakajima, Y; Nomi, T; Sho, M; Yamato, I; Yasuda, S, 2012) |
| "Sixty-seven patients with advanced pancreatic cancer (6 in stage III, 61 in stage IV) received PCC and (125)I seed implantation combined with concomitant gemcitabine hydrochloride and DDP chemotherapy." | ( He, LH; Niu, LZ; Xu, KC; Yang, ZZ; Zhou, L; Zuo, JS, 2012) |
| "The sensitivity of a panel of human pancreatic cancer cell lines to treatment with NVP-AEW541 used alone or in combination with afatinib, anti-EGFR antibody ICR62, and cytotoxic agents was determined using the Sulforhodamine B colorimetric assay." | ( Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM, 2013) |
| "Treatment for pancreatic cancer with pharmacological ascorbate (ascorbic acid, vitamin C) decreases tumor progression in preclinical models." | ( Berg, DJ; Bodeker, KL; Buettner, GR; Cullen, JJ; Drisko, J; Du, J; Halfdanarson, TR; Levine, M; Roberts, LJ; van't Erve, TJ; Wagner, BA; Welsh, JL; Yee, NS; Zehr, PS, 2013) |
| "Patients with untreated metastatic pancreatic cancer received oral capecitabine at 1,000 mg/m(2) twice daily on days 1-14, of a 21-day treatment cycle; and oral erlotinib at 150 mg daily." | ( Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR, 2013) |
| "The major obstacles to treatment of pancreatic cancer are the highly invasive capacity and resistance to chemo- and radiotherapy." | ( Chikano, Y; Endo, Y; Higashi, T; Hirose, M; Ishigaki, Y; Kawakami, K; Kitano, A; Minamoto, T; Miyamoto, K; Motoo, Y; Nakada, M; Sai, Y; Sato, H; Shimasaki, T; Takino, T, 2013) |
| "The function of Bmi1 in pancreatic cancer was assessed by alteration of Bmi1 expression in several cell model systems by measuring cell proliferation, cell apoptosis, in vitro invasion, chemotherapy resistance, and in vivo growth and metastasis in an orthotopic model of pancreatic cancer." | ( Bednar, F; Heidt, DG; Lee, CJ; Li, C; Proctor, E; Simeone, DM; Waghray, M; Yalamanchili, M, 2013) |
| "Metformin also inhibited the growth of pancreatic cancer xenografts when administered orally (2." | ( Eibl, G; Kisfalvi, K; Moro, A; Rozengurt, E; Sinnett-Smith, J, 2013) |
| "Studies that were conducted in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib (with or without comparison with gemcitabine alone) and reporting objective response rate, disease control rate, progression-free survival, time-to-progression, overall survival, 1-year survival rate and/or adverse events were included." | ( Chen, JZ; Di, MY; Ding, H; Huang, YF; Mao, C; Tang, JL; Wu, XY; Yang, ZY; Yuan, JQ; Zheng, DY, 2013) |
| "Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied." | ( Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN, 2013) |
| "The interactions between PSCs and pancreatic cancer have attracted substantial attention as a novel therapeutic target for the treatment of pancreatic cancer." | ( Hamada, S; Kikuta, K; Masamune, A; Miura, S; Nakano, E; Shimosegawa, T; Takikawa, T, 2013) |
| "Treatment of MiaPaCa-2 and Panc-1 pancreatic cancer cell lines with CDDO-Me induced the production of hydrogen peroxide and superoxide anions and inhibited the telomerase activity." | ( Arbab, AS; Deeb, D; Gao, X; Gautam, SC; Liu, Y; Varma, NR, 2013) |
| "The human pancreatic cancer cell line Bxpc-3 was cultured in vitro and treated with or without ginsenoside Rh2." | ( Fang, CY; Liang, ZH; Tang, GD; Tang, XP; Zhang, LY, 2013) |
| "Treatments of BxPC-3 or PANC-1 pancreatic cancer cell lines with chidamide resulted in dose- and time-dependent growth arrest, accompanied by induction of p21 expression." | ( Ge, Y; Guo, Y; He, M; He, Y; Li, W; Qiao, Z; Ren, S; Sun, L; Wang, X; Yu, Q, 2013) |
| "The human pancreatic cancer cell lines BxPC3, PANC-1 and a stably gemcitabine-resistant subline, PANC1(GemRes), were treated with combinations of gemcitabine and the ERK1/2 inhibitor, U0126." | ( Jiang, Y; Jiao, X; Sun, S; Zheng, C, 2013) |
| "ERK1/2 activity may protect pancreatic cancer cells from chemotherapy-induced apoptosis." | ( Jiang, Y; Jiao, X; Sun, S; Zheng, C, 2013) |
| "In advanced pancreatic cancer, oxaliplatin has been found to be clinically effective in phase II trials in which it was combined with either 5-fluorouracil (5-FU) or gemcitabine, the current standard chemotherapy for this disease." | ( Scheithauer, W; Van Cutsem, E, 2003) |
| "CD147, high expression in pancreatic cancer, is involved in the metastatic process and is considered a good candidate for targeted therapy." | ( Koizumi, M; Kurosawa, G; Kurosawa, Y; Nagatsu, K; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB; Ukai, Y; Zhang, MR, 2013) |
| "Treatment of pancreatic cancer cells with gemcitabine has been shown to induce the activity of the transcription factor nuclear factor-kappaB (NF-κB) which regulates the expression of genes involved in the inflammatory response and tumorigenesis." | ( Agaram, N; Crooks, PA; Schmidt, CM; Stantz, K; Wu, H; Yip-Schneider, MT, 2013) |
| "Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin (85 mg/m(2)) on days 1 and 15 followed by leucovorin (20 mg/m(2)) and 5-fluorouracil (500 mg/m(2)) on days 1, 8, and 15." | ( El-Hadaad, HA; Wahba, HA, 2013) |
| "We present a first description of a pancreatic cancer patient treated with standard chemotherapy and TL-118, an anti-angiogenic combination of 4 drugs that target non-overlapping aspects of the angiogenic process (Provided by Tiltan Pharma Ltd for compassionate use)." | ( Appelbaum, L; Breuer, S; Hubert, A; Maimon, O; Peretz, T, 2013) |
| "Unlike the aforementioned tumour cells, pancreatic cancer cells show a reduced migratory activity upon norepinephrine treatment." | ( Entschladen, F; Hahn, SA; Niggemann, B; Powe, DG; Stock, AM; Troost, G; Zänker, KS, 2013) |
| "Human pancreatic cancer cell line MiaPaca2 cells were treated with different concentrations of 5-Aza-CdR." | ( Guo, RD; Han, X; Li, ZJ; Tan, ZJ; Wang, YL, 2013) |
| "New agents are needed to treat pancreatic cancer, one of the most lethal human malignancies." | ( Alston, N; Constantinides, PP; Huang, L; Mackenzie, GG; Mattheolabakis, G; Ouyang, N; Rigas, B; Vrankova, K, 2013) |
| "Chemotherapy of advanced pancreatic cancer has mainly been gemcitabine-based for the past 15 years, with only limited effect." | ( Boettcher, M; Fredebohm, J; Hoheisel, JD; Wolf, J, 2013) |
| "Treatment of Panc1, L3." | ( Abdelrahim, M; Basha, R; Jutooru, I; Nair, V; Pathi, S; Safe, S; Samudio, I; Sreevalsan, S, 2013) |
| "Human pancreatic cancer cell lines AsPC-1, BxPC-3 and Panc-1 were irradiated with photons and carbon ions at various doses and treated with gemcitabine." | ( Brons, S; Combs, SE; Debus, J; El Shafie, RA; Haberer, T; Habermehl, D; Mairani, A; Orschiedt, L; Rieken, S; Weber, KJ, 2013) |
| "A pilot study was conducted on 40 pancreatic cancer patients, all treated with gemcitabine-based therapy." | ( Ciccolini, J; Dahan, L; Duluc, M; Fina, F; Lacarelle, B; Norguet, E; Ouafik, L; Seitz, JF; Serdjebi, C, 2013) |
| "Metastatic pancreatic cancer remains a difficult disease to treat; however, there are more new drug combinations on the horizon each week." | ( Jarboe, J; Saif, MW, 2013) |
| "In non-metastatic, non-resectable pancreatic cancer, treatment primarily aims to induce disease control, but may achieve conversion to surgical resectability in some patients." | ( Boeck, S; Haas, M; Heinemann, V, 2013) |
| "Lamin B1 plays an important role in pancreatic cancer pathogenesis and is a novel therapeutic target of betulinic acid treatment." | ( Cui, J; Du, Y; Gao, J; Jia, Z; Kong, X; Li, L; Li, Z; Wang, G; Xie, K, 2013) |
| "Fifty-three patients with pancreatic cancer were enrolled in this study, of which 32 received GEM- based chemotherapy." | ( Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K, 2014) |
| "Because the pancreatic cancer recurred 4 months after surgery, however, he was treated with combination chemotherapy(S- 1+GEM at 750mg/m2)." | ( Araki, K; Hachisuka, H; Iwamura, Y; Kushima, A; Nagano, K; Nakajima, T; Nakamoto, T; Nunomura, M; Takahashi, K; Takahashi, M; Wakata, M, 2013) |
| "Pretreatment of BxPC-3 human pancreatic cancer cells with low concentrations of Api or Lut effectively aid in the anti-proliferative activity of chemotherapeutic drugs." | ( Gonzalez de Mejia, E; Johnson, JL, 2013) |
| "The patient was a 76-year-old man with pancreatic cancer who was receiving adjuvant gemcitabine chemotherapy after surgery." | ( Kimura, S; Kitahara, K; Komiya, K; Noshiro, H; Sueoka-Aragane, N; Sugioka, T; Yakabe, T, 2013) |
| "In human pancreatic cancer xenografts, fractionated radiation combined with AZD8055 treatment further increased the anti-tumor effect, the tumor volume was shrinked to 278 mm3 after combination treatment for 3 weeks compared with single radiation (678 mm3) or AZD8055 (708 mm3) treatment (P < 0." | ( Guo, Y; Liu, Y; Lu, Z; Wang, G; Wei, F; Xiang, A; Xue, X, 2013) |
| "Intrinsic or acquired resistance of pancreatic cancer to gemcitabine (2'-deoxy-2'-difluorodeoxycytidine) is an important factor in the failure of gemcitabine treatment." | ( Akada, J; Kitagawa, T; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Suenaga, S; Tanaka, T; Tokuda, K; Wang, Y, 2013) |
| "The BxPC-3 pancreatic cancer xenogeneic mice model received treatment with physiological saline, inhibition of SIRT1, gemcitabine, and combination therapy with inhibition of SIRT1 and gemcitabine in vivo and the results showed that the tumor volumes decreased and the survival rate within 45 days increased according to the order of the given drugs and the difference was significant (P < 0." | ( Gong, DJ; Guo, QQ; Yu, M; Zhang, JM; Zhuang, B, 2013) |
| "The BxPC-3 pancreatic cancer xenogeneic mice model received treatment with physiological saline, inhibition of SIRT1, gemcitabine, and combination therapy with inhibition of SIRT1 and gemcitabine in vivo and the results showed that the tumor volumes decreased and the survival rate within 45 days increased according to the order of the given drugs and the difference was significant (P < 0." | ( Gong, DJ; Guo, QQ; Yu, M; Zhang, JM; Zhuang, B, 2013) |
| "Current therapy for pancreatic cancer is multimodal, involving surgery and chemotherapy." | ( Hu, Y; Liao, Q; Wen, Z; You, L; Zhao, Y; Zhou, L, 2013) |
| "Pancreatic adenocarcinoma or pancreatic cancer is often diagnosed at a very late stage at which point treatment options are minimal." | ( Padmanabhan, J; Woods, NK, 2013) |
| "Treatment of pancreatic cancer remains a major challenge." | ( Chen, Y; Huang, K; Li, J; Liang, J; Lin, Z; Qian, C; Shuai, X; Wang, Y; Wu, W; Zeng, L; Zhang, Q, 2014) |
| "Treatment of pancreatic cancer cells with TGF-β induced Nox4 expression, indicating that Nox4 represents a major source for ROS production." | ( Hiraga, R; Kamata, T; Kato, M; Miyagawa, S, 2013) |
| "A total of 60 C57/BL6 nude mice pancreatic cancer xenograft models were randomized into four groups of 15 mice per group: control group, allicin treatment group, rIL-2 treatment group, combined treatment with allicin and rIL-2 group." | ( Han, J; Shen, DW; Tang, L; Wang, C; Wang, CJ; Wang, YK; Xu, RH; Zhang, H; Zhao, Y, 2013) |
| "A total of 60 C57/BL6 nude mice pancreatic cancer xenograft models were randomized into four groups of 15 mice per group: control group, allicin treatment group, rIL-2 treatment group, combined treatment with allicin and rIL-2 group." | ( Han, J; Shen, DW; Tang, L; Wang, C; Wang, CJ; Wang, YK; Xu, RH; Zhang, H; Zhao, Y, 2013) |
| "Cisplatin (CDDP) efficiency in pancreatic cancer therapy is limited due to development of drug resistance." | ( Bie, P; Deng, H; Tan, J; Wu, D; Xu, T; You, Y; Yu, P; Zhang, Y, 2014) |
| "The viability of human pancreatic cancer cell lines (BxPC-3 and PANC-1) treated with HF10 and erlotinib, on their own or in combination, was determined." | ( Fujii, T; Fujiwara, M; Fukuda, S; Hotta, Y; Kanda, M; Kasuya, H; Kobayashi, D; Kodera, Y; Koike, M; Nakayama, G; Nomoto, S; Sahin, TT; Sugimoto, H; Tan, G; Tanaka, C; Tanaka, M; Tsurumaru, N; Yamada, S; Yamamura, K, 2014) |
| "A case of recurrent pancreatic cancer effectively responded to S-1 and irinotecan combined with third-line chemotherapy (IRIS) with PSK." | ( Asano, T; Ishii, M; Iwata, K; Kobayashi, H; Kobayashi, S; Koizumi, S; Okamura, R; Otsubo, T; Saji, O; Sumiyoshi, K, 2013) |
| "Treatment of pancreatic cancer L3." | ( Hu, X; Sharma, S; Wang, MH; Yao, HP; Zeng, JY; Zhang, R; Zhou, YQ, 2014) |
| "Treatment of pancreatic cancer L3." | ( Hu, X; Sharma, S; Wang, MH; Yao, HP; Zeng, JY; Zhang, R; Zhou, YQ, 2014) |
| "Long-term outcomes in pancreatic cancer has improved even within the gemcitabine era, suggesting the importance of offering chemotherapy to patients previously only considered for best supportive care." | ( Abe, M; Azemoto, N; Furukawa, S; Hiasa, Y; Hirooka, M; Ikeda, Y; Imai, Y; Imamine, S; Inada, N; Koizumi, M; Kumagi, T; Kuroda, T; Matsuura, B; Miyaike, J; Miyake, T; Nishiyama, M; Ohno, Y; Okada, S; Onji, M; Seike, H; Shibata, N; Tanaka, Y; Tatsukawa, H; Utsunomiya, H; Yamanishi, H; Yokota, T, 2013) |
| "Although there are many reports using pancreatic cancer cells derived from patients who did not receive chemotherapy, characteristics of pancreatic cancer cells from chemotherapy-resistant patients remain unclear." | ( Chiba, S; Hori, Y; Shimizu, K, 2013) |
| "Although there are many reports using pancreatic cancer cells derived from patients who did not receive chemotherapy, characteristics of pancreatic cancer cells from chemotherapy-resistant patients remain unclear." | ( Chiba, S; Hori, Y; Shimizu, K, 2013) |
| "Chemoresistance is a major challenge in pancreatic cancer (PC) treatment." | ( Chen, G; Du, X; Shu, H; Wang, TX; You, L; Zhang, TP; Zhao, YP; Zhou, L, 2014) |
| "Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy." | ( Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS, 2014) |
| "The results showed that GEM-treated pancreatic cancer cell medium stimulated maturation of DCs." | ( Ding, X; Liu, W; Luo, H; Lv, Y; Pan, J; Pei, Q; Zhu, H; Zou, X, 2014) |
| "Gemcitabine (GEM), a key drug for pancreatic cancer treatment, stimulates the expression of cell surface MICA in tumor cells to enhance the cytotoxicity of NK cells." | ( Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakanuma, S; Ohta, T; Sakai, S; Shoji, M; Tajima, H; Takamura, H, 2013) |
| "Pain in pancreatic cancer is often a major problem of treatment." | ( Seicean, A, 2014) |
| "For in vivo studies, pancreatic cancer cells (CAPAN-2/PaTu-8902) were xenotransplanted subcutaneously into athymic mice, subsequently treated with carbon monoxide-releasing molecule (35 mg/kg b." | ( Ahmad, S; Ahmed, A; Fujisawa, T; Gbelcová, H; Knejzlík, Z; Koníčková, R; Muchová, L; Ruml, T; Suk, J; Váňová, K; Vítek, L; Zadinova, M; Zelenka, J, 2014) |
| "As a potential novel agent for treating pancreatic cancer, methylseleninic acid (MSeA) was evaluated in cell culture and xenograft models." | ( Cheng, Y; Deng, Y; Hu, H; Liao, JD; Lü, J; Wang, L; Wang, Z; Xiong, H, 2014) |
| "Patients with low-grade resected pancreatic cancer may have better outcomes with 5-fluorouracil-based chemotherapy without radiation when compared with 5-fluorouracil with radiation." | ( Jaiyesimi, I; Kizilbash, SH; Liang, JJ; Lipscomb, J; Ward, KC, 2014) |
| "Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion." | ( Chen, YJ; Chu, L; Fang, JM; Han, YC; Liu, ZQ; Xu, Q; Zhang, X; Zhao, HX, 2014) |
| "Treatment of pancreatic cancer cells with the NR4A1 antagonist 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) gave similar results." | ( Guthrie, AS; Jin, UH; Kang, JH; Kim, SB; Lee, JS; Lee, SO; Safe, S; Sreevalsan, S, 2014) |
| "A total of five pancreatic cancer murine models (two cell line-based xenografts (CXs) and three tumour grafts (TGs)) were treated with either GEM (100 mg kg(-1), q3d × 4) alone or GEM plus iRGD peptide (8 μmol kg(-1))." | ( Akashi, Y; Enomoto, T; Hashimoto, S; Kurokawa, T; Miyamoto, R; Oda, T; Ohara, Y; Ohkohchi, N; Satake, M; Yamada, K, 2014) |
| "We identified a subset of pancreatic cancer models that showed NRP1 overexpression sensitive to iRGD co-administration." | ( Akashi, Y; Enomoto, T; Hashimoto, S; Kurokawa, T; Miyamoto, R; Oda, T; Ohara, Y; Ohkohchi, N; Satake, M; Yamada, K, 2014) |
| "A total of five pancreatic cancer murine models (two cell line-based xenografts (CXs) and three tumour grafts (TGs)) were treated with either GEM (100 mg kg(-1), q3d × 4) alone or GEM plus iRGD peptide (8 μmol kg(-1))." | ( Akashi, Y; Enomoto, T; Hashimoto, S; Kurokawa, T; Miyamoto, R; Oda, T; Ohara, Y; Ohkohchi, N; Satake, M; Yamada, K, 2014) |
| "We identified a subset of pancreatic cancer models that showed NRP1 overexpression sensitive to iRGD co-administration." | ( Akashi, Y; Enomoto, T; Hashimoto, S; Kurokawa, T; Miyamoto, R; Oda, T; Ohara, Y; Ohkohchi, N; Satake, M; Yamada, K, 2014) |
| "Borderline resectable pancreatic cancer is best treated by multimodality therapy." | ( Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L, 2014) |
| "During in vitro studies, pancreatic cancer cell growth is significantly inhibited (≈82% reduction) with chemohyperthermia compared to chemotherapy or hyperthermia alone." | ( Guo, Y; Kim, DH; Larson, AC; Nicolai, J; Omary, RA; Procissi, D; Zhang, Z, 2014) |
| "To achieve better treatment outcome of pancreatic cancer, in the current study we explore the underlying molecular mechanism of drug resistance in pancreatic cancer cells." | ( Cheng, L; Wang, R; Wang, Z; Wu, Q; Xia, J, 2014) |
| "Lack of effective therapeutics for pancreatic cancer at the present time underscores the dire need for safe and effective agents for the treatment of this malignancy." | ( Deeb, D; Gao, X; Gautam, SC; Liu, YB; Pindolia, K, 2014) |
| "In the field of treatment of pancreatic cancer, there has been significant progress lately." | ( Oikonomopoulos, GM; Saif, MW; Skoura, E; Syrigos, KN, 2014) |
| "Metastatic pancreatic cancer continues to be a difficult disease to treat because of its aggressive nature, advanced stage at presentation and lack of treatment options." | ( Brennan, GT; Relias, V; Saif, MW, 2014) |
| "Biomarkers for early diagnosis of pancreatic cancer among diabetic patients and metformin as a biologic therapy for pancreatic cancer are herein discussed." | ( De Souza, AL; Saif, MW, 2014) |
| "30 patients with Stage III or IV pancreatic cancer were equally divided into two groups (control and treatment group)." | ( Di, XY; Guo, JM; Jiang, HT; Yu, Q; Yu, YP; Zhu, Y, 2014) |
| "30 patients with Stage III or IV pancreatic cancer were equally divided into two groups (control and treatment group)." | ( Di, XY; Guo, JM; Jiang, HT; Yu, Q; Yu, YP; Zhu, Y, 2014) |
| "BxPC3 human pancreatic cancer cells were treated with metformin, and Sonic hedgehog (Shh) mRNA and protein levels were examined by real time reverse transcription-polymerase chain reaction, immunohistochemistry and immunoblotting, respectively." | ( Nakamura, M; Nakashima, H; Ogo, A; Yamaguchi, Y; Yamura, M, 2014) |
| "Treatment for advanced pancreatic cancer is still very unsatisfactory." | ( Ayuk, F; Bokemeyer, C; Brammer, I; Kröger, N; Mina, S; Nitsch, E; Pace, A; Schuch, G; Zander, A, 2014) |
| "Treatment for advanced pancreatic cancer is still very unsatisfactory." | ( Ayuk, F; Bokemeyer, C; Brammer, I; Kröger, N; Mina, S; Nitsch, E; Pace, A; Schuch, G; Zander, A, 2014) |
| "Treatment of pancreatic cancer BxPc-3 and Panc-1 cells with α -mangostin resulted in loss of cell viability, accompanied by enhanced cell apoptosis, cell cycle arrest at G1 phase, and decrease of cyclin-D1." | ( Chen, X; Duan, W; Hu, A; Lei, J; Li, X; Ma, J; Ma, Q; Sheng, L; Wang, Z; Wu, E; Wu, Z; Xu, Q, 2014) |
| "He suffered from advanced pancreatic cancer, underwent gastrojejunostomy, and was scheduled to undergo chemotherapy." | ( Ikegaki, J; Komasawa, N, 2014) |
| "PaTu8988 pancreatic cancer cells were treated with different concentrations of suberoylanilide hydroxamic acid (SAHA), cell survival, proliferation, migration and vasculogenic mimicry (VM) were analyzed." | ( Cao, C; Cao, ZF; Pan, YY; Xu, XD; Yang, B; Yang, L; Zhang, ZQ; Zheng, LY; Zhou, QS, 2014) |
| "Patients with advanced pancreatic cancer who showed disease progression during gemcitabine-based chemotherapy were enrolled in this study." | ( Bang, S; Chung, MJ; Park, JY; Park, SW; Song, SY, 2014) |
| "Treatment of invasive pancreatic cancer cells grown on a cell-derived matrix or as subcutaneous tumours in nude mice with the macroketone inhibited E-cadherin dynamics in a manner consistent with increased cell adhesion and reduced invasive potential." | ( Anderson, KI; Lo Re, D; Murphy, PV; Nobis, M; Zhou, Y, 2014) |
| "However, the chemoresistance of pancreatic cancer is the major barrier to efficient chemotherapy." | ( Kornmann, M; Liu, X; Ma, Y; Tian, X; Wang, F; Yang, Y, 2014) |
| "Recently, treatment of pancreatic cancer has changed based on a multidisciplinary approach." | ( Choi, BI; Han, JK; Kim, H; Kim, JH; Kim, YJ; Lee, JY, 2014) |
| "Recently, treatment of pancreatic cancer has changed based on a multidisciplinary approach." | ( Choi, BI; Han, JK; Kim, H; Kim, JH; Kim, YJ; Lee, JY, 2014) |
| "Chemotherapy for pancreatic cancer is hampered by the tumor's physio-pathological complexity." | ( Cattel, L; Couvreur, P; Desmaële, D; Giraudo, E; Maione, F; Mura, S; Noiray, M; Stella, B; Valetti, S; Vauthier, C; Vergnaud, J, 2014) |
| "Twenty-five percent of patients with pancreatic cancer present with locally advanced disease that is unresectable, and the treatment strategy for these patients is controversial, with options including chemotherapy alone, concurrent chemoradiation, or induction chemotherapy followed by chemoradiation." | ( Chang, BW; Johung, KL; Saif, MW, 2014) |
| "Patients with advanced pancreatic cancer who had received no prior chemotherapy were eligible for this study." | ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2014) |
| "Novel approaches to treatment of pancreatic cancer (PCa) are urgently needed." | ( Bruchertseifer, F; Bryan, RA; Dadachova, E; Epstein, AL; Jandl, T; Jiang, Z; Koba, W; Morgenstern, A; Onyedika, C; Strauss, J, 2014) |
| "MTT-tested viability of all pancreatic cancer cell lines decreased dose-dependently up to 50 % of the untreated control." | ( Arndt, M; Buhr, HJ; Erben, U; Hotz, B; Hotz, HG, 2014) |
| "The human pancreatic cancer cell line MIA PaCa-2 was treated with three different concentrations of Res." | ( Dang, X; Li, W; Ma, Q; Ma, Z; Qin, Y, 2014) |
| "We report two cases of pancreatic cancer with multiple liver metastases for which successful gemcitabine (GEM) +S-1 therapy facilitated radical resection." | ( Aizawa, M; Nashimoto, A; Nomura, T; Sato, Y; Tsuchiya, Y, 2014) |
| "First-line therapy for pancreatic cancer is gemcitabine." | ( Distler, AM; Hill, EG; Lemasters, JJ; Manevich, Y; Mieyal, JJ; Nieminen, AL; Qanungo, S; Shaner, B; Townsend, DM; Uys, JD, 2014) |
| "Consecutive patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy were retrospectively studied." | ( Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2015) |
| "The inhibition of RAS in advanced pancreatic cancer might improve clinical outcomes in cases without a history of smoking or in cases receiving gemcitabine monotherapy." | ( Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2015) |
| "Human pancreatic ductal epithelial and pancreatic cancer cells treated with omega-6 FA generated increased LTB4 levels in vitro." | ( Bentrem, DJ; Gounaris, E; Grippo, PJ; Knab, LM; Mascarinas, WE; Munshi, HG; Principe, DR; Schultz, M, 2015) |
| "A 57-year-old Hispanic male with pancreatic cancer initially received 7 cycles of FOLFIRINOX followed by capecitabine with radiation therapy for 28 fractions for a total of 5,040 cGy." | ( Graziani, C; Hegde, S; Saif, MW, 2014) |
| "The clinical prognosis of pancreatic cancer remains rather disappointing despite tremendous efforts in exploring medical treatments in the past two decades." | ( Chen, Y; Pan, Y; Qin, Y; Xiang, R; Yang, J; Yang, SY; Zheng, M; Zhong, L; Zhou, S, 2015) |
| "BxPC-3 pancreatic cancer cells were cultured under hypoxic conditions and treated with or without the nanoparticles." | ( Fang, W; Li, K; Li, L; Pan, X; Sun, Y; Zhao, Z; Zhu, Q; Zhu, Y; Zuo, J, 2015) |
| "Metastatic human pancreatic cancer cells (the SW1990 line) that are resistant to the EGFR-targeting tyrosine kinase inhibitor drugs (TKI) erlotinib and gefitinib were treated with 1,3,4-O-Bu3ManNAc, a 'metabolic glycoengineering' drug candidate that increased sialylation by ∼2-fold." | ( Bhattacharya, R; Bovonratwet, P; Liu, L; Mathew, MP; Saeui, CT; Tan, E; Yarema, KJ, 2015) |
| "However, in patients with advanced pancreatic cancer (APC) who receive palliative chemotherapy, the impact of DM on the prognosis of APC is unclear." | ( Bang, YJ; Choi, Y; Han, SW; Im, SA; Kim, TY; Lee, KH; Oh, DY, 2016) |
| "PIT holds promise in the treatment of pancreatic cancer and may serve as a useful adjunct to surgery in the eradication of microscopic residual disease that can lead to both local and metastatic recurrence." | ( Bouvet, M; Garcia-Guzman, M; Hiroshima, Y; Hoffman, RM; Kobayashi, H; Luiken, GA; Maawy, AA; Zhang, Y, 2015) |
| "Preclinical evidence that pancreatic cancer is a systemic disease suggests a possible benefit for early administration of systemic therapy in these patients." | ( Garrido-Laguna, I; Hidalgo, M, 2015) |
| "Treatment of highly invasive Panc1 pancreatic cancer cells with TCDD, omeprazole, and seven other AhR-active pharmaceuticals showed that only omeprazole and tranilast, but not TCDD, inhibited invasion in a Boyden chamber assay." | ( Jin, UH; Kim, SB; Safe, S, 2015) |
| "We explored if known risk factors for pancreatic cancer such as type II diabetes and chronic inflammation, influence the pathophysiology of an established primary tumor in the pancreas and if administration of metformin has an impact on tumor growth." | ( Albert, AC; Amme, J; Bürtin, F; Partecke, LI; Radecke, T; Vollmar, B; Zechner, D, 2015) |
| "The bleak prognosis associated with pancreatic cancer (PDAC) drives the need for the development of novel treatment methodologies." | ( Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A, 2015) |
| "The overall survival of resectable pancreatic cancer was significantly better than that of BRPC regardless of whether the patients were treated with or without NACRT." | ( Akahori, T; Hasegawa, M; Kichikawa, K; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiofuku, H; Nishiwada, S; Ohbayashi, C; Sho, M; Tamamoto, T; Tanaka, T, 2015) |
| "Therefore, resectable pancreatic cancer may be good indication for multimodal treatment including NACRT." | ( Akahori, T; Hasegawa, M; Kichikawa, K; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiofuku, H; Nishiwada, S; Ohbayashi, C; Sho, M; Tamamoto, T; Tanaka, T, 2015) |
| "Human pancreatic cancer cell line PANC-1 cells were treated with diverse concentrations of celecoxib (20, 60, 100 μmol/L)." | ( Gu, Z; Li, J; Li, S; Sun, K; Xiao, Z; Zhou, T, 2015) |
| "In radiation therapy of pancreatic cancer, tumor alignment prior to each treatment fraction is improved when intratumoral gold fiducial markers (from here onwards: markers), which are visible on computed tomography (CT) and cone beam CT, are used." | ( Bel, A; Gurney-Champion, OJ; Houweling, AC; Klaassen, R; Lens, E; Nederveen, AJ; Stoker, J; van der Horst, A; van Hooft, JE; van Tienhoven, G, 2015) |
| "CD133-positive pancreatic cancer is correlated with unfavorable survival despite current development of therapy." | ( Ding, Q; Matsubara, S; Miyazaki, Y; Takao, S; Tsukasa, K; Yoshimitsu, M, 2015) |
| "Improved treatments for pancreatic cancer remain a clinical imperative." | ( Azab, B; Bhoopathi, P; Das, SK; Dash, R; Emdad, L; Fisher, PB; Pellecchia, M; Quinn, BA; Sarkar, D; Sarkar, S; Wei, J, 2015) |
| "Using different pancreatic cancer cell lines, we evaluated the effect of RA alone or in combination with chemotherapy regulating cancer stem cells properties and pathways." | ( Bujanda, L; Er, TK; Herreros-Villanueva, M, 2015) |
| "Moreover, treatment of pancreatic cancer cells with H2O2 to induce oxidative stress resulted in upregulated ROS levels, decreased Ape1 at both the mRNA and protein level, and alterations in WNT/β-catenin pathway components." | ( Chen, Z; Fei, J; Han, B; Jiang, S; Tang, H; Zhang, M; Zhu, L; Zou, GM, 2015) |
| "The treatment of pancreatic cancer frequently fails due to local recurrence and hepatic metastasis." | ( Chen, C; Guo, M; Huynh, T; Kang, SG; Lu, Y; Pan, Y; Wang, L; Yang, Z; Zhao, Y; Zhou, R, 2015) |
| "A xenograft tumor model of pancreatic cancer was established in athymic nude mice and the tumor size was measured to evaluate the outcome of TL treatment." | ( Ding, X; Jiang, B; Zhao, Q; Zhou, G; Zhou, X, 2015) |
| "Gemcitabine, a first-line treatment for pancreatic cancer, prolongs patient survival by several months, and combination treatment with gemcitabine and other anti-cancer drugs in the clinic do not show any significant effects on overall survival." | ( Hoshino, T; Kodama, R; Mizushima, T; Moritomo, S; Namba, T, 2015) |
| "The effects of miR‑138‑3p regulation on pancreatic cancer cell migration and sensitivity to chemotherapy were examined." | ( Chen, M; Huang, Y; Jiang, J; Wang, M; Yu, C, 2015) |
| "Chemotherapy for unresectable pancreatic cancer should not only prolong survival but maintain quality of life, considering its limited life expectancy." | ( Amano, H; Ikeda, Y; Ito, H; Kainuma, M; Miura, F; Sano, K; Shibuya, M; Takada, T; Toyota, N; Wada, K, 2015) |
| "A major challenge in pancreatic cancer treatment is the resistance of human pancreatic cancer cells to apoptosis." | ( Dreißiger, K; Rothe, J; Wakileh, M; Weber, H, 2015) |
| "A major challenge in pancreatic cancer treatment is the resistance of human pancreatic cancer cells to apoptosis." | ( Dreißiger, K; Rothe, J; Wakileh, M; Weber, H, 2015) |
| "Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35." | ( Fujikawa, K; Fujino, Y; Goji, T; Ikushima, H; Kagemoto, K; Kimura, M; Kimura, T; Kitamura, S; Matsumoto, S; Mitsui, Y; Miyamoto, H; Miyamoto, Y; Muguruma, N; Okada, Y; Okahisa, T; Okamoto, K; Okazaki, J; Sagawa, T; Sato, Y; Sogabe, M; Sueuchi, T; Takaoka, T; Takaoka, Y; Takayama, T; Takehara, M; Tanaka, K, 2015) |
| "We treated pancreatic cancer cell lines BxPC-3 and PANC-1 with AduPARE1A and gemcitabine individually or in combination and analyzed cell viability, combination index, apoptosis and viral production." | ( Fillat, C; José, A; Maliandi, MV; Mato-Berciano, A; Roué, G; Sobrevals, L, 2015) |
| "Resistance to gemcitabine in pancreatic cancer (PC) may account for the failure of conventional treatments." | ( Amini, M; Azizi, M; Daman, Z; Gilani, K; Montazeri, H; Ostad, SN; Rezaie, F, 2015) |
| "We treated human pancreatic cancer MiaPaCa-2 cells with gemcitabine and the AKT inhibitor triciribine, alone and in combination, and evaluated treatment effects using trypan blue assay, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium (MTT) assay, and cell death enzyme-linked immunosorbant assay." | ( Husain, K; Kim, R; Malafa, M; Sebti, S; Yamauchi, T, 2015) |
| "Forty patients resected for pancreatic cancer who underwent adjuvant gemcitabine monotherapy after curative surgery were included." | ( Aoyama, T; Higuchi, A; Kanazawa, A; Katayama, Y; Kobayashi, S; Morimoto, M; Morinaga, S; Murakawa, M; Shiozawa, M; Ueno, M; Yamaoku, K, 2015) |
| "Nestin plays a key role in pancreatic cancer cell metastasis and stemness and that administration of nestin siRNA may offer a novel therapeutic strategy for pancreatic cancer." | ( Arai, T; Ishiwata, T; Matsuda, Y; Ushijima, T; Yamashita, S; Yoshimura, H, 2016) |
| "Survival rates associated with pancreatic cancer remain dismal despite advancements in detection and experimental treatment strategies." | ( Dosch, JS; Rehemtulla, A; Sebolt-Leopold, JS; Shettigar, A; Ziemke, EK, 2015) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "The prognosis of pancreatic cancer remains dismal, with little advance in chemotherapy because of its high frequency of chemoresistance." | ( Chai, X; Chu, H; Gou, S; Meng, Y; Shi, P; Yang, X, 2015) |
| "MICA and CD16 expressions from resected pancreatic cancer patient specimens, which received neoadjuvant chemotherapy (NAC) with GEM, were analyzed by immunohistochemistry." | ( Ahmed, AK; Duncan, MD; Fushida, S; Harmon, JW; Kamigaki, T; Kitagawa, H; Makino, I; Miki, K; Miyashita, T; Nakagawara, H; Ohta, T; Tajima, H; Takamura, H, 2017) |
| "Bevacizumab-resistant FGBR pancreatic cancer cells were treated in vitro with bevacizumab, the recombinant human IL1 receptor antagonist anakinra, the monoclonal antibody against TGFβ receptor type II TR1, and a novel recombinant antibody binding CXCR1/2 ligands." | ( Boschi, F; Carbone, C; Cataldo, I; Melisi, D; Mina, MM; Piro, G; Sbarbati, A; Scarpa, A; Tamburrino, A; Tortora, G; Zanini, S; Zanotto, M, 2016) |
| "We treated two human pancreatic cancer cell lines with the histone deacetylase inhibitor (HDACi) SAHA." | ( Choi, EK; Hong, SW; Hong, YS; Hwang, IY; Jin, DH; Kim, JE; Kim, JH; Kim, KP; Kim, SM; Kim, TW; Lee, DH; Lee, EY; Lee, JS; Lee, WK; Moon, JH; Park, SJ; Shin, JS; Shin, YJ, 2016) |
| "Using the human pancreatic cancer cell lines Panc-1 and BxPC-3 in vitro, the effects of gemcitabine and erlotinib therapy on growth, proliferation, and invasion were tested by cytotoxicity, cell cycle, and Annexin V-Fluorescein Isothiocyanate analysis, reverse transcription polymerase chain reaction, protein expression, and Chip assays." | ( Alejandre, MJ; Delgado, JR; Linares, A; Palomino-Morales, RJ; Perales, S; Torres, C, 2016) |
| "Oxaliplatin is part of pancreatic cancer therapy in the FOLFIRINOX or GEMOX/XELOX regimen." | ( Arora, N; Banerjee, S; Dudeja, V; Giri, B; Kir, D; Majumder, K; Modi, S; Saluja, AK, 2016) |
| "Highly aggressive pancreatic cancer cells (MIA PaCa-2 and PANC-1) were treated with oxaliplatin (0-10 μM), low-dose triptolide (50 nM), or a combination of both for 24-48 h." | ( Arora, N; Banerjee, S; Dudeja, V; Giri, B; Kir, D; Majumder, K; Modi, S; Saluja, AK, 2016) |
| "Proliferation of pancreatic cancer cells was markedly inhibited by combination treatment." | ( Arora, N; Banerjee, S; Dudeja, V; Giri, B; Kir, D; Majumder, K; Modi, S; Saluja, AK, 2016) |
| "In a metastatic murine model of pancreatic cancer, combination therapy with GVAX vaccine and a TGF-β blocking antibody improved the cure rate of PDA-bearing mice." | ( Foley, K; Jaffee, EM; Kim, V; Rucki, AA; Soares, KC; Solt, S; Wolfgang, CL; Zheng, L, 2015) |
| "To achieve this feat, BxPC3 and Panc1 pancreatic cancer cells overexpressing firefly luciferase were treated with gemcitabine in a dose and time gradient manner in vitro." | ( Gu, M; Li, F; Liu, J; Sun, Y; Wei, Y; Xiong, Y; Zhu, L, 2016) |
| "The adaptation of pancreatic cancer cells to limited oxygen delivery promotes the induction of an invasive and treatment-resistant phenotype, triggering metastases at an early stage of tumor development, which resist in most cases adjuvant therapies following tumor resection." | ( Erkan, M; Kleeff, J; Kurtoglu, M, 2016) |
| "In a murine model of pancreatic cancer, we showed that combining CT-guided radiotherapy with a novel ligand of murine and human STING could synergize to control local and distant tumors." | ( Bahjat, K; Baird, JR; Bambina, S; Cottam, B; Crittenden, MR; Dubensky, TW; Friedman, D; Gough, MJ; Kanne, DB, 2016) |
| "Patients with advanced pancreatic cancer who received FOLFIRINOX with G-CSF prophylaxis during the first cycle of treatment from January 2014 to August 2014 were investigated and the frequency of adverse events during the first cycle was measured." | ( Asaishi, K; Goto, M; Higuchi, K; Kii, T; Kuwakado, S; Miyamoto, T; Nishitani, H; Shimamoto, F; Terazawa, T, 2015) |
| "A human pancreatic cancer xenograft model was established in nude mice, 36 of which were randomly divided into 6 treatment groups." | ( Li, B; Shen, ZT; Wang, L; Wu, XH; Zhu, XX, 2015) |
| "The treatment of pancreatic cancer remains unsatisfactory, with an average 5-year survival of less than 5%." | ( Amiji, M; Mattheolabakis, G; Singh, A; Xu, J, 2016) |
| "In patient-derived pancreatic cancer xenografts, nicotine treatment augmented tumor growth and metastasis; tumor lysates from nicotine-treated mice demonstrated elevated HGF expression by qRT-PCR and phospho-Met levels by ELISA." | ( Behrns, KE; Black, BS; Delitto, D; George, TJ; Han, S; Hughes, SJ; Knowlton, AE; Liu, C; Lu, X; Sarosi, GA; Thomas, RM; Trevino, JG; Vlada, AC; Wallet, SM; Zhang, D, 2016) |
| "Human pancreatic cancer cells (Panc-1 and SUIT-2 cells) were treated with conditioned medium of immortalized human PSCs (PSC-CM)." | ( Hamada, S; Masamune, A; Shimosegawa, T; Takikawa, T; Yoshida, N, 2016) |
| "The SCAN pancreatic cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for pancreatic adenocarcinoma in Singapore." | ( , 2015) |
| "We encountered a case of pancreatic cancer with multiple liver metastases that developed postoperatively and showed a complete response with S-1 monotherapy for a long time." | ( Asai, K; Baba, M; Hiratsuka, M; Katsuyama, S; Murata, M; Saso, K; Sawami, H; Takahashi, H; Takayama, O; Tanaka, N; Yagi, T; Yamada, M; Yamamoto, M, 2015) |
| "We report a case of a patient with pancreatic cancer who underwent this chemotherapy." | ( Egawa, C; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Matsushita, K; Morimoto, Y; Motoyama, Y; Murakami, K; Naito, A; Ohmura, Y; Okishiro, M; Takeda, Y; Takeno, A; Tamura, S, 2015) |
| "The tumor was diagnosed as unresectable pancreatic cancer, and chemotherapy of gemcitabine and S-1 was administered, resulting in a remarkable reduction of the tumor size." | ( Hashimoto, M; Hayashi, H; Ikeda, Y; Ishii, T; Katayama, T; Kawasaki, Y; Ohtsuru, M; Okubo, Y; Senba, H; Shinozaki, K; Tono, T; Yasuda, S, 2015) |
| "Patients with borderline resectable pancreatic cancer have a poorer prognosis than patients with resectable pancreatic cancer, but some cases treated with neoadjuvant chemoradiation therapy and radical surgery (R0 surgery) show long-term survival." | ( Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Miyahara, Y; Miyazaki, M; Nishida, T; Ohtsuka, M; Okamura, D; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H, 2015) |
| "Treatment of orthotopic pancreatic cancer xenografts with either gemcitabine, JNKi or TRAIL alone for 4 weeks showed only modest effects compared to control, while the combination of JNKi and TRAIL resulted in significantly lower tumor burden (69%; p < 0." | ( Alt, E; Heinemann, ML; Ilmer, M; Kettlun, C; Recio-Boiles, A; Rhea, PR; Ruetering, J; Vykoukal, J, 2016) |
| "There is still no suitable drug for pancreatic cancer treatment, which is one of the most aggressive human tumors." | ( Bao, J; Chen, R; Hu, D; Jiang, M; Shen, Y; Shen, Z; Shi, A; Su, C; Tang, W; Zhao, F, 2016) |
| "In the surgical treatment of pancreatic cancer, margin-negative status is one of the most important determinants of survival." | ( Anazawa, T; Doi, R; Ito, T; Kawaguchi, Y; Masui, T; Nakano, K; Sato, A; Takaori, K; Uemoto, S, 2016) |
| "Locally advanced pancreatic cancer (LAPC) is associated with high mortality, and biomarker-driven treatment approach is currently lacking." | ( Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D, 2016) |
| "Interactions of inflammatory cells with pancreatic cancer cells play crucial roles in pancreatic cancer, however the dynamic changes of inflammatory cell populations in pancreatic cancerogensis and after chemotherapy have not been well eclucidated." | ( Li, Y; Liao, Q; Liu, Q; Lu, Z; Niu, Z; Wang, M; Yao, L; Zhao, Y; Zong, Y, 2016) |
| "Consequently, Lip-FLLL32 suppressed pancreatic cancer cell growth, and exhibited synergetic effects with gemcitabine and radiation treatment in vitro and in vivo." | ( Fuchs, JR; He, F; Highfill, CA; Ji, M; Li, K; Li, L; Lian, J; Lin, J; Marquez, RT; Tang, W; Wu, X; Xu, L, 2016) |
| "We retrospectively assessed 49 biopsied pancreatic cancer tissue samples that were obtained prior to the treatment with gemcitabine." | ( Adachi, S; Doi, S; Hirose, Y; Iwashita, T; Kawaguchi, J; Kozawa, O; Moriwaki, H; Nakashima, M; Okuno, M; Shimizu, M; Yasuda, I; Yoshimi, N, 2016) |
| "Patients with advanced pancreatic cancer treated with curcumin showed significantly greater loss of subcutaneous fat and muscle than matched untreated controls." | ( Abbruzzese, J; Baracos, VE; Bruera, E; Hong, DS; Kurzrock, R; Parsons, HA, 2016) |
| "Advances made in pancreatic cancer therapy have been far from sufficient and have allowed only a slight improvement in global survival of patients with pancreatic ductal adenocarcinoma (PDA)." | ( Bartholin, L; Berthezene, P; Bressy, C; Calvo, E; Chan, P; Guillaumond, F; Iovanna, JL; Lac, S; Leca, J; Nigri, J; Thakur, AK; Tomasini, R; Vasseur, S, 2016) |
| "Individual treatment strategies for pancreatic cancer can be suggested based on patients' preoperative MTV2." | ( Hwang, HK; Kang, CM; Lee, SH; Lee, WJ; Yun, M, 2016) |
| "Patients with (borderline) resectable pancreatic cancer are randomized to A: direct explorative laparotomy or B: after negative diagnostic laparoscopy, preoperative radiochemotherapy, followed by explorative laparotomy." | ( Besselink, MG; Boerma, D; Bonsing, BA; Busch, OR; de Hingh, IH; de Vos-Geelen, J; Dohmen, MA; Erdmann, JI; Festen, S; Groothuis, KB; Klaase, JM; Molenaar, IQ; Patijn, GA; Punt, CJ; Rasch, CR; Suker, M; Ten Tije, AJ; van der Harst, E; van der Kolk, MB; van Eijck, CH; van Tienhoven, G; Versteijne, E; Zwinderman, AH, 2016) |
| "First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine." | ( Barile, E; Das, SK; De, SK; Emdad, L; Fisher, PB; Morvaridi, SK; Pandol, SJ; Pellecchia, M; Quinn, BA; Sarkar, D; Stebbins, JL; Wang, S, 2016) |
| "Chemotherapy treatment of pancreatic cancer-associated fibroblasts results in a proinflammatory response driven by stress-associated MAPK signaling that enhances tumor cell growth and invasiveness." | ( Bikhchandani, M; Dawson, DW; Donahue, TR; Duong, M; Gawlas, I; Kadera, BE; Li, L; Nguyen, AH; Patel, SG; Toste, PA; Tran, LM; Wu, N, 2016) |
| "The human pancreatic cancer cell line Panc-1, was treated with hypoxic condition and curcumin." | ( Cao, L; Duan, W; Lei, J; Li, W; Ma, Q; Xiao, X, 2016) |
| "Treating metastatic pancreatic cancer (MPC) remains a challenging issue." | ( Cavaglione, G; Evesque, L; Follana, P; François, E; Gal, J; Reure, J; Saint, A, 2016) |
| "Three human pancreatic cancer cell lines were treated with S-1, nab-paclitaxel, alone or in combination." | ( Fujii, T; Fujiwara, M; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Suenaga, M; Sugimoto, H; Tanaka, C; Yamada, S, 2016) |
| "PL treatment of pancreatic cancer cells resulted in differential expression of 683 mRNA transcripts with known protein functions, 351 of which were upregulated and 332 of which were downregulated compared to control-treated cells." | ( Dhillon, H; Mamidi, S; McClean, P; Reindl, KM, 2016) |
| "A total of 67 resected pancreatic cancer patients, treated with adjuvant GEM, were included." | ( Akaike, M; Godai, T; Higuchi, A; Katayama, Y; Masuda, M; Morinaga, S; Numata, K; Numata, M; Rino, Y; Sawazaki, S; Shiozawa, M, 2016) |
| "In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of erlotinib is unknown." | ( André, T; Artru, P; Bonnetain, F; Borbath, I; Bouché, O; Chibaudel, B; Glimelius, B; Goldstein, D; Hammel, P; Huguet, F; Louvet, C; Mineur, L; Shannon, J; van Laethem, JL, 2016) |
| "Patients with locally advanced pancreatic cancer treated with FOLFIRINOX had a median overall survival of 24·2 months-longer than that reported with gemcitabine (6-13 months)." | ( Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A, 2016) |
| "As the standard therapy for pancreatic cancer, gemcitabine shows limited efficacy in pancreatic cancer patients because of chemoresistance." | ( Camara, SN; Cao, B; Duan, Q; Shen, Q; Shi, P; Wang, C; Yin, T; Zhang, Z; Zhao, H, 2016) |
| "Using multiple human pancreatic cancer cells we found that combination treatment with Nx and GEM resulted in significant alterations of proteins in the STAT3/NF-κB signaling axis culminating in growth inhibition in a synergistic manner." | ( Chan, DE; Freeman, JW; Ghosh, R; Gong, J; Kumar, AP; Muñoz, AR; Payton-Stewart, F; Pingali, S, 2017) |
| "Patients with advanced and metastatic pancreatic cancer refractory to gemcitabine based therapy have a dismal prognosis and limited therapeutic options." | ( Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN, 2016) |
| "Patients with resected pancreatic cancer were randomly assigned (in a 1:1 ratio) to receive gemcitabine (1000 mg/m(2), intravenously administered on days 1, 8, and 15, every 4 weeks [one cycle], for up to six cycles) or S-1 (40 mg, 50 mg, or 60 mg according to body-surface area, orally administered twice a day for 28 days followed by a 14 day rest, every 6 weeks [one cycle], for up to four cycles) at the data centre by a modified minimisation method, balancing residual tumour status, nodal status, and institutions." | ( Boku, N; Fukutomi, A; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R, 2016) |
| "Since recurrence and metastasis of pancreatic cancer has a worse prognosis, chemotherapy has been typically performed to attack the remained malignant cells after resection." | ( Cho, DW; Choi, YJ; Hong, JM; Kang, KS; Kim, SC; Lee, CM; Park, MN; Pati, RG; Shim, IK; Yi, HG, 2016) |
| "Among 123 patients with unresectable pancreatic cancer referred to our Institution between 2006 and 2014, 58 treated with endoscopic ultrasound-guided celiac plexus neurolysis (Group 1) and 65 with the combined approach (Group 2) were compared." | ( Costamagna, G; Di Maso, M; Facciorusso, A; Larghi, A; Muscatiello, N; Serviddio, G, 2017) |
| "The treatment of pancreatic cancer, one of the most aggressive gastrointestinal tract malignancies, with current chemotherapeutic drugs has had limited success due to its chemoresistance and poor prognosis." | ( Higuchi, Y; Honma, Y; Kasukabe, T; Kato, N; Kumakura, S; Okabe-Kado, J, 2016) |
| "High mortality in pancreatic cancer patients is partly due to resistance to chemotherapy." | ( Asimakopoulos, AG; Boroujerdi, M; Davis, PJ; Kannan, K; Kohan, HG; Mousa, SA; Muralidharan-Chari, V; Sell, S; Sudha, T, 2016) |
| "436 patients with unresectable pancreatic cancers received HIFU treatment; the other 253 patients received non-HIFU treatment." | ( Chen, QW; Cheng, CS; Meng, ZQ; Ning, ZY; Shi, WD; Song, LB; Wang, K; Wang, P; Xie, J; Xu, LT; Zhang, CY; Zhu, XY; Zhuang, LP, 2016) |
| "Treating pancreatic cancer is extremely challenging due to multiple factors, including chemoresistance and poor disease prognosis." | ( Barraud, M; Bian, B; Bigonnet, M; Delpero, JR; Duconseil, P; Dusetti, N; Garcia, S; Garnier, J; Gasmi, M; Gayet, O; Gilabert, M; Giovannini, M; Grandval, P; Guibert, N; Iovanna, J; Lequeue, C; Loncle, C; Maignan, A; Moutardier, V; Ouaissi, M; Poizat, F; Secq, V; Turrini, O; Vasseur, S, 2016) |
| "As part of the Know Your Tumor project (Pancreatic Cancer Action Network), a 48-year-old female was diagnosed with metastatic PDA and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed." | ( Bender, J; Brody, JR; Curtis, M; Fortuna, D; Heartwell, C; Jiang, W; Madhavan, S; Mason, K; Matrisian, LM; Peiper, SC; Petricoin, E; Pishvaian, MJ; Rahib, L; Varieur, K; Wang, ZX; Winter, JM; Yabar, CS; Yeo, CJ; Zarei, M, 2018) |
| "Effective therapies against metastatic pancreatic cancer remain limited, and despite treatment, many will ultimately progress." | ( Bien, H; Choi, M; Mackenzie, GG, 2016) |
| "A 54-year-old female with unresectable pancreatic cancer received gemcitabine in combination with radiation therapy followed by chemotherapy with gemcitabine and erlotinib." | ( Bak, YT; Choi, SJ; Kim, HJ; Kim, JS, 2016) |
| "The extremely poor prognosis in pancreatic cancer is due to the late diagnosis and lack of effective therapy in advanced disease." | ( Hussain, SP; Wang, J, 2017) |
| "We found that PIM-1 knockdown in pancreatic cancer cells suppressed proliferation, induced cell cycle arrest, enhanced apoptosis, resensitized cells to gemcitabine and erlotinib treatment, and inhibited ABCG2 and EZH2 mRNA expression." | ( Cao, Z; Hu, Y; Huang, H; Wang, T; Xiong, G; Xu, J; You, L; Zhang, T; Zhao, Y; Zheng, L; Zhou, L, 2016) |
| "Human pancreatic cancer cell line BxPC-3 was treated with 10 ng/ml TGF-β1 and 200 ng/ml BMP2 for 72 h, respectively, and the mRNA and protein expression levels of PPM1H and EMT-related markers (E-cadherin, vimentin) were detected by real-time PCR and western blotting, respectively." | ( Li, DM; Liu, J; Qin, H; Zhao, Q; Zhu, H, 2016) |
| "As a effective chemotherapy drug for pancreatic cancer patients, gemcitabine is reported to inhibit cell proliferation as a nucleotide analog." | ( Huang, M; Huang, Q; Lin, X; Xie, F; Yang, J; Zhou, H, 2016) |
| "Because the 5-year survival rate for pancreatic cancer remains under 10%, new drugs are needed for the prevention and treatment of this devastating disease." | ( Leal, AS; Liby, KT; Pioli, PA; Sporn, MB, 2016) |
| "There are no effective treatments for pancreatic cancer peritoneal carcinomatosis (PC) or cancer dissemination in abdominal cavity." | ( Aoki, H; Aoki, M; Idowu, MO; Katsuta, E; Ramanathan, R; Spiegel, S; Takabe, K, 2016) |
| "Esculetin treatment in all three pancreatic cancer cell lines resulted in significant growth inhibition with G1-phase cell cycle arrest and induction of mitochondrial dependent apoptosis through activation of caspases 3, 8 and 9." | ( Arora, R; Saini, V; Saluja, D; Sawney, S; Steffi, C; Tiwari, M, 2016) |
| "In the mouse xenograft pancreatic cancer model, triple VEGFRs silencing significantly reduced tumor growth, had synergistic effect with standard chemotherapy, and was associated with inhibition of epithelial mesenchymal transition (EMT)." | ( Huang, F; Huang, J; Jin, Q; Li, J; Lu, Y; Mei, H; Tang, Z; Wang, Z; Zhang, X, 2017) |
| "Among the greatest hurdles to pancreatic cancer (PC) therapy is the limited tissue penetration of systemic chemotherapy because of tumor desmoplasia." | ( Alberts, SR; Bamlet, WR; Burch, PA; Chari, ST; Farnell, MB; Gleeson, FC; Haddock, MG; Kendrick, ML; Levy, MJ; Oberg, AL; Petersen, GM; Takahashi, N, 2017) |
| "A number of PTMs have been linked to pancreatic cancer and are frequently studied as potential targets for cancer therapy or diagnosis." | ( Andersson, R; Ansari, D; Bauden, M; Kristl, T; Marko-Varga, G, 2017) |
| "In this study, pancreatic cancer cell lines Miacapa-2 and PANC-1 were cultured, and cell viability was examined in these two cells treated with different doses of aconitine." | ( Ji, BL; Mao, GZ; Xia, LP; Xu, LX; Zhou, FX, 2016) |
| "Patients with advanced pancreatic cancer were treated in first line with lenalidomide orally for 21 days of a 28 days cycle and the standard regimen for gemcitabine." | ( Broberg, M; Liljefors, M; Mellstedt, H; Mozaffari, F; Ullenhag, GJ, 2017) |
| "In the advanced stages of pancreatic cancer with cisplatin treatment, we observed chemoresistance behavior with overexpression, especially for β-catenin." | ( Fang, KF; Fang, Z; Li, Y; Wang, L; Zhong, RL, 2017) |
| "What confers pancreatic cancer resistance to checkpoint immunotherapy is unknown." | ( Liu, K; Lu, C; Oberlies, NH; Paschall, AV; Pearce, C; Sabbatini, ME; Savage, N; Shi, H; Waller, JL, 2017) |
| "We report a case of remnant pancreatic cancer after pancreatoduodenectomy that was successfully treated using chemotherapy and carbon-ion radiotherapy." | ( Ando, S; Kamei, R; Kitamura, Y; Tokunou, K; Yamamoto, H; Yamamoto, T, 2016) |
| "SUIT-2 human pancreatic cancer cell line cells overexpressing pro-inflammatory cytokines, including interleukin (IL)-1β, IL-8, and tumor necrosis factor (TNF)-α, were treated with colchicine." | ( Hisatomi, H; Kawahito, Y; Machida, T; Uchida, M; Yajima, C; Yokoyama, C, 2017) |
| "Prognosis of advanced pancreatic cancer is dismal and the novel targeted therapies, albeit successfully used to treat many advanced tumors, have shown modest results." | ( Avallone, A; Botti, G; Capozzi, M; De Divitiis, C; De Stefano, A; Ottaiano, A; Tafuto, S, 2017) |
| "The Vandetanib in Pancreatic Cancer (ViP) trial was a phase 2 double-blind, multicentre, randomised placebo-controlled trial in previously untreated adult patients (aged ≥18 years) diagnosed with locally advanced or metastatic carcinoma of the pancreas confirmed by cytology or histology." | ( Campbell, F; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Evans, A; Falk, S; Ghaneh, P; Greenhalf, W; Hickish, T; Jackson, R; Madhusudan, S; Middleton, G; Neoptolemos, JP; Palmer, DH; Propper, D; Rawcliffe, C; Ross, P; Shaw, VE; Valle, JW; Wadd, N; Wadsley, J; Wasan, H, 2017) |
| "SAHA is a good radiosensitizer for pancreatic cancer treatment." | ( Chen, X; Gao, Y; Jing, S; Li, Y; Li, Z; Ma, S; Piao, J; Wu, Z; Yu, S; Zhao, Y, 2017) |
| "Gemcitabine remains a pillar in pancreatic cancer treatment." | ( Abakar-Mahamat, A; Ciccolini, J; Dahan, L; Deplanque, G; Fein, F; François, E; Gagnière, J; Gattacceca, F; Lacarelle, B; Rachid, M; Seitz, JF; Serdjebi, C, 2017) |
| "Although gemcitabine is a mainstay of pancreatic cancer therapy, it is only moderately effective, and it would be desirable to measure drug uptake in patients." | ( Desai, P; Haimovitz-Friedman, A; Humm, JL; Kramer, RM; Lowery, MA; Pillarsetty, N; Romesser, PB; Russell, J, 2017) |
| "BACKGROUND Pancreatic cancer is considered a chemoresistant neoplasm with extremely dismal prognosis and gemcitabine treatment is associated with many side effects and poor overall survival." | ( Xiao, J; Yu, H, 2017) |
| "AZ20 treatment of the pancreatic cancer cell lines resulted in growth inhibition, with IC50 values ranging from 0." | ( Edwards, H; Ge, Y; Jiang, Y; Liu, S; Quan, C; Ren, Q; Wang, G; Wang, T, 2017) |
| "Five patients with PM from pancreatic cancer were treated with a total of 16 PIPAC procedures." | ( Bjerregaard, JK; Detlefsen, S; Graversen, M; Mortensen, MB; Pfeiffer, P, 2017) |
| "Data for 895 pancreatic cancer patients who were treated using chemotherapy or best supportive care were analyzed considering demographics, clinical stage, treatment, and outcome." | ( Azemoto, N; Hasebe, A; Hiasa, Y; Imai, Y; Imamura, Y; Inada, N; Kawamura, T; Koizumi, M; Kumagi, T; Kuroda, T; Miyata, H; Nishiyama, M; Ohno, Y; Seike, H; Shibata, N; Tanaka, Y; Terao, T; Ueno-Toshimori, A; Yamanishi, H; Yokota, T, 2017) |
| "Treatment of pancreatic cancer with gemcitabine (GEM) is limited due to its rapid plasma metabolism and development of chemoresistance." | ( Chaudhary, AK; Kattel, K; Kumar, V; Mahato, RI; Mondal, G, 2017) |
| "In advanced pancreatic cancer patients, MDM2 expression is associated with shorter OS and PFS after gemcitabine-based chemotherapy." | ( Cheng, AL; Guo, JC; Kuo, SH; Kuo, TC; Lee, JC; Tien, YW; Yang, SH; Yeh, KH, 2017) |
| "Gemcitabine treatment for pancreatic cancer may result in resumption of ovulation in women with polycystic ovarian syndrome and these women should be counseled accordingly." | ( Carlan, SJ; Guzman, A; Holloman, C; Madruga, M; Sundharkrishnan, L, 2017) |
| "In four established pancreatic cancer cell lines we investigated clonogenic survival, analyzed cell cycle distribution and compared DNA damage via flow cytometry and western blot after treatment with SFN and RT." | ( Combs, SE; Debus, J; Fortunato, F; Liermann, J; Naumann, P; Schmid, TE; Weber, KJ, 2017) |
| "The economic burden of metastatic pancreatic cancer (mPC) is substantial while treatment options are limited." | ( Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O, 2017) |
| "The identification of pancreatic cancer stem cell functions has been as important strategy for understanding of pancreatic cancer biology and novel drug and therapy development." | ( Li, R; Ma, J; Yang, J; Yin, X; Zeng, D, 2018) |
| "Although the prognosis in pancreatic cancer remains grim in part due to poor response to therapy, previous attempts at identifying and targeting the resistance mechanisms have not been very successful." | ( Abrego, J; Berim, L; Chaika, NV; Grem, J; Gunda, V; King, RJ; Lazenby, AJ; Sasson, AR; Shukla, SK; Singh, PK; Tadros, S; Vernucci, E; Yu, F, 2017) |
| "The prognosis of metastatic pancreatic cancer remains poor despite recent advances in treatment with multidrug chemotherapy regimens." | ( Cecchini, M; Lacy, J; Sklar, J, 2017) |
| "Capan-2 pancreatic cancer cells were pre-treated for 24 h with calcitriol, BHT, BHA, or silibinin, followed by gemcitabine treatment." | ( Boroujerdi, M; Gilzad-Kohan, H; Sani, S, 2017) |
| "Pre-treatment of the pancreatic cancer cells with calcitriol significantly increased gemcitabine cellular uptake and consequently decreased cell viability after treatment with gemcitabine, whereas BHA significantly reduced gemcitabine uptake and decreased cell death rate, which were at least partially attributed to the alteration of expression of efflux and influx proteins." | ( Boroujerdi, M; Gilzad-Kohan, H; Sani, S, 2017) |
| "The incidence of pancreatic cancer has been obviously increasing in China over the last decade, however, those patients with advanced pancreatic cancer are suffering from limited treatment strategies and poor clinical prognosis." | ( Shen, L; Wang, ZH; Zhou, J, 2017) |
| "For the current treatment of pancreatic cancer, the available chemotherapy regimens have shown modest but statistically significant improvements in survival." | ( Saung, MT; Zheng, L, 2017) |
| "Using an orthotopic pancreatic cancer model in syngeneic C57BL/6 mice we show that the local administration of HCA-EF-ZP achieves better tumor/liver ratio of luciferase production than the intravenous route." | ( Bunuales, M; German, B; Gonzalez-Aparicio, M; Hernandez-Alcoceba, R; Poutou, J; Zugasti, I, 2017) |
| "However, in TRAIL-resistant pancreatic cancer, responsiveness to TRAIL treatment is terribly poor." | ( Gao, Y; Hu, W; Jia, X; Zhang, Q, 2018) |
| "Six patients with unresectable pancreatic cancer, treated at Tokyo Metropolitan Geriatric Hospital, were used in this open-labeled, investigator-initiated trial." | ( Arai, T; Fujii, Y; Itoi, T; Matsuda, Y; Matsukawa, M; Nishimura, M; Ochiai, Y; Yahagi, N, 2018) |
| "Identifying a marker for pancreatic cancer among high-risk patients such as new-onset diabetics might lead to the identification of a subpopulation needing to be screened in order to enable early diagnosis and treatment of a highly lethal tumor." | ( Antolino, L; Aurello, P; Bollanti, L; Catarinozzi, E; D'Angelo, F; Ramacciato, G; Rocca, M; Todde, F, 2018) |
| "Overall, the pancreatic cancer risk was not increased in patients administered incretin drugs compared with controls (Peto odds ratio [OR] 0." | ( Haukka, J; Hong, T; Liu, Y; Lu, R; Tian, Q; Wang, H; Yang, J; Zhan, S, 2018) |
| "LY2603618 treatment of the pancreatic cancer cell lines resulted in growth inhibition, with IC50 values ranging from 0." | ( Guo, Y; Liang, M; Ma, L; Zhao, T, 2018) |
| "Despite all efforts in pancreatic cancer treatment, the five-year survival rates at diagnosis over the past 20 years have only increased from 5% to 8%." | ( Friess, H; Goess, R, 2018) |
| "Mismatch repair status in pancreatic cancer patients is not only a prognostic indicator but also a potential guiding factor for the use of 5-fluorouracil-based adjuvant chemotherapy." | ( Liang, C; Liang, D; Meng, Q; Ni, Q; Shi, S; Xu, J; Yu, X; Zhang, B, 2018) |
| "Human pancreatic cancer cells were treated with Anacardic acid and assessed for the cytotoxic effect using MTT and spheroid formation assays." | ( Blackmon, M; Craver, S; Dixon, V; Neal, D; Park, M; Perkins, D; Upton, D, 2018) |
| "Eight patients with resectable pancreatic cancer undergoing surgery either combined with S-1 or S-1 plus gemcitabine therapy were enrolled." | ( Kobayashi, M; Koido, S; Koizumi, T; Koya, T; Nagai, K; Okamoto, M; Sano, K; Shimodaira, S; Sugiyama, H; Yanagisawa, R, 2018) |
| "Patients with pancreatic cancer were given the digestive enzyme supplement LipaCreon® from the fifth week after the start of administration." | ( Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K, 2018) |
| "Five weeks after implantation, 40 pancreatic cancer PDOX mouse models were randomized into four groups of 10 mice each: untreated control (n = 10); GEM (100 mg/kg, i." | ( Bouvet, M; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Lwin, TM; Miyake, K; Miyake, M; Oshiro, H; Tan, Y; Unno, M, 2018) |
| "To determine the action of 2DG in pancreatic cancer, we performed proteomic analysis of pancreatic cancer cell line after 2DG treatment." | ( Fujii, T; Ishino, K; Kawahara, K; Kawamoto, Y; Kitamura, T; Kudo, M; Kure, S; Naito, Z; Peng, WX; Teduka, K; Wada, R; Yamamoto, T, 2018) |
| "Pain caused by infiltrating pancreatic cancer is complex in nature and may therefore be difficult to treat." | ( Geitung, JT; Rosland, JH, 2018) |
| "Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy." | ( Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K, 2018) |
| "Patients with metastatic pancreatic cancer received first-line nab-paclitaxel plus gemcitabine or gemcitabine alone in the MPACT study; this analysis focused on those treated in Australia." | ( Aly, A; Asghari, G; Beale, P; Botteman, M; Clingan, P; Ferrara, S; Harris, M; Mainwaring, P; Margunato-Debay, S; Parnis, FX; Romano, A; Young, R, 2018) |
| "Treatments for metastatic pancreatic cancer include monotherapy with gemcitabine (GEM); combinations of GEM with oxaliplatin (OX + GEM), cisplatin (CIS + GEM), capecitabine (CAP + GEM), or nab-paclitaxel (NAB-P + GEM); and the non-GEM combination FOLFIRINOX." | ( Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M, 2018) |
| "In a pancreatic cancer model, combined treatment with 10-DEBC and PP2 also significantly suppressed the growth of pancreatic cancer." | ( Ahn, K; Cho, HJ; Ji, YG; Lee, DH; O, YM, 2018) |
| "Inhibiting pancreatic cancer progression after chemotherapy is a rational application of this metabolism-disturbing combination strategy." | ( Chen, C; Fei, K; Guo, L; Ju, R; Li, J; Li, S; Ye, C; Zhang, D; Zhu, L, 2018) |
| "Current chemotherapy drugs for pancreatic cancer only offer an increase in survival of up to six months." | ( Bond, DR; Goldsmith, CD; Jankowski, H; Roach, PD; Scarlett, CJ; Stathopoulos, CE; Weidenhofer, J, 2018) |
| "Chemotherapy for unresectable pancreatic cancer has moved from using gemcitabine (GEM) and/or S-1 to using 5- fluorouracil plus Leucovorin plus oxaliplatin plus irinotecan (FOLFIRINOX) or GEM and nano albumin-bound paclitaxel (nab- PTA)." | ( Saito, K; Sato, A; Takahata, T; Yu, C, 2018) |
| "Recent studies on metastatic pancreatic cancer have shown that combination chemotherapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel (GnP) prolonged the overall survival compared with gemcitabine alone." | ( Fukuda, H; Fukutomi, A; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Katayama, H; Mizuno, N; Mizusawa, J; Okusaka, T; Ozaka, M; Ueno, H; Ueno, M, 2018) |
| "Gemcitabine is the cornerstone of pancreatic cancer treatment." | ( Chen, BW; Chen, W; Hu, L; Li, H; Liang, T; Liu, H; Ma, T; Shen, J; Zhang, B; Zhang, S; Zheng, X; Zhi, X; Zhou, Y, 2018) |
| "The hallmark of pancreatic cancer is its high mortality rate attributed to the existence of cancer stem cell (CSC) subpopulations which result in therapy resistance and recurrence." | ( Aliebrahimi, S; Arab, SS; Kouhsari, SM; Ostad, SN; Shadboorestan, A, 2018) |
| "Indiana University Simon Cancer Center pancreatic cancer database was used to identify patients with metastatic PDAC, treated with FOLFIRINOX and had tissue available for DNA sequencing." | ( Gbolahan, O; Hancock, BA; O'Neil, BH; Radovich, M; Sehdev, A; Shahda, S; Stanley, M; Wan, J; Wu, HH, 2018) |
| "Locally advanced pancreatic cancer (LAPC) is an emerging entity lacking in level III evidence-based recommendations for its treatment." | ( de Liguori Carino, N; McNamara, MG; O'Reilly, DA; Pihlak, R; Radhakrishna, G; Siriwardena, AK; Valle, JW, 2018) |
| "Thirteen patients with metastatic pancreatic cancer underwent clinical, sonographic, and electrophysiological evaluation before, 3 and 7 months after treatment with 12 two-week cycles of FOLFIRINOX." | ( Fisse, AL; Gold, R; Höffken, N; Lönneker, N; Pitarokoili, K; Reinacher-Schick, A; Trampe, N; Yoon, MS, 2019) |
| "Cantharidin can sensitize pancreatic cancer cells to radiotherapy." | ( Gong, FR; Li, W; Liu, SL; Tao, M; Wu, J; Wu, MY; Xu, MD; Zhang, J; Zhang, Y; Zheng, BB, 2018) |
| "The assessment of drug-combinations for pancreatic cancer treatment is usually performed in 2D cell cultures." | ( Barros, AS; Correia, IJ; Costa, EC; de Melo-Diogo, D; Nunes, AS, 2018) |
| "The poor prognosis of pancreatic cancer requires the development of more effective therapy." | ( Higashi, T; Koizumi, M; Kurosawa, G; Kurosawa, Y; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB; Ukai, Y, 2018) |
| "A novel therapy can be designed for pancreatic cancer by using ECM modulation." | ( Endo, M; Hakamada, K; Kakizaki, I; Kudo, D; Nagase, H; Shimoda, H; Suto, A; Suto, S; Yoshida, E, 2018) |
| "The major challenges of eliminating pancreatic cancer are treatment resistance and stromal barriers to optimal drug access within the tumor." | ( Fan, C; Huang, RY; Li, F; Liao, J; Ling, X; Repasky, EA; Rich, LJ; Wang, X; Wu, W; Xu, C, 2018) |
| "Molecular targeting therapy for pancreatic cancer is still limited." | ( Chen, H; Ding, K; Du, Z; Liao, W; Shao, C; Wang, P; Yao, Y; Zhou, L, 2019) |
| "Gemcitabine-resistant pancreatic cancer cells (KLM1-R) were treated with AHCC (10 mg/ml) for 48 h." | ( Baron, B; Hamada, JI; Harada, K; Kitagawa, T; Kobayashi, M; Kuhara, K; Kuramitsu, Y; Nagayasu, H; Ohta, T; Shimo, T; Takai, R; Terasaki, M; Tokuda, K; Tokunaga, M; Uehara, O, 2018) |
| "In borderline resectable pancreatic cancer (BRPC), neoadjuvant treatment regimens have been introduced with the rationale to downstage and downsize the tumor in order to enable resection and eliminate -microscopic distant metastases." | ( D'Haese, JG; Friess, H; Gloor, B; Hartmann, D; Kaufmann, B; Radenkovic, D; Stupakov, P, 2019) |
| "Advanced pancreatic cancer (APC), one of the most aggressive tunors, was considered to be resistant to chemotherapy for decades." | ( Farhat, F; Kattan, J; Kourie, HR; Tabchi, S, 2016) |
| "MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy." | ( Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD, 2018) |
| "Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40-60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40-60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle)." | ( Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S, 2019) |
| "Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy." | ( Artru, P; Assenat, E; Bachet, JB; Ben Abdelghani, M; Biagi, JJ; Bouhier-Leporrier, K; Breysacher, G; Castan, F; Choné, L; Conroy, T; Cripps, C; Di Fiore, F; Faroux, R; Francois, E; Gourgou, S; Hammel, P; Hebbar, M; Jouffroy-Zeller, C; Juzyna, B; Kavan, P; Khemissa-Akouz, F; Lecomte, T; Legoux, JL; Malka, D; O'Callaghan, CJ; Raoul, JL; Rat, P; Sauvanet, A; Texereau, P; Volet, J; Wei, AC; Ychou, M, 2018) |
| "Locally advanced pancreatic cancer (LAPC) has a dismal prognosis with current treatment modalities and one-third of patients die from local progression of disease." | ( Bryant, M; Davis, MJ; Hendifar, A; Hoffman, D; Jamil, L; Kim, S; Klempner, SJ; Lo, S; Nissen, N; Noe, P; Osipov, A; Piantadosi, S; Placencio-Hickok, V; Ristow, L; Rokhsar, S; Sandler, H; Scher, K; Shiao, SL; Tighiouart, M; Tuli, R; Wachsman, A, 2019) |
| "However, treatment for locally advanced pancreatic cancer is still controversial." | ( Fukutomi, A; Kamei, K; Kobayashi, M; Kobayashi, S; Matsumoto, I; Matsuoka, H; Mizuno, N; Omae, K; Ozaka, M; Suzuki, S; Todaka, A; Ueno, H; Uesugi, K, 2019) |
| "Unresectable pancreatic cancer is almost universally lethal because chemotherapy and radiation cannot completely stop the growth of the cancer." | ( Chan, WK; Dantzer, R; de la Cruz Bonilla, M; Deorukhkar, A; Fujimoto, TN; Garcia, CJG; Grossberg, AJ; Horvath, TD; Lin, D; Lorenzi, PL; Mason, KA; Molkentine, JM; Piwnica-Worms, H; Samuel, ELG; Taniguchi, CM; Tour, JM, 2019) |
| "Unresectable pancreatic cancer is almost universally lethal because chemotherapy and radiation cannot completely stop the growth of the cancer." | ( Chan, WK; Dantzer, R; de la Cruz Bonilla, M; Deorukhkar, A; Fujimoto, TN; Garcia, CJG; Grossberg, AJ; Horvath, TD; Lin, D; Lorenzi, PL; Mason, KA; Molkentine, JM; Piwnica-Worms, H; Samuel, ELG; Taniguchi, CM; Tour, JM, 2019) |
| "Heavily pretreated pancreatic cancer patients have a grave prognosis." | ( Cheng, AL; Guo, JC; Hsu, C; Kuo, SH; Tien, YW; Yang, SH; Yeh, KH, 2020) |
| "Recent research has found that most pancreatic cancers develop resistance to the current first-line chemotherapeutic drug, gemcitabine (Gem), and high expression of Mcl-1 can reduce the sensitivity of pancreatic cancer cells to Gem chemotherapy." | ( Gao, F; He, M; Jiang, X; Kuai, Q; Nie, G; Pan, Y; Ren, S; Shi, W; Wang, Y; Yu, Q; Zhao, X, 2019) |
| "Advanced pancreatic cancer (aPC) has a poor prognosis with limited survival benefit from current standard treatment." | ( Kempenich, R; Kienle, GS; Lang-Avérous, G; Werthmann, PG, 2019) |
| "Anti-pancreatic cancer activities following combined treatment of naringenin and hesperetin were demonstrated in vitro and in vivo experiments." | ( Kim, DH; Kim, JH; Lee, J, 2019) |
| "Key words: pancreatic cancer - prognosis - chemotherapy The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study." | ( Bumberová, M; Dolinský, J; Janega, P; Jurišová, S; Kašperová, B; Macúch, J; Mego, M, 2018) |
| "Key words: pancreatic cancer - prognosis - chemotherapy The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study." | ( Bumberová, M; Dolinský, J; Janega, P; Jurišová, S; Kašperová, B; Macúch, J; Mego, M, 2018) |
| "In a xenograft pancreatic cancer mouse-model DCA treatment resulted in retarding cancer progression." | ( Agriesti, F; Capitanio, N; Laurenzana, I; Mazzoccoli, C; Pacelli, C; Panebianco, C; Pazienza, V; Piccoli, C; Ruggieri, V; Sala, GD; Tataranni, T, 2019) |
| "A 52-year-old man with a diagnosis of pancreatic cancer who began treatment for a bone metastases pain with fentanyl TTS, at a dose of 50 micrograms per hour (mcg/h) is the subject of the study." | ( Albéndiz-Gutiérrez, V; Micozzi, S; Noguerado-Mellado, B; Rodríguez-Fernández, A; Rojas-Pérez-Ezquerra, P; Torrado-Español, I, 2019) |
| "SREBP1 may represent a novel target for pancreatic cancer prevention and treatment." | ( Chen, X; Cheng, L; Duan, W; Jiang, Z; Li, J; Li, X; Ma, J; Ma, Q; Qian, W; Wang, Z; Wu, Z; Zhou, C, 2019) |
| "Human pancreatic cancer cell lines SW1990 was treated with Silibinin and/or JNK/SAPK inhibitor SP600125 followed by measurement of cell viability, apoptosis, autophagy, ROS and ATP, and western blotting." | ( Cao, M; Chen, Z; Jiang, J; Zhang, X, 2019) |
| "Human pancreatic cancer cell lines SW1990 was treated with Silibinin and/or JNK/SAPK inhibitor SP600125 followed by measurement of cell viability, apoptosis, autophagy, ROS and ATP, and western blotting." | ( Cao, M; Chen, Z; Jiang, J; Zhang, X, 2019) |
| "The majority of pancreatic cancers are diagnosed at an advanced stage, when surgical options are limited and treatment relies on systemic chemotherapy." | ( Arango, MJ; Noonan, AM; Porter, K; Reardon, J; Tossey, JC; VanDeusen, JB, 2019) |
| "A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity." | ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019) |
| "While the incidence of pancreatic cancer is displaying a rising tendency every year, the mortality rate has not decreased significantly because of late diagnosis, early metastasis, and limited reaction to chemotherapy or radiotherapy." | ( Grützmann, R; Lan, B; Pilarsky, C; Pöttler, M; Yang, H; Zeng, S, 2019) |
| "Primary systemic therapy in resectable pancreatic cancer is currently under investigation." | ( Joseph, NE; Marsh, RW; Polish, A, 2019) |
| "In human pancreatic cancer cell lines, the messenger RNA and protein levels of IL17RB were significantly enhanced after gemcitabine treatment." | ( Chen, ZM; Huang, H; Ji, B; Jiang, CX; Mukaida, N; Song, Y; Yao, NH, 2019) |
| "However, pancreatic cancers are still intractable and difficult to treat once recurrence or metastasis occurs; thus, novel combined use of immune checkpoint blockade (ICB) with molecular targeted drugs is considered a therapeutic option." | ( Akiyama, Y; Asai, A; Ashizawa, T; Deguchi, S; Hayashi, N; Iizuka, A; Ito, M; Kawata, T; Kondou, R; Maeda, C; Mitsuya, K; Miyata, H; Sugino, T; Tanaka, E; Yamaguchi, K, 2019) |
| "SW1990 pancreatic cancer cells were treated with an increased dose of gemcitabine, and the mRNA levels of ADAM28 were evaluated by RT-PCR." | ( Chen, J; Chen, ZH; Huang, JL; Ma, XK; Wei, L; Wen, JY; Wu, DH, 2019) |
| "The therapy resistance of pancreatic cancer is associated with the loss of gap junction intercellular communication and connexin 43 expression." | ( Georgikou, C; Gladkich, J; Gretz, N; Gross, W; Herr, I; Karakhanova, S; Schäfer, M; Sticht, C; Torre, C; Xiao, X; Yin, L, 2020) |
| "We obtained 93 pancreatic cancer specimens (tumor and adjacent nontumor tissues) from patients who underwent surgery and gemcitabine chemotherapy and analyzed them by immunohistochemistry." | ( Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z, 2020) |
| "Patients with advanced pancreatic cancer (n = 203; 131 metastatic pancreatic cancer patients (MPC) and 72 locally advanced pancreatic cancer patients (LAPC)) were treated using modified-FFX (mFFX) or AG and mFFX sequentially." | ( Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC, 2020) |
| "2M4VP might be used as a pancreatic cancer treatment supplement." | ( Go, B; Han, SI; Jung, YH; Kim, CS; Kim, DH; Kim, JH; Lee, J; Oh, UH, 2019) |
| "Metastatic pancreatic cancer (PC) is an aggressive malignancy, with most patients deriving benefit only from first-line chemotherapy." | ( Frank, RC; Lee, R; Levy, G; Lo, T; Lobo, S; Martino, C; Pandya, D, 2020) |
| "We retrospectively enrolled advanced pancreatic cancer patients aged ≥75 years who received GnP as first-line treatment between December 2014 and December 2016." | ( Fukushima, T; Hashimoto, Y; Hirotani, A; Ikeda, M; Imaoka, H; Kobayashi, S; Mitsunaga, S; Morimoto, M; Moriya, S; Ohno, I; Ozaka, M; Sano, Y; Sasahira, N; Sasaki, M; Sasaki, T; Tezuka, S; Tozuka, Y; Ueno, M; Umemoto, K; Watanabe, K; Yamada, I, 2020) |
| "Treatment options for pancreatic cancer (PC) are severely limited due to late diagnosis, early metastasis and the inadequacy of chemotherapy and radiotherapy to combat the aggressive biology of the disease." | ( Beckett, EL; Bond, DR; Chalmers, A; Scarlett, CJ; Turner, A; Vuong, QV; Weidenhofer, J, 2020) |
| "Locally advanced pancreatic cancer (LAPC) is a devastating disease and irreversible electroporation (IRE) is a non-thermal ablation method that is especially suitable for the treatment of LAPC." | ( He, C; Li, S; Lin, X; Wang, J; Zhang, Y, 2020) |
| "Here, pancreatic cancer and treatment associated pain are reviewed along with current treatment strategies." | ( Brothers, SP; Lohse, I, 2020) |
| "In patients with BR or LA pancreatic cancer, FOLFIRINOX is a valuable neoadjuvant treatment that enables curative surgery in approximately one-quarter of patients and significantly improves overall survival." | ( Choi, YH; Jang, JY; Kim, SW; Kim, YT; Kwon, W; Lee, SH; Paik, WH; Ryu, JK; Shin, BS; You, MS, 2021) |
| "MUC1 may be a therapeutic target in pancreatic cancer treatment." | ( Fu, X; Mao, L; Qiu, YD; Tang, N; Xie, WQ, 2020) |
| "After pancreatic cancer Panc-1 cells were treated with polyphyllin D(0, 1, 2, 3, 4, 5 μg·μL~(-1)) for 24, 48 and 72 hours, CCK-8 method was used to detect the effect of polyphyllin D on the proliferation of pancreatic cancer Panc-1 cells." | ( Xiao, MF, 2020) |
| "After resection for pancreatic cancer patients should receive intensive chemotherapy with mFOLFIRINOX, gemcitabine plus capecitabine or gemcitabine/5-fluorouracil (5-FU) monotherapy." | ( Büchler, MW; Hackert, T; Jäger, D; Neoptolemos, JP; Springfeld, C, 2020) |
| "In addition, pancreatic cancer has excessive stroma which serves as a severe biological barrier for anticancer drug delivery and successful treatment." | ( Arima, H, 2020) |
| "Peritoneal metastasis from pancreatic cancer (PM-PC) may be treated with repeated pressurised intraperitoneal aerosol chemotherapy (PIPAC)." | ( Detlefsen, S; Ellebæk, SB; Fristrup, C; Graversen, M; Kristensen, TK; Mortensen, MB; Nielsen, M; Pfeiffer, P, 2021) |
| "In metastatic pancreatic cancer, combined chemotherapy such as FOLFIRINOX and gemcitabine plus nab-paclitaxel became standard of care." | ( Ueno, M, 2020) |
| "Locally advanced pancreatic cancer (LAPC) remains a challenge for current treatments." | ( Cai, Z; He, C; Li, S; Lin, X; Wang, J; Zhang, Y, 2020) |
| "The high rate of mortality in pancreatic cancer patients is due to the inability to detect early-stage disease and the disease being highly refractory to therapy." | ( Ahn, HM; Kim, DG; Kim, YJ, 2020) |
| "The increased resistance of pancreatic cancer to chemotherapy demonstrates a dilemma in the clinical field." | ( Guo, Y; Sun, L; Wang, C; Weng, M; Zhu, H, 2020) |
| "The human pancreatic cancer cells were cultured and divided into four groups: control group (A) without any treatment, group B that received 2Gy radiotherapy alone, group C that was treated with 4mM AA alone, and group D that was co-treated with AA and radiotherapy." | ( Dayer, D; Kazemi, M; Tabandeh, MR, 2020) |
| "Drug therapies for pancreatic cancer currently being developed in Japan, as well as the position of this therapy in pancreatic cancer therapy in Japan and what the expectations are in the clinical setting, are also discussed." | ( Ueno, M, 2020) |
| "Patients with borderline or resectable pancreatic cancer treated with neoadjuvant intent between November 2011 and December 2017 were reviewed." | ( Ahmad, S; Barrord, M; Choe, K; Esslinger, H; Kharofa, J; Latif, T; Olowokure, O; Patel, S; Poreddy, S; Smith, M; Sussman, J, 2020) |
| "Chemotherapy for advanced pancreatic cancer has limited efficacy due to the difficultly of treating established tumours and the evolution of tumour resistance." | ( Dalgleish, AG; Kasow, S; Samad, M; Smith, PL; Yogaratnam, Y, 2021) |
| "Pharmacological FAK inhibition in pancreatic cancer has received increased attention over the last few years, either alone or in combination with other therapeutics including chemotherapy and immunotherapy." | ( Amen, A; Bronsert, P; Brunner, TB; Follo, M; Grosu, AL; Mekawy, M; Mohamed, AA; Mostafa, H; Thomsen, A; Zamboglou, C, 2021) |
| "In the xenograft model of pancreatic cancer, nude mice were treated with GEM." | ( Han, Y; Ma, J; Qian, J; Shi, Y; Wang, Y; Yan, X; Yao, N, 2020) |
| "Furthermore, utilizing an orthotopic pancreatic cancer cachexia mouse model, we demonstrated that treatment of tumor-bearing mice with SP600125 improved longitudinal measurements of forelimb grip strength." | ( Abrego, J; Attri, KS; Dasgupta, A; King, RJ; Mulder, SE; Murthy, D; Shukla, SK; Singh, PK, 2020) |
| "Moreover, miR-421/SPINK1 expressions in pancreatic cancer, with or without K73-03 treatment, were evaluated." | ( Ahmad, N; Ai, J; Almoiliqy, M; Alshwmi, M; Awsh, M; Chu, P; Gamallat, Y; Jamalat, Y; Li, H; Li, X; Mousa, H; Niu, M; Qaed, E; Shobet, L; Shopit, A; Tang, Z; Tesfaldet, T; Wang, H; Wang, S, 2020) |
| "• Margin-negative resection rate of pancreatic cancer following FOLFIRINOX therapy did not differ among each resectability (67-73%, p = 0." | ( Byun, JH; Hong, SM; Jang, JK; Kang, JH; Kim, HJ; Kim, JH; Kim, KP; Kim, SC; Lee, MG; Lee, SS; Seo, DW; Son, JH; Yoo, C, 2021) |
| "Nanomaterial-based pancreatic cancer treatment has received widespread attention and rapid development in the past few years." | ( Dong, Q; Jia, X; Li, D; Wang, E; Wang, J; Wang, Y; Xu, W; Ye, Z, 2020) |
| "Tumor resectability of pancreatic cancer staged as unresectable at primary diagnosis should be reassessed after neoadjuvant treatment." | ( Adler, W; Bechstein, WO; Boeck, S; Croner, RS; Fietkau, R; Ghadimi, M; Golcher, H; Grützmann, R; Hohenberger, WM; Imhoff, D; Jacobasch, L; Keilholz, L; Lubgan, D; Neumann, UP; Oettle, H; Pirkl, A; Reinacher-Schick, A; Rutzner, S; Semrau, S; Uhl, W; Wittel, UA, 2021) |
| "The treatment of pancreatic cancer with gemcitabine is hampered by its rapid metabolism in vivo, the dense stroma around the tumor site which prevents the drug from reaching the cancerous cells and drug resistance." | ( Ferrara, KW; Ingham, ES; Kakwere, H; Tumbale, SK, 2020) |
| "Treatment of pancreatic cancer cells with the antioxidant N-acetyl-L-cysteine decreased ROS activity and expression level of NRF2 and ITGB7." | ( Fan, G; Hu, Q; Ji, S; Liu, M; Liu, W; Qin, Y; Sun, Q; Xu, W; Xu, X; Ye, Z; Yu, X; Zhang, Z; Zhuo, Q, 2020) |
| "Regarding the types of cancer, pancreatic cancer is prone to display significant resistance to conventional therapy, therefore there 5-year survival rate is only 2% to 9%." | ( Chen, SH; Li, F; Wang, L; Wu, D; Xu, JW; Yan, Y; Ye, NK, 2021) |
| "Eighty percent of pancreatic cancer patients relapse after chemotherapy and develop early metastasis and drug resistance." | ( Cheng, WC; Chiang, CM; Hsu, KW; Liu, YH; Peng, PH; Tsai, LH; Wu, HH; Yang, HJ; Yang, SF, 2020) |
| "The trend in treatment options of pancreatic cancer remained stable from 2010 to 2018, with chemotherapy being the most common therapeutic option and surgery performed in approximately half that of chemotherapy." | ( Kawai, S; Kikuchi, S; Lin, Y; Suzuki, T; Ueno, M, 2021) |
| "Patients with locally advanced pancreatic cancer were randomly assigned to the chemoradiotherapy arm (Arm A) or induction chemotherapy followed by the chemoradiotherapy arm (Arm B)." | ( Fukutomi, A; Furuse, J; Hara, H; Hiraoka, N; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Ito, Y; Katayama, H; Kawashima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Nakamori, S; Nakamura, S; Okano, N; Okusaka, T; Ozaka, M; Sata, N; Shimizu, K; Sugimori, K; Tobimatsu, K; Todaka, A; Ueno, M; Yamaguchi, T; Yanagimoto, H, 2021) |
| "The treatment of pancreatic cancer is mainly surgery, but the development of traditional surgery, chemoradiotherapy has entered the plateau stage, and immunotherapy has received more and more attention." | ( Wang, Z; Zhou, S, 2021) |
| "Most pancreatic cancers, however, are HR proficient and thus resistant to PARP inhibitor monotherapy." | ( Canman, CE; Engelke, CG; Flanagan, SA; Lawrence, TS; Morgan, MA; Parsels, J; Parsels, LA; Tanska, D; Wahl, DR; Zhang, Q, 2021) |
| "Most pancreatic cancers, however, are HR proficient and thus resistant to PARP inhibitor monotherapy." | ( Canman, CE; Engelke, CG; Flanagan, SA; Lawrence, TS; Morgan, MA; Parsels, J; Parsels, LA; Tanska, D; Wahl, DR; Zhang, Q, 2021) |
| "Downregulation of GSTM2 in pancreatic cancer may benefit gemcitabine treatment." | ( Arumugam, T; Fujii, T; Huang, H; Ji, B; Jiang, H; Jin, Z; Li, Z; Lin, K; Logsdon, C; Peng, L; Sun, L; Yao, Y; Zhang, Y; Zhuang, L, 2021) |
| "PANC-1 and BxPC-3 pancreatic cancer cells were treated with juglone at | ( Arikoglu, H; Erkoc-Kaya, D; Gokturk, F, 2021) |
| "This study shows that pancreatic cancer cells undergoing cell death by valproic acid (VPA) treatment activated dendritic cells (DCs) more efficiently than those treated with trichostatin A (TSA), as demonstrated by CD86 and CD80 surface expression." | ( Bei, R; Benedetti, R; Cirone, M; D'Orazi, G; Gilardini Montani, MS; Masuelli, L; Mattei, M; Piconese, S; Pulcinelli, FM; Romeo, MA; Timperio, AM, 2021) |
| "KRAS mutations occur in 90% of the pancreatic cancer patients and are a major obstacle for treatment of pancreatic cancer." | ( Choi, KY; Han, G; Lee, SH; Ryu, WJ, 2021) |
| "This model has implications for pancreatic cancer prognosis and treatment response to ICIs." | ( Chen, W; Fung, KM; He, Y; Houchen, CW; Li, M; Li, X; Liu, M; Luo, W; McNally, LR; Shi, X; Xu, C; Yang, J; Zhan, H; Zhang, C; Zhang, J; Zhang, Y; Zhou, Z, 2021) |
| "Advanced, unresectable pancreatic cancer is often treated with either gemcitabine plus nab-paclitaxel (Gem/NabP) or FOLFIRINOX, although these regimens have never been compared in a head-to-head trial." | ( Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M, 2021) |
| "Advanced, unresectable pancreatic cancer is often treated with either gemcitabine plus nab-paclitaxel (Gem/NabP) or FOLFIRINOX, although these regimens have never been compared in a head-to-head trial." | ( Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M, 2021) |
| "Elderly pancreatic cancer (PC) patients are often considered vulnerable to treatment and standard treatment strategy for this subpopulation is uncertain." | ( Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Suzumori, C; Takeda, T; Yamada, Y, 2021) |
| "Treatment of localized pancreatic cancer has also evolved to prioritize preoperative (neoadjuvant) multimodality therapy over a surgery-first approach." | ( Evans, DB; Tsai, S; Ward, EP, 2021) |
| "For patients with localized pancreatic cancer, neoadjuvant therapy (NT) is increasingly delivered before surgery to maximize the receipt of multimodality therapy and the odds of a margin-negative resection." | ( Brown, ZJ; Cloyd, JM, 2021) |
| "To explore the role of solasodine in pancreatic cancer, human pancreatic cell lines including SW1990 and PANC1 were treated with different concentrations of solasodine for 48 h, and cell viability was evaluated by MTT assay, cell invasion and migration were evaluated by Transwell assay." | ( Fan, Y; Li, Z; Lin, F; Ma, X; Shao, J; Wang, Y; Wu, L; Yao, Y; Zhuang, W, 2021) |
| "Our functional studies showed that pancreatic cancer cells (PANC-1 and MIA PaCa-2) were more resistant to glyceraldehyde treatment compared to normal pancreatic ductal epithelial cells (HPDE), while cytotoxicity effects were observed in all cell types." | ( Chen, R; Ma, C; Pan, S; Senavirathna, L, 2021) |
| "Patients with locally advanced pancreatic cancer (LAPC) are increasingly treated with FOLFIRINOX, resulting in improved survival and resection of tumors that were initially unresectable." | ( Besselink, MG; Bosscha, K; Brada, LJH; Bruijnen, RC; Busch, OR; Daamen, LA; de Hingh, IH; de Meijer, VE; de Vries, JJJ; Festen, S; Liem, MLS; Los, M; Mohammad, NH; Patijn, GA; Polée, MB; Quintus Molenaar, I; Stommel, MWJ; van Dam, RM; van Lienden, KP; van Roessel, S; van Santvoort, HC; Walma, MS; Wessels, FJ; Wilmink, HW; Yung Nio, C, 2021) |
| "However, most patients with advanced pancreatic cancer die within the first 2 years after diagnosis, even when treated with standard of care chemotherapy." | ( Asby, S; Beatty, M; Blauvelt, J; Innamarato, P; Kidd, S; Mackay, A; Morse, J; Mullinax, JE; Pilon-Thomas, S; Sarnaik, AA, 2021) |
| "However, most patients with advanced pancreatic cancer die within the first 2 years after diagnosis, even when treated with standard of care chemotherapy." | ( Asby, S; Beatty, M; Blauvelt, J; Innamarato, P; Kidd, S; Mackay, A; Morse, J; Mullinax, JE; Pilon-Thomas, S; Sarnaik, AA, 2021) |
| "Human pancreatic cancer cell lines, MIA PaCa-2, AsPC-1, BxPC-3 and PANC-1 were treated with gemcitabine (10 nM) and/or olaparib (1 µM)." | ( Amé, JC; Burckel, H; Mura, C; Noël, G; Waissi, W, 2021) |
| "Human pancreatic cancer cell lines, MIA PaCa-2, AsPC-1, BxPC-3 and PANC-1 were treated with gemcitabine (10 nM) and/or olaparib (1 µM)." | ( Amé, JC; Burckel, H; Mura, C; Noël, G; Waissi, W, 2021) |
| "GW5074 significantly reduced pancreatic cancer cell growth in vitro when treated in combination with DFMO and a rescuing dose of spermidine." | ( Altomare, DA; Dobrovolskaite, A; Madan, M; Pandey, V; Phanstiel, O, 2021) |
| "Clinical data of pancreatic cancer patients who underwent GnP therapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research from December 2014 to December 2016 were retrospectively collected." | ( Aoyama, T; Hama, T; Hashiguchi, M; Hori, S; Ito, G; Kawakami, K; Kizaki, H; Nakamura, M; Ozaka, M; Sasahira, N; Yokokawa, T, 2021) |
| "Clinical data of pancreatic cancer patients who underwent GnP therapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research from December 2014 to December 2016 were retrospectively collected." | ( Aoyama, T; Hama, T; Hashiguchi, M; Hori, S; Ito, G; Kawakami, K; Kizaki, H; Nakamura, M; Ozaka, M; Sasahira, N; Yokokawa, T, 2021) |
| "Treatment options for patients with pancreatic cancer are limited and survival prospects have barely changed over the past 4 decades." | ( Able, S; Allen, PD; Bau, L; Browning, RJ; Callan, JF; Kamila, S; Kartsonaki, C; Kersemans, V; Kinchesh, P; Logan, K; McHale, AP; Ruan, JL; Smart, S; Stride, E; Taylor, MA; Vallis, KA; Wallington, S, 2021) |
| "The prognosis of pancreatic cancer is poor and new treatment strategies are urgently needed." | ( Andreassen, BK; Botteri, E; Bouche, G; Pantziarka, P; Sloan, EK; Støer, NC, 2021) |
| "Although pancreatic cancers are common in older age-groups, the prognosis remains poor due to limited studies on treatment approaches and outcomes in a given population." | ( Han, BR; Jung, HA; Jung, JY; Kim, HJ; Kim, HY; Zang, DY, 2021) |
| "Knockdown of ANRIL in pancreatic cancer repressed cellular proliferation, invasion, migration, and reduced chemotherapy resistance to gemcitabine." | ( Bi, R; Li, L; Wang, L; Yin, H; Zhou, K, 2021) |
| "Here, we present an advanced pancreatic cancer patient, who respond to anlotinib targeted therapy after the failure of multiline chemotherapy and apatinib targeted therapy." | ( Deng, W; Li, N; Li, S; Luo, S; Niu, M; Wei, C, 2022) |
| "In locally advanced pancreatic cancer (LAPC), the combination of chemotherapy and radiotherapy is a widely used treatment option." | ( Bartolini, G; Ercolani, G; Frassineti, GL; Ghigi, G; Matteucci, L; Monti, M; Neri, E; Passardi, A; Rapposelli, IG; Romeo, A; Ruscelli, S; Scarpi, E; Sullo, FG; Tontini, L; Valgiusti, M, 2021) |
| "Herein, we report a case of pancreatic cancer who benefited from a combination of anti-PD-1 immunotherapy and chemotherapy." | ( Chen, YW; Chen, ZL; Deng, YY; Pan, SY; Wang, MX; Yang, L; Zhu, PF, 2022) |
| "We propose that patients with pancreatic cancer could be treated using a scheme that contains dual-specific CAR T cells, a vaccine that activates the dual-specific CAR T cells through their TCR, and the administration of Pano." | ( Ali, AI; Bai, Y; Chan, JD; Darcy, PK; Dominguez, PM; Du, X; Harrison, AJ; Johnstone, RW; Kang, J; Kershaw, MH; Lee, B; Oliver, AJ; Slaney, CY; Tantalo, DGM; von Scheidt, B; Wang, M, 2021) |
| "Locally advanced (unresectable) pancreatic cancer (LAPC) is surgically unresectable and often treated with chemotherapy." | ( Chie, EK; Jang, JY; Kang, JS; Kim, H; Kim, YT; Kwon, W; Lee, M; Lee, SH; Oh, DY; Ryu, JK, 2023) |
| "GSH2 silencing in pancreatic cancer cells inhibited cell proliferation, migration and invasion, increased cell apoptosis and sensitized pancreatic cancer cells to gemcitabine treatment." | ( Chen, C; Cui, F; Lin, K; Peng, L; Sun, L; Yao, Y; Yu, Q; Zhang, Y; Zhuang, L, 2022) |
| "GSH2 silencing in pancreatic cancer cells inhibited cell proliferation, migration and invasion, increased cell apoptosis and sensitized pancreatic cancer cells to gemcitabine treatment." | ( Chen, C; Cui, F; Lin, K; Peng, L; Sun, L; Yao, Y; Yu, Q; Zhang, Y; Zhuang, L, 2022) |
| "Elderly pancreatic cancer patients can benefit from palliative chemotherapy, and it should be considered, especially in patients with fewer medical comorbidities and better functional status." | ( Amundsen, T; Doyle, J; Hall, JA; Raiyani, C; Wong, L, 2021) |
| "Patients with pancreatic cancer also respond poorly to chemotherapy or radiation therapy and may be accompanied by serious adverse reactions." | ( Chen, B; Huang, H; Sun, L; Tang, H; Wang, X; Wang, Y; Zhang, H; Zhang, Y; Zhou, Z; Zhu, X, 2022) |
| "The treatment of pancreatic cancer (PDAC) remains clinically challenging, and neoadjuvant therapy (NAT) offers down staging and improved surgical resectability." | ( Doi, N; Esaki, M; Hiraoka, N; Ino, Y; Ishimoto, U; Iwasaki, T; Kishi, Y; Naito, C; Nakajima, K; Nara, S; Shimada, K; Shimasaki, M, 2022) |
| "MicroRNA-34a sensitized pancreatic cancer cells to gemcitabine treatment by inhibiting Notch 1 signaling in pancreatic cancer stem cells, indicating that miR-34a has the potential to be developed as a novel therapeutic agent for the treatment of gemcitabine-resistant pancreatic ductal adenocarcinoma cells." | ( Chen, Q; Gao, G; Go, VLW; Guo, J; Li, K; Li, N; Liu, J; Pan, Y; Tao, X; Xiao, GG; Zhao, Y, 2021) |
| "Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome." | ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Falzone, L; Follo, ML; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Ratti, S; Steelman, LS, 2022) |
| "While irresectable pancreatic cancer has still a dismal overall prognosis, evidence about the optimal chemotherapy sequence is scarce." | ( Elango, S; Finkelmeier, F; Koch, C; Pession, U; Queck, A; Schmidt, J; Trebicka, J; Trojan, J; Waidmann, O; Walter, D, 2022) |
| "Here, we report a case of stage IV pancreatic cancer in a patient with TSC2 and SMAD4 mutations treated with immunotherapy when the disease progressed after multi-line chemotherapy." | ( Ye, Y; Zheng, S, 2021) |
| "The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP))." | ( Asama, H; Hashimoto, M; Hikichi, T; Irie, H; Kato, T; Kobashi, R; Konno, N; Nakamura, J; Ohira, H; Okubo, Y; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T; Takasumi, M, 2021) |
| "Although second-line treatment for pancreatic cancer has been proven to have survival benefit, it is not clear which is the most preferred regimen." | ( Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Konno, N; Maeda, S; Morimoto, M; Nagashima, S; Oishi, R; Sano, Y; Tanaka, S; Tezuka, S; Ueno, M, 2022) |
| "Although second-line treatment for pancreatic cancer has been proven to have survival benefit, it is not clear which is the most preferred regimen." | ( Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Konno, N; Maeda, S; Morimoto, M; Nagashima, S; Oishi, R; Sano, Y; Tanaka, S; Tezuka, S; Ueno, M, 2022) |
| "Older patients with metastatic pancreatic cancer may suffer increased toxicity from intensive chemotherapy." | ( Belle, S; Betge, J; Ebert, MP; Härtel, N; Hegele, L; Jesenofsky, R; Kleiß, M; Krammer-Steiner, B; Lammert, F; Larcher-Senn, J; Maenz, M; Moulin, JC; Räth, S; Schulte, N; Wedding, U; Zhan, T, 2022) |
| "Older patients with metastatic pancreatic cancer may suffer increased toxicity from intensive chemotherapy." | ( Belle, S; Betge, J; Ebert, MP; Härtel, N; Hegele, L; Jesenofsky, R; Kleiß, M; Krammer-Steiner, B; Lammert, F; Larcher-Senn, J; Maenz, M; Moulin, JC; Räth, S; Schulte, N; Wedding, U; Zhan, T, 2022) |
| "Medical records of patients with pancreatic cancer treated in Celal Bayar University Medical Faculty Hospital Medical Oncology Clinic between February 2012 and April 2020 were retrospectively reviewed." | ( Çelik, C; Dirican, A; Ekinci, F; Erdoğan, AP; Gökse, G; Sarı, D, 2021) |
| "We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy." | ( Asagi, A; Furuse, J; Higuchi, R; Konishi, M; Mizuno, N; Morinaga, S; Motoi, F; Nagano, H; Nara, S; Okuyama, H; Shioji, K; Shirakawa, H; Sugimachi, K; Todaka, A; Toshiyama, R; Tsumura, H, 2022) |
| "PANC-1 human pancreatic cancer cells were treated with 5-fluorouracil (5-FU) at 0." | ( Cao, C; Dong, C; Liu, R; Shi, X; Su, L; Zhao, J, 2022) |
| "Fifty-seven pancreatic cancer patients who were followed in University of Health Sciences Gazi Yasargil Training and Research Hospital between January 2017 and June 2020, declined surgical treatment and/or radiation therapy or had medically inoperable, unresectable, or metastatic disease, and received chemotherapy were included in the study." | ( Erdur, E; Guzel, Y; Kaplan, H; Poyraz, K; Yildirim, MS; Yildirim, OA, 2022) |
| "Patients with borderline-resectable pancreatic cancer were enrolled and randomly assigned to receive neoadjuvant chemotherapy with either FOLFIRINOX or gemcitabine with nab-paclitaxel (GEM/nab-PTX)." | ( Ebata, T; Fujii, T; Ishikawa, T; Kawashima, H; Kodera, Y; Maeda, O; Nagino, M; Ogawa, H; Ohno, E; Takami, H; Yamada, S; Yamaguchi, J; Yokoyama, Y, 2022) |
| "Patients with borderline-resectable pancreatic cancer were enrolled and randomly assigned to receive neoadjuvant chemotherapy with either FOLFIRINOX or gemcitabine with nab-paclitaxel (GEM/nab-PTX)." | ( Ebata, T; Fujii, T; Ishikawa, T; Kawashima, H; Kodera, Y; Maeda, O; Nagino, M; Ogawa, H; Ohno, E; Takami, H; Yamada, S; Yamaguchi, J; Yokoyama, Y, 2022) |
| "The prognosis of initially unresectable pancreatic cancer (UR-PC) has improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GNP) treatment." | ( Inoue, Y; Ito, H; Mie, T; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Ushida, Y, 2022) |
| "The prognosis of initially unresectable pancreatic cancer (UR-PC) has improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GNP) treatment." | ( Inoue, Y; Ito, H; Mie, T; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Ushida, Y, 2022) |
| "(1) Background: pancreatic cancer is one of the most serious cancers due to its rapid and inevitable fatality, which has been proved very difficult to treat, compared with many other common cancers." | ( Cai, C; Cheng, W; Huo, M; Jin, W; Liao, Y; Liao, Z; Shi, T; Wang, J; Xia, A; Zhou, M, 2022) |
| "(1) Background: pancreatic cancer is one of the most serious cancers due to its rapid and inevitable fatality, which has been proved very difficult to treat, compared with many other common cancers." | ( Cai, C; Cheng, W; Huo, M; Jin, W; Liao, Y; Liao, Z; Shi, T; Wang, J; Xia, A; Zhou, M, 2022) |
| "Ketogenic diet sensitizes murine pancreatic cancer tumors to cytotoxic chemotherapy." | ( Cowan, A; Davidson, S; Downes, M; Evans, R; Guo, JY; Han, H; Lan, T; Liang, G; Lu, W; McBride, M; Ng, S; Nofal, M; Oh, TG; Rabinowitz, JD; TeSlaa, T; Von Hoff, D; Wang, L; Yang, L; Zeng, X, 2022) |
| "Ketogenic diet sensitizes murine pancreatic cancer tumors to cytotoxic chemotherapy." | ( Cowan, A; Davidson, S; Downes, M; Evans, R; Guo, JY; Han, H; Lan, T; Liang, G; Lu, W; McBride, M; Ng, S; Nofal, M; Oh, TG; Rabinowitz, JD; TeSlaa, T; Von Hoff, D; Wang, L; Yang, L; Zeng, X, 2022) |
| "Patients with unresectable pancreatic cancer who underwent CH-EUS before first-line gemcitabine and nab-paclitaxel (GEM and nab-PTX) therapy were classified into four groups according to vascularity on the early and late phases of contrast enhancement: "Group A″, poor on both phases; "Group B″, rich and poor on the early and late phases, respectively; "Group C″, poor and rich on the early and late phases; "Group D″, rich on both phases." | ( Ashida, R; Emori, T; Hatamaru, K; Higashino, N; Ikoma, A; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y, 2022) |
| "Patients with unresectable pancreatic cancer who underwent CH-EUS before first-line gemcitabine and nab-paclitaxel (GEM and nab-PTX) therapy were classified into four groups according to vascularity on the early and late phases of contrast enhancement: "Group A″, poor on both phases; "Group B″, rich and poor on the early and late phases, respectively; "Group C″, poor and rich on the early and late phases; "Group D″, rich on both phases." | ( Ashida, R; Emori, T; Hatamaru, K; Higashino, N; Ikoma, A; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y, 2022) |
| "Chemoresistance of pancreatic cancer is the main reason for the poor treatment effect of pancreatic cancer patients." | ( Chen, S; Chen, ZW; Hu, JF; Huang, L; Huang, Y; Kang, FP; Liao, CY; Lin, CF; Tian, YF; Wang, ZW, 2022) |
| "Chemoresistance of pancreatic cancer is the main reason for the poor treatment effect of pancreatic cancer patients." | ( Chen, S; Chen, ZW; Hu, JF; Huang, L; Huang, Y; Kang, FP; Liao, CY; Lin, CF; Tian, YF; Wang, ZW, 2022) |
| "Eligible patients with metastatic pancreatic cancer receiving chemotherapy with nab-paclitaxel and gemcitabine were assessed in a multicenter study." | ( Aprile, G; Catalano, M; Conca, R; Petrioli, R; Ramello, M; Roviello, G, 2022) |
| "Eligible patients with metastatic pancreatic cancer receiving chemotherapy with nab-paclitaxel and gemcitabine were assessed in a multicenter study." | ( Aprile, G; Catalano, M; Conca, R; Petrioli, R; Ramello, M; Roviello, G, 2022) |
| "We engineered human pancreatic cancer cell (PANC-1)-derived extracellular vesicles (EVs) by conjugating the functional ligand RGD and magnetic nanoparticles (MNPs) onto EV surfaces (rmExo), for pancreatic cancer therapy." | ( Al Faruque, H; Choi, ES; Kim, E; Kim, JH, 2022) |
| "We engineered human pancreatic cancer cell (PANC-1)-derived extracellular vesicles (EVs) by conjugating the functional ligand RGD and magnetic nanoparticles (MNPs) onto EV surfaces (rmExo), for pancreatic cancer therapy." | ( Al Faruque, H; Choi, ES; Kim, E; Kim, JH, 2022) |
| "Treatment of Panc1 and MiaPaca2 pancreatic cancer cells with gemcitabine induced expression of the orphan nuclear receptor 4A2 (NURR1) and analysis of the cancer genome atlas indicated the NURR1 is overexpressed in pancreatic tumors and is a negative prognostic factor for patient survival." | ( Du, H; Epps, J; Johnson, S; Karki, K; Safe, S; Shrestha, R; Suva, L; Vaziri-Gohar, A; Yu, Z; Zarei, M, 2021) |
| "Treatment of Panc1 and MiaPaca2 pancreatic cancer cells with gemcitabine induced expression of the orphan nuclear receptor 4A2 (NURR1) and analysis of the cancer genome atlas indicated the NURR1 is overexpressed in pancreatic tumors and is a negative prognostic factor for patient survival." | ( Du, H; Epps, J; Johnson, S; Karki, K; Safe, S; Shrestha, R; Suva, L; Vaziri-Gohar, A; Yu, Z; Zarei, M, 2021) |
| "The preferred regimen for unresectable pancreatic cancer following gemcitabine-based chemotherapy is not well-established." | ( Fukushima, T; Hamaguchi, T; Kobayashi, S; Morimoto, M; Nagashima, S; Oishi, R; Shin, M; Tezuka, S; Ueno, M; Yamachika, Y, 2022) |
| "The preferred regimen for unresectable pancreatic cancer following gemcitabine-based chemotherapy is not well-established." | ( Fukushima, T; Hamaguchi, T; Kobayashi, S; Morimoto, M; Nagashima, S; Oishi, R; Shin, M; Tezuka, S; Ueno, M; Yamachika, Y, 2022) |
| "The 116 pancreatic cancer patients treated in our hospital from September 2019 to September 2021 were selected and divided into 58 cases each in the (instance of watching, noticing, or making a statement) group and the comparison group according to the method based on random number table." | ( Dai, S; Jiang, C; Wu, Z; Zhou, L, 2022) |
| "The 116 pancreatic cancer patients treated in our hospital from September 2019 to September 2021 were selected and divided into 58 cases each in the (instance of watching, noticing, or making a statement) group and the comparison group according to the method based on random number table." | ( Dai, S; Jiang, C; Wu, Z; Zhou, L, 2022) |
| "Although the treatment of pancreatic cancer has made tremendous progress, the options for effective treatment are still limited, and new treatment methods are in crying needs to improve prognosis in clinic." | ( Bao, ZH; Hou, XB; Li, HL; Mao, YF; Wang, WR, 2022) |
| "Although the treatment of pancreatic cancer has made tremendous progress, the options for effective treatment are still limited, and new treatment methods are in crying needs to improve prognosis in clinic." | ( Bao, ZH; Hou, XB; Li, HL; Mao, YF; Wang, WR, 2022) |
| "The number of elderly patients with pancreatic cancer has increased in an aging society; therefore, there is an urgent need to develop specific treatments for elderly patients with pancreatic cancer." | ( Furuse, J; Ishii, H; Kobayashi, S; Ueno, M, 2022) |
| "The number of elderly patients with pancreatic cancer has increased in an aging society; therefore, there is an urgent need to develop specific treatments for elderly patients with pancreatic cancer." | ( Furuse, J; Ishii, H; Kobayashi, S; Ueno, M, 2022) |
| "Treatments for patients suffering from pancreatic cancer with oligo-hepatic metastasis have always been a cause of certain controversy." | ( Lou, J; Lu, W; Tang, K; Wang, L, 2023) |
| "A total of 87 pancreatic cancer patients with synchronous oligo-metastatic hepatic lesions who received treatments in the 2nd Affiliated Hospital of Zhejiang University between January 2017 and July 2020 were enrolled." | ( Lou, J; Lu, W; Tang, K; Wang, L, 2023) |
| "Treatments for patients suffering from pancreatic cancer with oligo-hepatic metastasis have always been a cause of certain controversy." | ( Lou, J; Lu, W; Tang, K; Wang, L, 2023) |
| "A total of 87 pancreatic cancer patients with synchronous oligo-metastatic hepatic lesions who received treatments in the 2nd Affiliated Hospital of Zhejiang University between January 2017 and July 2020 were enrolled." | ( Lou, J; Lu, W; Tang, K; Wang, L, 2023) |
| "Therefore, the classification of pancreatic cancer patients and precise treatment becomes particularly important." | ( Fang, Y; Feng, J; Guo, P; Huang, H; Liu, W; Teng, T; Wei, B, 2022) |
| "Therefore, the classification of pancreatic cancer patients and precise treatment becomes particularly important." | ( Fang, Y; Feng, J; Guo, P; Huang, H; Liu, W; Teng, T; Wei, B, 2022) |
| "Postoperative chemotherapy following pancreatic cancer resection is the standard of care." | ( Burkhart, RA; Burns, WR; Cameron, JL; Delitto, DJ; Habib, JR; He, J; Ivey, GD; Kinny-Köster, B; Lafaro, KJ; Narang, A; Shoucair, S; Shubert, CR; Thompson, EL; Wolfgang, CL; Zheng, L, 2022) |
| "Postoperative chemotherapy following pancreatic cancer resection is the standard of care." | ( Burkhart, RA; Burns, WR; Cameron, JL; Delitto, DJ; Habib, JR; He, J; Ivey, GD; Kinny-Köster, B; Lafaro, KJ; Narang, A; Shoucair, S; Shubert, CR; Thompson, EL; Wolfgang, CL; Zheng, L, 2022) |
| "We have previously shown that treating pancreatic cancer cells in vitro with a combination of gemcitabine and the cytokine TRAIL significantly reduced both cell viability and survival." | ( Elia, A; Kraev, I; Miralles, F; Rashid, S; Rimmer, E, 2022) |
| "We have previously shown that treating pancreatic cancer cells in vitro with a combination of gemcitabine and the cytokine TRAIL significantly reduced both cell viability and survival." | ( Elia, A; Kraev, I; Miralles, F; Rashid, S; Rimmer, E, 2022) |
| "First-line treatments for metastatic pancreatic cancer are chemotherapy regimens consisting of 5-fluorouracil or gemcitabine; however, there are no biomarkers to help determine which patients might benefit from which treatment regimens." | ( Çakan Demirel, B; Çakıroğlu, U; Değirmencioğlu, S; Demiray, A; Demiray, AG; Doğan, T; Gököz Doğu, G; Karan, C; Özdemir, M; Özhan, N; Yapar Taşköylü, B; Yaren, A, 2022) |
| "Nude mice bearing SW1990 pancreatic cancer cells derived tumor were treated with DEX (4 mg/kg, i." | ( Guo, YC; Jian, WZ; Qiu, XY; Xue, JS; Yao, QY; Yao, Y; Zhang, RW; Zhou, J; Zhou, TY, 2023) |
| "Nude mice bearing SW1990 pancreatic cancer cells derived tumor were treated with DEX (4 mg/kg, i." | ( Guo, YC; Jian, WZ; Qiu, XY; Xue, JS; Yao, QY; Yao, Y; Zhang, RW; Zhou, J; Zhou, TY, 2023) |
| "From 2016 to 2020, of 1551 pancreatic cancer patients, 615 received palliative-intent chemotherapy." | ( Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R, 2022) |
| "From 2016 to 2020, of 1551 pancreatic cancer patients, 615 received palliative-intent chemotherapy." | ( Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R, 2022) |
| "Moreover, the survival model of pancreatic cancer patients treated with gemcitabine in The Cancer Genome Atlas (TCGA) database was utilized to obtain key genes." | ( Cai, J; Li, J; Luo, S; Peng, C; Yu, P, 2022) |
| "Moreover, the survival model of pancreatic cancer patients treated with gemcitabine in The Cancer Genome Atlas (TCGA) database was utilized to obtain key genes." | ( Cai, J; Li, J; Luo, S; Peng, C; Yu, P, 2022) |
| "Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome." | ( Abrams, SL; Cervello, M; Follo, MY; Manzoli, L; Martelli, AM; McCubrey, JA; Ratti, S, 2023) |
| "Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome." | ( Abrams, SL; Cervello, M; Follo, MY; Manzoli, L; Martelli, AM; McCubrey, JA; Ratti, S, 2023) |
| "Of patients with pancreatic cancer treated with lower doses, 40% had therapeutic blood levels." | ( Baranseh, J; Khatib, AW; Selub, SM; Shai, A; Uryvaey, A, 2023) |
| "Of patients with pancreatic cancer treated with lower doses, 40% had therapeutic blood levels." | ( Baranseh, J; Khatib, AW; Selub, SM; Shai, A; Uryvaey, A, 2023) |
| "Despite ongoing developments, pancreatic cancer remains one of the most difficult tumors to treat." | ( Balsano, R; Garajová, I; Gelsomino, F; Leonardi, F, 2022) |
| "We describe a case of a patient with pancreatic cancer harboring BRCA2 mutation, treated with radical surgery, adjuvant treatment and three different palliative chemotherapy regimens at disease recurrence (FOLFOX in first line with progression-free survival of five months, gemcitabine and nab-paclitaxel in the second line with progression-free survival of six months and FOLFIRI in the third line with progression-free survival of three months) before olaparib off-label treatment." | ( Balsano, R; Garajová, I; Gelsomino, F; Leonardi, F, 2022) |
| "Despite ongoing developments, pancreatic cancer remains one of the most difficult tumors to treat." | ( Balsano, R; Garajová, I; Gelsomino, F; Leonardi, F, 2022) |
| "We describe a case of a patient with pancreatic cancer harboring BRCA2 mutation, treated with radical surgery, adjuvant treatment and three different palliative chemotherapy regimens at disease recurrence (FOLFOX in first line with progression-free survival of five months, gemcitabine and nab-paclitaxel in the second line with progression-free survival of six months and FOLFIRI in the third line with progression-free survival of three months) before olaparib off-label treatment." | ( Balsano, R; Garajová, I; Gelsomino, F; Leonardi, F, 2022) |
| "Therefore, in the battle with pancreatic cancer, novel treatment strategies, particularly antiinvasive and antimetastatic strategies, are needed." | ( Arikoglu, H; Avci, E; Dursunoglu, D; Kaya, DE, 2022) |
| "Therefore, in the battle with pancreatic cancer, novel treatment strategies, particularly antiinvasive and antimetastatic strategies, are needed." | ( Arikoglu, H; Avci, E; Dursunoglu, D; Kaya, DE, 2022) |
| "Therefore, in the battle with pancreatic cancer, novel treatment strategies, particularly antiinvasive and antimetastatic strategies, are needed." | ( Arikoglu, H; Avci, E; Dursunoglu, D; Kaya, DE, 2022) |
| "Therefore, in the battle with pancreatic cancer, novel treatment strategies, particularly antiinvasive and antimetastatic strategies, are needed." | ( Arikoglu, H; Avci, E; Dursunoglu, D; Kaya, DE, 2022) |
| "Therefore, in the battle with pancreatic cancer, novel treatment strategies, particularly antiinvasive and antimetastatic strategies, are needed." | ( Arikoglu, H; Avci, E; Dursunoglu, D; Kaya, DE, 2022) |
| "Therefore, in the battle with pancreatic cancer, novel treatment strategies, particularly antiinvasive and antimetastatic strategies, are needed." | ( Arikoglu, H; Avci, E; Dursunoglu, D; Kaya, DE, 2022) |
| "Prospectively maintained pancreatic cancer databases at both institutes were searched to identify patients with localized PDAC treated with preoperative therapy and subsequent surgical resection between 2010 and 2019, with N0 disease on final histopathology." | ( Aldakkak, M; AlMasri, S; Bahary, N; Ellsworth, SG; Evans, DB; Hammad, AY; Hodges, JC; Lee, KK; Paniccia, A; Singhi, AD; Tsai, S; Zureikat, A, 2023) |
| "Prospectively maintained pancreatic cancer databases at both institutes were searched to identify patients with localized PDAC treated with preoperative therapy and subsequent surgical resection between 2010 and 2019, with N0 disease on final histopathology." | ( Aldakkak, M; AlMasri, S; Bahary, N; Ellsworth, SG; Evans, DB; Hammad, AY; Hodges, JC; Lee, KK; Paniccia, A; Singhi, AD; Tsai, S; Zureikat, A, 2023) |
| "Prospectively maintained pancreatic cancer databases at both institutes were searched to identify patients with localized PDAC treated with preoperative therapy and subsequent surgical resection between 2010 and 2019, with N0 disease on final histopathology." | ( Aldakkak, M; AlMasri, S; Bahary, N; Ellsworth, SG; Evans, DB; Hammad, AY; Hodges, JC; Lee, KK; Paniccia, A; Singhi, AD; Tsai, S; Zureikat, A, 2023) |
| "Prospectively maintained pancreatic cancer databases at both institutes were searched to identify patients with localized PDAC treated with preoperative therapy and subsequent surgical resection between 2010 and 2019, with N0 disease on final histopathology." | ( Aldakkak, M; AlMasri, S; Bahary, N; Ellsworth, SG; Evans, DB; Hammad, AY; Hodges, JC; Lee, KK; Paniccia, A; Singhi, AD; Tsai, S; Zureikat, A, 2023) |
| "Prospectively maintained pancreatic cancer databases at both institutes were searched to identify patients with localized PDAC treated with preoperative therapy and subsequent surgical resection between 2010 and 2019, with N0 disease on final histopathology." | ( Aldakkak, M; AlMasri, S; Bahary, N; Ellsworth, SG; Evans, DB; Hammad, AY; Hodges, JC; Lee, KK; Paniccia, A; Singhi, AD; Tsai, S; Zureikat, A, 2023) |
| "Prospectively maintained pancreatic cancer databases at both institutes were searched to identify patients with localized PDAC treated with preoperative therapy and subsequent surgical resection between 2010 and 2019, with N0 disease on final histopathology." | ( Aldakkak, M; AlMasri, S; Bahary, N; Ellsworth, SG; Evans, DB; Hammad, AY; Hodges, JC; Lee, KK; Paniccia, A; Singhi, AD; Tsai, S; Zureikat, A, 2023) |
| "Here, we utilized a mouse pancreatic cancer model to characterize the effects of gemcitabine chemotherapy on immature bone marrow cells in the context of tumor immunogenicity." | ( Benguigui, M; Cooper, TJ; Haj-Shomaly, J; Levin, S; Manobla, B; Menachem, R; Raviv, Z; Shaked, Y; Timaner, M; Vorontsova, A, 2023) |
| "The treatment of pancreatic cancer depends on the tumor stage and type, and includes local treatment (surgery, radiotherapy and ablation intervention) and systemic therapy (chemotherapy, targeted therapy and immunotherapy)." | ( Guo, W; Huang, JH; Liu, Z, 2023) |
| "The treatment of pancreatic cancer depends on the tumor stage and type, and includes local treatment (surgery, radiotherapy and ablation intervention) and systemic therapy (chemotherapy, targeted therapy and immunotherapy)." | ( Guo, W; Huang, JH; Liu, Z, 2023) |
| "We diagnosed unresectable pancreatic cancer(T3N0M1, cStage Ⅳ)and administered 10 courses of gemcitabine(GEM)plus nab-paclitaxel(nab-PTX)therapy." | ( Endo, S; Fujiwara, Y; Higashida, M; Ito, Y; Iwamoto, R; Kinoshita, S; Kitagawa, S; Kubota, H; Mineta, S; Okada, T; Sanuki, F; Tanaka, H; Ueno, M; Ueno, T; Yoshimatsu, K, 2022) |
| "We diagnosed unresectable pancreatic cancer(T3N0M1, cStage Ⅳ)and administered 10 courses of gemcitabine(GEM)plus nab-paclitaxel(nab-PTX)therapy." | ( Endo, S; Fujiwara, Y; Higashida, M; Ito, Y; Iwamoto, R; Kinoshita, S; Kitagawa, S; Kubota, H; Mineta, S; Okada, T; Sanuki, F; Tanaka, H; Ueno, M; Ueno, T; Yoshimatsu, K, 2022) |
| "Anlotinib may boost the efficacy of pancreatic cancer (PC) treatment if timely added to the GS regimen (Gemcitabine, Tegafur-gimeracil-oteracil potassium); however, no data has been published." | ( Da, S; Fang, F; Hu, J; Liu, S; Luo, P; Shen, E; Su, Y; Wen, F; Weng, J; Xu, M; Zhan, D; Zhan, G; Zhou, C; Zhou, Q, 2023) |
| "Anlotinib may boost the efficacy of pancreatic cancer (PC) treatment if timely added to the GS regimen (Gemcitabine, Tegafur-gimeracil-oteracil potassium); however, no data has been published." | ( Da, S; Fang, F; Hu, J; Liu, S; Luo, P; Shen, E; Su, Y; Wen, F; Weng, J; Xu, M; Zhan, D; Zhan, G; Zhou, C; Zhou, Q, 2023) |
| "Human pancreatic cancer cell lines were treated with or without CD-BSB." | ( Baba, T; Ebata, T; Igami, T; Kano, MT; Kokuryo, T; Miyata, K; Mizuno, T; Nagino, M; Ogura, A; Onoe, S; Sunagawa, M; Uehara, K; Watanabe, N; Yamaguchi, J; Yamazaki, K; Yokoyama, Y, 2023) |
| "Human pancreatic cancer cell lines were treated with or without CD-BSB." | ( Baba, T; Ebata, T; Igami, T; Kano, MT; Kokuryo, T; Miyata, K; Mizuno, T; Nagino, M; Ogura, A; Onoe, S; Sunagawa, M; Uehara, K; Watanabe, N; Yamaguchi, J; Yamazaki, K; Yokoyama, Y, 2023) |
| "There are few reports of pancreatic cancer with pCR after GS-based chemoradiation therapy and subsequent GS therapy." | ( Akamune, A; Johira, H; Kagajo, Y; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Yunoki, S, 2023) |
| "There are few reports of pancreatic cancer with pCR after GS-based chemoradiation therapy and subsequent GS therapy." | ( Akamune, A; Johira, H; Kagajo, Y; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Yunoki, S, 2023) |
| "Patients with advanced pancreatic cancer treated with FOLFIRINOX chemotherapy alone or with FOLFIRINOX chemotherapy followed by stereotactic body radiotherapy between 2015 and 2021 in 2 tertiary referral centers were included." | ( Aziz, MH; Bonsing, BA; Groot Koerkamp, B; Homs, MYV; Luelmo, SAC; Michiels, N; Mieog, JSD; Papageorgiou, G; van 't Land, FR; van Eijck, CHJ, 2023) |
| "Patients with advanced pancreatic cancer treated with FOLFIRINOX chemotherapy alone or with FOLFIRINOX chemotherapy followed by stereotactic body radiotherapy between 2015 and 2021 in 2 tertiary referral centers were included." | ( Aziz, MH; Bonsing, BA; Groot Koerkamp, B; Homs, MYV; Luelmo, SAC; Michiels, N; Mieog, JSD; Papageorgiou, G; van 't Land, FR; van Eijck, CHJ, 2023) |
| "Chemotherapy failure in pancreatic cancer patients is widely attributed to cancer cell reprogramming towards drug resistance by cancer associated fibroblasts (CAFs), which are the abundant cell type in the tumor microenvironment." | ( Adair, S; Bauer, TW; Honrado, C; Moore, J; Salahi, A; Swami, NS, 2023) |
| "Chemotherapy failure in pancreatic cancer patients is widely attributed to cancer cell reprogramming towards drug resistance by cancer associated fibroblasts (CAFs), which are the abundant cell type in the tumor microenvironment." | ( Adair, S; Bauer, TW; Honrado, C; Moore, J; Salahi, A; Swami, NS, 2023) |
| "An orthotopic murine model of pancreatic cancer and adjuvant therapy-mimicking xenograft murine model that underwent splenectomy was created." | ( Cho, IR; Choi, JH; Hong, JM; Kim, YT; Lee, SH; Nam, GH; Paik, WH; Ryu, JK, 2022) |
| "An orthotopic murine model of pancreatic cancer and adjuvant therapy-mimicking xenograft murine model that underwent splenectomy was created." | ( Cho, IR; Choi, JH; Hong, JM; Kim, YT; Lee, SH; Nam, GH; Paik, WH; Ryu, JK, 2022) |
| "Significant variation between pancreatic cancer networks was found for time to chemotherapy." | ( Besselink, MG; Brosens, LAA; de Hingh, IHJT; de Vos-Geelen, J; Hopstaken, JS; Quispel, R; Stommel, MWJ; van der Geest, LG; van Laarhoven, KJHM; Vissers, PAJ, 2023) |
| "Significant variation between pancreatic cancer networks was found for time to chemotherapy." | ( Besselink, MG; Brosens, LAA; de Hingh, IHJT; de Vos-Geelen, J; Hopstaken, JS; Quispel, R; Stommel, MWJ; van der Geest, LG; van Laarhoven, KJHM; Vissers, PAJ, 2023) |
| "However, since chemotherapy for pancreatic cancer has not yet reached satisfactory therapeutic results, adjuvant chemotherapy methods are attempted." | ( Bae, JH; Kim, J; Koh, EK; Lee, HR; Park, GY; Park, YS; Son, WC, 2023) |
| "However, since chemotherapy for pancreatic cancer has not yet reached satisfactory therapeutic results, adjuvant chemotherapy methods are attempted." | ( Bae, JH; Kim, J; Koh, EK; Lee, HR; Park, GY; Park, YS; Son, WC, 2023) |
| "Participants had a confirmed pancreatic cancer diagnosis and received at least one systemic chemotherapy, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, gemcitabine, and S-1." | ( Akazawa, M; Asami, H; Shibahara, R; Takumoto, Y, 2023) |
| "Participants had a confirmed pancreatic cancer diagnosis and received at least one systemic chemotherapy, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, gemcitabine, and S-1." | ( Akazawa, M; Asami, H; Shibahara, R; Takumoto, Y, 2023) |
| "Patients with metastatic pancreatic cancer refractory to first-line chemotherapy (CTx) have few treatment options." | ( Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Okabe, Y; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N, 2023) |
| "Owing to the strong drug resistance of pancreatic cancer, adjuvant chemotherapy has failed to achieve good results in clinical practice." | ( Han, C; Hu, D; Wang, H; Wang, M; Zhang, L; Zheng, H, 2023) |
| "Owing to the strong drug resistance of pancreatic cancer, adjuvant chemotherapy has failed to achieve good results in clinical practice." | ( Han, C; Hu, D; Wang, H; Wang, M; Zhang, L; Zheng, H, 2023) |
| "Here we examined patients with pancreatic cancer, a disease known to induce myeloid-derived suppressor cells (MDSCs), and for which pegfilgrastim is routinely administered concurrently with FOLFIRINOX but not with gemcitabine-based chemotherapy regimens." | ( Abrams, TA; Biller, LH; Bollenrucher, N; Brais, LK; Cardot-Ruffino, V; Cleary, JM; Delius, L; Dougan, M; Dougan, SK; Enzinger, PC; Keheler, CE; McCleary, NJ; Ng, K; Patel, AK; Perez, K; Remland, J; Rubinson, DA; Schlechter, B; Singh, H; Slater, S; Sullivan, KM; Wang, SJ; Wolpin, BM; Yurgelun, MB, 2023) |
| "Here we examined patients with pancreatic cancer, a disease known to induce myeloid-derived suppressor cells (MDSCs), and for which pegfilgrastim is routinely administered concurrently with FOLFIRINOX but not with gemcitabine-based chemotherapy regimens." | ( Abrams, TA; Biller, LH; Bollenrucher, N; Brais, LK; Cardot-Ruffino, V; Cleary, JM; Delius, L; Dougan, M; Dougan, SK; Enzinger, PC; Keheler, CE; McCleary, NJ; Ng, K; Patel, AK; Perez, K; Remland, J; Rubinson, DA; Schlechter, B; Singh, H; Slater, S; Sullivan, KM; Wang, SJ; Wolpin, BM; Yurgelun, MB, 2023) |
| "The treatment of pancreatic cancer has evolved; however, real-world data on treatment trends remain scarce." | ( Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ, 2023) |
| "Survival rates for pancreatic cancer have generally improved over the past decade and are greater in patients undergoing surgery or chemotherapy and in younger age groups." | ( Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ, 2023) |
| "The treatment of pancreatic cancer has evolved; however, real-world data on treatment trends remain scarce." | ( Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ, 2023) |
| "Survival rates for pancreatic cancer have generally improved over the past decade and are greater in patients undergoing surgery or chemotherapy and in younger age groups." | ( Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ, 2023) |
| "The dilemma of pancreatic cancer treatment has become a global challenge." | ( Dong, S; DU, Y; Jiang, W; Li, W; Li, X; Zhang, H; Zhou, W, 2023) |
| "In BR/UR-LA pancreatic cancer without disease progression after GnP, multimodal treatment including CRT, conversion surgery and the scheduled postoperative chemotherapy may be effective." | ( Jingu, K; Kishida, K; Mizuma, M; Nakagawa, K; Omata, S; Suzuki, Y; Takahashi, N; Umezawa, R; Unno, M; Yamamoto, T, 2023) |
| "In BR/UR-LA pancreatic cancer without disease progression after GnP, multimodal treatment including CRT, conversion surgery and the scheduled postoperative chemotherapy may be effective." | ( Jingu, K; Kishida, K; Mizuma, M; Nakagawa, K; Omata, S; Suzuki, Y; Takahashi, N; Umezawa, R; Unno, M; Yamamoto, T, 2023) |
| "A total of 554 patients with pancreatic cancer of all stages were screened, and 73 patients treated with Gem-Nab and 48 patients treated with Gem-Ox in the palliative first-line setting were identified and included in this analysis." | ( Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L, 2023) |
| "A total of 554 patients with pancreatic cancer of all stages were screened, and 73 patients treated with Gem-Nab and 48 patients treated with Gem-Ox in the palliative first-line setting were identified and included in this analysis." | ( Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L, 2023) |
| "As a new strategy for treating pancreatic cancer, combination therapy is now available, but the dense mesenchymal barrier in the tumor tissue blocks drug delivery and impairs its therapeutic efficacy." | ( Jia, M; Lin, C; Tan, X; Yan, P; Yu, H; Yuan, Z; Zhu, W, 2023) |
| "As a new strategy for treating pancreatic cancer, combination therapy is now available, but the dense mesenchymal barrier in the tumor tissue blocks drug delivery and impairs its therapeutic efficacy." | ( Jia, M; Lin, C; Tan, X; Yan, P; Yu, H; Yuan, Z; Zhu, W, 2023) |
| "Aggressive pancreatic cancer is typically treated using chemotherapeutics to reduce the tumor pre-operatively and prevent metastasis post-operatively, as well as surgical approaches." | ( Baek, S; Kang, YG; Kwon, SH; Lee, KP; Lee, SJ; Moon, BS; Nah, S; Oh, SJ; Park, JY, 2023) |
| "Aggressive pancreatic cancer is typically treated using chemotherapeutics to reduce the tumor pre-operatively and prevent metastasis post-operatively, as well as surgical approaches." | ( Baek, S; Kang, YG; Kwon, SH; Lee, KP; Lee, SJ; Moon, BS; Nah, S; Oh, SJ; Park, JY, 2023) |
| "Multidrug resistance in pancreatic cancer poses a significant challenge in clinical treatment." | ( Abd El-Aty, AM; Ashrafizadeh, M; Cheng, Y; Fan, Y; Fang, S; Gong, P; Hacimuftuoglu, A; Hu, M; Li, W; Linnebacher, M; Shi, D; Yuan, J; Zhang, J; Zhang, W; Zhang, X, 2023) |
| "Multidrug resistance in pancreatic cancer poses a significant challenge in clinical treatment." | ( Abd El-Aty, AM; Ashrafizadeh, M; Cheng, Y; Fan, Y; Fang, S; Gong, P; Hacimuftuoglu, A; Hu, M; Li, W; Linnebacher, M; Shi, D; Yuan, J; Zhang, J; Zhang, W; Zhang, X, 2023) |
| "Using cell models of colorectal and pancreatic cancers, we show that cotreatment with Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone, AcB), a natural flavone from Achyrocline bogotensis, allows for four-fold reduction in 5-Fu dosage without loss of efficacy." | ( Cartwright, BM; Corso, JN; Krishnan, K; Lightner, J; Palau, VE; Torrenegra, RD; Whitted, C, 2023) |
| "Using cell models of colorectal and pancreatic cancers, we show that cotreatment with Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone, AcB), a natural flavone from Achyrocline bogotensis, allows for four-fold reduction in 5-Fu dosage without loss of efficacy." | ( Cartwright, BM; Corso, JN; Krishnan, K; Lightner, J; Palau, VE; Torrenegra, RD; Whitted, C, 2023) |
| "For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy." | ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023) |
| "For patients with pancreatic cancer with little to no cancer near the blood vessels, the best life expectancy usually requires surgery and chemotherapy." | ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023) |
| "For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy." | ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023) |
| "For patients with pancreatic cancer with little to no cancer near the blood vessels, the best life expectancy usually requires surgery and chemotherapy." | ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023) |
| "Gemcitabine, a standard treatment for pancreatic cancer, often has poor outcomes for patients as a result of chemoresistance." | ( Cheong, JH; Hong, WC; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, M; Kim, MJ; Lee, DE; Park, JS, 2023) |
| "Gemcitabine, a standard treatment for pancreatic cancer, often has poor outcomes for patients as a result of chemoresistance." | ( Cheong, JH; Hong, WC; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, M; Kim, MJ; Lee, DE; Park, JS, 2023) |
| "Since autophagy provides pancreatic cancer cells with metabolic plasticity to cope with various metabolic stress conditions, while at the same time promoting their pathogenesis and resistance to KRAS pathway inhibitors, this hypomethylating treatment could represent a therapeutic opportunity for pancreatic adenocarcinomas." | ( Cabezas-Herrera, J; Martí-Díaz, R; Montenegro, MF; Navarro, A; Rodríguez-López, JN; Sánchez-Del-Campo, L; Tolivia, J, 2023) |
| "Since autophagy provides pancreatic cancer cells with metabolic plasticity to cope with various metabolic stress conditions, while at the same time promoting their pathogenesis and resistance to KRAS pathway inhibitors, this hypomethylating treatment could represent a therapeutic opportunity for pancreatic adenocarcinomas." | ( Cabezas-Herrera, J; Martí-Díaz, R; Montenegro, MF; Navarro, A; Rodríguez-López, JN; Sánchez-Del-Campo, L; Tolivia, J, 2023) |
| "Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments." | ( Abbas, AE; Azzoli, CG; Cruz, A; El-Deiry, WS; George, A; Huntington, KE; Liguori, NR; Sevilla Uruchurtu, AS; Tummala, T; Zhang, L; Zhou, L, 2023) |
| "Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments." | ( Abbas, AE; Azzoli, CG; Cruz, A; El-Deiry, WS; George, A; Huntington, KE; Liguori, NR; Sevilla Uruchurtu, AS; Tummala, T; Zhang, L; Zhou, L, 2023) |